<SEC-DOCUMENT>0001171843-16-013725.txt : 20161221
<SEC-HEADER>0001171843-16-013725.hdr.sgml : 20161221
<ACCEPTANCE-DATETIME>20161220173143
ACCESSION NUMBER:		0001171843-16-013725
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20161221
DATE AS OF CHANGE:		20161220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RedHill Biopharma Ltd.
		CENTRAL INDEX KEY:			0001553846
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-209702
		FILM NUMBER:		162062250

	BUSINESS ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
		BUSINESS PHONE:		972-3-541-3131

	MAIL ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>f424b5_122016.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; color: red">The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(5)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No.&nbsp;333-209702</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0; color: red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"><B>SUBJECT TO COMPLETION, DATED&nbsp;DECEMBER
20, 2016</B></P>





<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>(to Prospectus dated March 11, 2016)</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 14pt"><B>American Depositary Shares Representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ordinary Shares</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Warrants
to Purchase American Depositary Shares&nbsp;</B></FONT></P>



<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><img src="logo.jpg"></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>RedHill Biopharma Ltd.</B></P>


<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;American
Depositary Shares (&ldquo;ADSs&rdquo;) representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of
our ordinary shares, par value NIS 0.01 per share (&ldquo;Ordinary Shares&rdquo;), and warrants to purchase ADSs. Each ADS represents
10 Ordinary Shares. The ADSs and warrants will be issued separately, but the ADSs and warrants will be sold in a fixed combination
of one ADS and a warrant to purchase 0.5 of an ADS, for the combined purchase price of $ . The warrants may only be exercised to
purchase whole ADSs at an exercise price of $ per ADS and will expire three years from the date of issuance. Echelon Wealth Partners,
the Canadian Manager, will only be offering the ADSs and warrants to investors in Canada.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our ADSs are listed on The NASDAQ Capital Market (&ldquo;The
NASDAQ&rdquo;) under the symbol &ldquo;RDHL.&rdquo;&nbsp;On&nbsp;December 19, 2016, the last reported sale price of our ADSs on
The NASDAQ was $10.71 per ADS.&nbsp;Our Ordinary Shares are also listed on the Tel Aviv Stock Exchange (the &ldquo;TASE&rdquo;)
under the symbol &ldquo;RDHL.&rdquo;&nbsp;On December 19, 2016, the last reported sale price of our Ordinary Shares on the TASE
was NIS 4.37, or $1.13 per Ordinary Share (based on the exchange rate reported by the Bank of Israel on such date). There is no
established trading market for the warrants, and we do not expect a market to develop. In addition, we do not intend to list the
warrants on The NASDAQ, the TASE or any other national securities exchange or any other recognized trading system.</P>



<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We are an &ldquo;emerging growth company&rdquo; as that term is
used in the Jumpstart Our Business Startups Act of 2012 and, as such, we have elected to comply with certain reduced public company
reporting requirements for this prospectus and may elect to comply with certain reduced public company reporting requirements for
future filings.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Investing in our securities involves a high degree of risk. Please
read &ldquo;Risk Factors&rdquo; beginning on page S-11 of this prospectus supplement, on page 3 of the accompanying prospectus
and in the documents incorporated by reference into this prospectus supplement.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>None of the United States Securities and Exchange Commission, the Israeli Securities
Authority, any state securities commission or any other regulatory body, has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary
is a criminal offense.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">PER ADS(3) </FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">TOTAL</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%"><FONT STYLE="font-size: 10pt">Public Offering Price&#9;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Underwriting Discounts and Commissions for securities sold to certain agreed upon investors originally identified by us (1)&#9;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Underwriting Discounts and Commissions for securities sold to all other investors (1)&#9;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Proceeds to Us, before Expenses (2)&#9;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>


<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font-size: 10pt"><FONT STYLE="font-size: 10pt">(1)&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 93%; font-size: 10pt"><FONT STYLE="font-size: 10pt">We have agreed to reimburse the underwriters for certain offering-related expenses. See &ldquo;Underwriting.&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Does not include proceeds from the exercise of the warrants in cash, if any.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">(3) </TD>
    <TD STYLE="font-size: 10pt">Per ADS price represents the offering price for one ADS
and a warrant to purchase 0.5 of one ADS.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain of our directors have indicated an interest in purchasing
(or having their affiliates purchase) approximately $1,000,000 of our ADSs and warrants in this offering. Because indications of
interest are not binding agreements or commitments to purchase, these persons may decide to buy, or the underwriters may decide
to sell to them, a greater or lesser amount of ADSs and warrants or no ADSs or warrants at all. The underwriters will receive the
same underwriting discount on any ADSs and warrants purchased by these persons as they will on the other ADSs and warrants sold
to the public in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Delivery of the ADSs and warrants is expected to be made on
or about December 27, 2016. We have granted the underwriters an option for a period of 30 days to purchase up to an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
ADSs representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ordinary Shares If the underwriters exercise the
option in full, the total underwriting discounts and commissions payable by us will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
and the total proceeds to us, before expenses, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that none of the warrants
issued in this offering is exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 33%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><I>Sole Book-Running Manager</I></FONT></TD>
    <TD STYLE="width: 33%; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 12pt"><B>Roth Capital Partners</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>Canadian Manager</I></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><B>Echelon Wealth Partners</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Prospectus Supplement dated December &nbsp;&nbsp;&nbsp;,
2016.&nbsp;</P>




<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>





<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Table Of Contents</B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 90%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right; vertical-align: top"><FONT STYLE="font-size: 10pt"><B>&nbsp;Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><B>Prospectus Supplement</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_001"><FONT STYLE="font-size: 10pt">About this Prospectus Supplement</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">S-2</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_002"><FONT STYLE="font-size: 10pt">Cautionary Note Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">S-3</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_003"><FONT STYLE="font-size: 10pt">Prospectus Supplement Summary</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">S-4</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_004"><FONT STYLE="font-size: 10pt">Summary Financial Data</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">S-10</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_005"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">S-11</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_006"><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">S-37</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_007"><FONT STYLE="font-size: 10pt">Dilution</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">S-38</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_008"><FONT STYLE="font-size: 10pt">Capitalization and Indebtedness</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">S-39</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_009"><FONT STYLE="font-size: 10pt">Price Range of Our Ordinary Shares</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">S-40</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_010"><FONT STYLE="font-size: 10pt">Price Range of Our ADSs</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">S-41</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_011"><FONT STYLE="font-size: 10pt">Dividend Policy</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">S-41</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_011a">Description of Warrants We are Offering</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_011a">S-41</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_012"><FONT STYLE="font-size: 10pt">Material Tax Considerations</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">S-43</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_013">Underwriting</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_013">S-51</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_014">Notice to Investors</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_014"><FONT STYLE="font-size: 10pt">S-55</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_015"><FONT STYLE="font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_015"><FONT STYLE="font-size: 10pt">S-58</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_016"><FONT STYLE="font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_016"><FONT STYLE="font-size: 10pt">S-59</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_017"><FONT STYLE="font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_017"><FONT STYLE="font-size: 10pt">S-59</FONT></A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_018"><FONT STYLE="font-size: 10pt">Incorporation of Information by Reference</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_018"><FONT STYLE="font-size: 10pt">S-59</FONT></A></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: middle">
    <TD STYLE="width: 90%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: right; width: 10%">Page</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: left">Prospectus</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_019">About This Prospectus</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_019">2</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_020">RedHill Biopharma Ltd.</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_020">2</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_021">Risk Factors</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_021">3</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_022">Forward-Looking Statements</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_022">3</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_023">Capitalization</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_023">4</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_024">Price Range of Our Ordinary Shares</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_024">4</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_025">Price Range of Our ADSs</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_025">5</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_026">Use of Proceeds</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_026">6</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_027">Description of Ordinary Shares</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_027">6</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_028">Description of American Depositary Shares</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_028">6</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_029">Description of Warrants</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_029">7</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_030">Description of Subscription Rights</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_030">7</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_031">Description of Units</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_031">8</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_032">Plan of Distribution</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_032">8</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_033">Legal Matters</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_033">11</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_034">Experts</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_034">11</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_035">Where You Can Find More Information</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_035">11</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_036">Incorporation of Information by Reference</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_036">12</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_037">Enforceability of Civil Liabilities</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_037">12</A></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><A HREF="#a_038">Offering Expenses</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_038">13</A></TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>


<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><A NAME="a_001"></A><B>ABOUT THIS PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">You should rely only on the information  provided in this prospectus
supplement and the accompanying prospectus, all information incorporated by reference herein and therein, as well as the additional
information described under &ldquo;Incorporation of Information by Reference&rdquo; on page S-55 of this prospectus supplement.
We have not authorized anyone to provide you with different information. If anyone provides you with different or inconsistent
information, you should not rely on it. This prospectus supplement and the accompanying prospectus do not constitute an offer to
sell, or a solicitation of an offer to purchase, the securities offered by this prospectus supplement and the accompanying prospectus
in any jurisdiction where it is unlawful to make such offer or solicitation. You should not assume that the information contained
in this prospectus supplement or the accompanying prospectus, or any document incorporated by reference in this prospectus supplement
or the accompanying prospectus, is accurate as of any date other than the date on the front cover of the applicable document. Neither
the delivery of this prospectus supplement nor any distribution of securities pursuant to this prospectus supplement shall, under
any circumstances, create any implication that there has been no change in the information set forth or incorporated by reference
into this prospectus supplement or in our affairs since the date of this prospectus supplement. Our business, financial condition,
results of operations and prospects may have changed since that date.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus supplement and the accompanying prospectus are
part of a registration statement (No. 333-209702) that we filed with the Securities and Exchange Commission, or the SEC, using
a &ldquo;shelf&rdquo; registration process. This document comprises two parts. The first part is this prospectus supplement, which
describes the specific terms of this offering and also adds to and updates information contained in the accompanying prospectus
and the documents incorporated by reference herein, in addition to information concerning the option to purchase additional ADSs
granted by us to the underwriters. The second part, the accompanying prospectus, gives more general information, some of which
may not apply to this offering. Generally, when we refer to this prospectus, we are referring to both parts of this document combined.
If the description of the offering varies between this prospectus supplement and the accompanying prospectus or the documents incorporated
herein by reference filed prior to the date of this prospectus supplement, you should rely on the information contained in this
prospectus supplement. However, if any statement in one of these documents is inconsistent with a statement in another document
having a later date &mdash; for example, a document incorporated by reference in the accompanying prospectus &mdash; the statement
in the document having the later date modifies or supersedes the earlier statement.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Before purchasing any securities, you should carefully read both
this prospectus supplement and the accompanying prospectus, together with the additional information described under the headings,
&ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation of Information by Reference,&rdquo; on <FONT STYLE="background-color: white">page
S-55 of</FONT> this prospectus supplement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Unless the context otherwise requires, all references to &ldquo;RedHill,&rdquo;
&ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company&rdquo; and similar designations refer to RedHill Biopharma
Ltd. The term &ldquo;NIS&rdquo; refers to New Israeli Shekels, the lawful currency of the State of Israel, the terms &ldquo;dollar,&rdquo;
&ldquo;US$&rdquo; or &ldquo;$&rdquo; refer to U.S. dollars, the lawful currency of the United States (&ldquo;U.S.&rdquo;). Our
functional and presentation currency is the U.S. dollar. Foreign currency transactions in currencies other than the U.S. dollar
are translated in this prospectus supplement into U.S. dollars using exchange rates in effect at the date of the transactions.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We further note that the representations, warranties and covenants
made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely
for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties
to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations,
warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants
should not be relied on as accurately representing the current state of our affairs.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are offering to sell, and seeking offers to buy, ADSs representing
our Ordinary Shares and warrants to purchase ADSs only in jurisdictions where offers and sales are permitted. The distribution
of this prospectus supplement and the accompanying prospectus and the offering of the ADSs and warrants in certain jurisdictions
may be restricted by law. Persons outside the U.S. who come into possession of this prospectus supplement and the accompanying
prospectus must inform themselves about, and observe any restrictions relating to, the offering of the ADSs and warrants and the
distribution of this prospectus supplement and the accompanying prospectus outside the U.S. This prospectus supplement and the
accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer
to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction
in which it is unlawful for such person to make such an offer or solicitation.</P>



<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"><A NAME="a_002"></A><B>CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This prospectus supplement, the accompanying prospectus, and the
information incorporated by reference herein and therein may include forward looking statements. These statements involve known
and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some
cases, you can identify forward-looking statements by terms including &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;could,&rdquo;
&ldquo;estimates,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;plans,&rdquo; &ldquo;potential,&rdquo;
&ldquo;predicts,&rdquo; &ldquo;projects,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; and similar expressions
intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events
and are based on assumptions and subject to risks and uncertainties. In addition, certain sections of this prospectus supplement,
the accompanying prospectus, and the information incorporated by reference herein contain information obtained from independent
industry and other sources that we have not independently verified. You should not put undue reliance on any forward-looking statements.
Unless we are required to do so under U.S. federal securities laws or other applicable laws, we do not intend to update or revise
any forward-looking statements.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our ability to predict our operating results or the effects of various
events on our operating results is inherently uncertain. Therefore, we caution you to consider carefully the matters described
under the caption &ldquo;Risk Factors&rdquo; on <FONT STYLE="background-color: white">page&nbsp;S-11 of</FONT> this prospectus
supplement, and certain other matters discussed in this prospectus supplement, the accompanying prospectus, and the information
incorporated by reference herein and therein, and other publicly available sources. Such factors and many other factors beyond
our control could cause our actual results, performance or achievements to be materially different from any future results, performance
or achievements that may be expressed or implied by the forward-looking statements.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Factors that could cause our actual results to differ materially
from those expressed or implied in such forward-looking statements include, but are not limited to:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="vertical-align: top; text-align: left; width: 4%">&bull;</TD>
    <TD STYLE="vertical-align: middle; text-align: justify; width: 96%">the initiation, timing, progress and results of our research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts, as well as the extent and number of additional studies that we may be required to conduct;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&bull;</TD>
    <TD STYLE="vertical-align: middle; text-align: justify">our ability to advance our therapeutic candidates into clinical trials or to successfully complete our preclinical studies or clinical trials;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&bull;</TD>
    <TD STYLE="vertical-align: middle; text-align: justify">our receipt of regulatory clarity and approvals for our therapeutic candidates, and the timing of other regulatory filings and approvals;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&bull;</TD>
    <TD STYLE="vertical-align: middle; text-align: justify">the research, manufacturing, clinical development, commercialization, and market acceptance of our therapeutic candidates;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&bull;</TD>
    <TD STYLE="vertical-align: middle; text-align: justify">our ability to establish and maintain corporate collaborations;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&bull;</TD>
    <TD STYLE="vertical-align: middle; text-align: justify">our ability to acquire products approved for marketing in the U.S. that achieve commercial success and build our own marketing and commercialization capabilities;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&bull;</TD>
    <TD STYLE="vertical-align: middle; text-align: justify">the interpretation of the properties and characteristics of our therapeutic candidates and of the results obtained with our therapeutic candidates in research, preclinical studies or clinical trials;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&bull;</TD>
    <TD STYLE="vertical-align: middle; text-align: justify">the implementation of our business model, strategic plans for our business and therapeutic candidates;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&bull;</TD>
    <TD STYLE="vertical-align: middle; text-align: justify">the scope of protection we are able to establish and maintain for intellectual property rights covering our therapeutic candidates and our ability to operate our business without infringing the intellectual property rights of others;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&bull;</TD>
    <TD STYLE="vertical-align: middle; text-align: justify">estimates of our expenses, future revenues, capital requirements and our needs for additional financing;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&bull;</TD>
    <TD STYLE="vertical-align: middle; text-align: justify">parties from whom we license our intellectual property defaulting in their obligations towards us;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&bull;</TD>
    <TD STYLE="vertical-align: middle; text-align: justify">the impact of competitive companies and technologies within our industry; and</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&bull;</TD>
    <TD STYLE="vertical-align: middle; text-align: justify">the impact of the political and security situation in Israel and in the U.S. on our business.</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><A NAME="a_003"></A>PROSPECTUS SUPPLEMENT SUMMARY</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This summary highlights selected information about us, this
offering and information contained in greater detail elsewhere in this prospectus supplement, the accompanying prospectus, any
free writing prospectus that we have been authorized to use, and in the documents incorporated by reference. This summary is not
complete and does not contain all of the information that you should consider before investing in our ADSs and warrants. You should
carefully read and consider this entire prospectus supplement, the accompanying prospectus and the documents, including financial
statements and related notes, and information incorporated by reference into this prospectus supplement, including the financial
statements and &ldquo;Risk Factors&rdquo; starting <FONT STYLE="background-color: white">on page S-11 of</FONT> this prospectus
supplement, before making an investment decision. If you invest in our securities, you are assuming a high degree of risk.</I></P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Our Business</B>&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We are a biopharmaceutical company primarily focused on the development
of late clinical-stage, proprietary, orally-administered, small-molecule drugs for the treatment of gastrointestinal (&ldquo;GI&rdquo;)
and inflammatory diseases and cancer.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Depending on the specific development program, our therapeutic candidates
are designed to exhibit greater efficacy and provide improvements over existing drugs by improving their safety profile, reducing
side effects, reducing the number of administrations, using a more convenient administration form and/or providing a cost advantage.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to our primary focus on the
development of clinical-stage GI products, we are in the process of establishing commercial presence and capabilities in the U.S.
to support potential future launch of our GI-related therapeutic candidates currently under development in the U.S. We are also
seeking to acquire commercial rights and promote other GI products, as part of our vertical integration strategy to become a specialty
GI pharmaceutical company in the U.S.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Product Pipeline</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The table below summarizes our current pipeline of products and
product candidates, as well as the target indication.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img src="pipeline.jpg"></P>


<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Recent Developments</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>RHB-105</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We met with the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;)
in April 2016 to discuss the successful results of the ERADICATE Hp Phase III study and the proposed design of the confirmatory
Phase III study for the treatment of&nbsp;<I>Helicobacter pylori </I>(&ldquo;<I>H. pylori</I>&rdquo;) infection. In light of the
feedback received from the FDA, we expect to initiate a confirmatory Phase III randomized, double-blind, active comparator, two-arm
clinical study, comparing RHB-105 against a high dose amoxicillin and omeprazole regimen, in the first half of 2017.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As per a recommendation from the FDA, we intend to complete
a supportive pharmacokinetic (&ldquo;PK&rdquo;) program prior to initiating the confirmatory Phase III study, by end of the first
quarter of 2017. Subject to their successful outcome, the confirmatory Phase III study and the supportive PK program are expected
to complete the clinical package required for a submission of a New Drug Application (&ldquo;NDA&rdquo;) for RHB-105.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>RHB-104</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Crohn&rsquo;s Disease</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are currently conducting a randomized, double-blind, placebo-controlled
first Phase III study with RHB-104 for Crohn&rsquo;s disease (the &ldquo;MAP US&rdquo; study).The MAP US study is expected to enroll
410 patients with moderately to severely active Crohn&rsquo;s disease at up to 150 clinical sites in the U.S., Canada, Europe,
Israel, Australia and New Zealand. Patients are randomized 1:1 to receive either RHB-104 or a placebo for 52 weeks and are evaluated
for the primary endpoint of remission (Crohn&rsquo;s disease active index (&ldquo;CDAI&rdquo;) &lt;150) at week 26 of treatment.&nbsp;</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We plan to initiate, in the fourth quarter of 2016, an open-label
extension study for all patients who have completed 26 weeks of treatment in the MAP US study and failed to achieve remission at
week 26. Patients with a CDAI score of greater than 150 at week 26 will be offered the opportunity to receive treatment with RHB-104
for a 52-week period. This study is considered separate from the MAP US study, and the data collected from the open-label extension
study will be supplemental to the MAP US study data.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following a pre-planned review of safety data, an independent
interim Data and Safety Monitoring Board (&ldquo;DSMB&rdquo;) unanimously recommended in December 2016 that the MAP US study continue
as planned, without any modifications. Two additional DSMB meetings are expected to take place after 50% and after 75% of the 410
patients planned to be enrolled in the study complete the 26 weeks of study participation. Over half of the patients have already
been enrolled in the MAP US study, with the 205<SUP>th</SUP> patient enrolled in August 2016. As a result, we expect the second
independent DSMB meeting to be held in the second quarter of 2017, after the first 205 patients complete 26 weeks of study participation.
The second DSMB meeting will include safety and interim efficacy analysis and will evaluate the option of an early stop for success,
according to a pre-specified statistical significance threshold for analysis requiring overwhelming efficacy of RHB-104 versus
placebo in the primary endpoint (two sided p-value &lt;0.003). Assuming that the study is not stopped early for success or inefficacy
following the second DSMB meeting, we expect to complete the recruitment of all 410 subjects planned to enroll for the study by
the end of 2017. Additional studies will be required to support a U.S. NDA for RHB-104.</P>





<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We also intend to initiate in the coming months two additional ex-U.S.
small-scale open-label clinical studies with RHB-104, each with up to 20 Crohn&rsquo;s disease patients, to provide additional
supportive clinical data for potential future marketing applications, as well as to evaluate RHB-104&rsquo;s efficacy in newly
diagnosed and treatment-na&iuml;ve Crohn&rsquo;s disease patients and as an add-on therapy to current standard of care.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Multiple Sclerosis (&ldquo;MS&rdquo;)&#9;</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have completed a Phase IIa proof-of-concept study with RHB-104
for relapsing remitting multiple sclerosis (&ldquo;RRMS&rdquo;) (the &ldquo;CEASE MS&rdquo; study) at two clinical sites in Israel,
with top-line final results (48 weeks) announced on December 12, 2016. The top-line final results (48 weeks) were consistent with
the interim results (24 weeks) suggesting meaningful positive safety and clinical signals upon 24 weeks of treatment with RHB-104
as an add-on therapy, including an encouraging relapse-free rate, Expanded Disability Status Scale scores and MRI results, which
support further clinical development.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>BEKINDA</I></B><SUP>&reg; </SUP><B><I>(RHB-102)</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Acute Gastroenteritis and Gastritis</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We have initiated a randomized, double-blind, placebo controlled,
parallel group Phase III study (the &ldquo;GUARD&rdquo; study) that is being conducted at up to 30 clinical sites in the U.S. and
is expected to enroll 320 adults and children over the age of 12 who suffer from acute gastroenteritis and gastritis. Patients
are randomized to receive either BEKINDA<SUP>&reg; </SUP>or a placebo. The primary endpoint for the study is the absence of vomiting
and the need for rescue medications or intravenous hydration after 30 minutes and through 24 hours after the first dose of the
study medication. Secondary endpoints include, among others, frequency of vomiting, severity and time to resolution of nausea and
time to resumption of normal activities. We implemented a protocol amendment to the ongoing GUARD study to increase the safety
data collected, so that the study results may support a potential NDA filing, as recommended by the FDA. The study protocol now
requires patients to remain in the emergency room for a longer follow-up period and be subject to an electrocardiogram at the end
of the follow-up period before the patient is discharged. In light of this amendment,  we expect top-line results from the GUARD
study in mid-2017.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Irritable Bowel Syndrome with Diarrhea (&ldquo;IBS-D&rdquo;)
</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We are conducting a randomized, double-blind, placebo controlled
Phase II study to evaluate the safety and efficacy of BEKINDA<SUP>&reg; </SUP>12 mg with patients with IBS-D. The study is expected
to enroll 120 adults over the age of 18 who suffer from IBS-D, at up to 12 clinical sites in the U.S. Patients are randomized to
receive either BEKINDA<SUP>&reg; </SUP>12 mg once daily or a placebo. Top-line results are expected in mid-2017.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>YELIVA</I></B><I><SUP>&reg;</SUP> <B>(ABC294640)</B></I></P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A Phase Ib/II study with YELIVA<SUP>&reg;</SUP>, for the treatment
of refractory or relapsed multiple myeloma was initiated earlier this year at Duke University Medical Center. The study is supported
by a $2 million grant from the National Cancer Institute (&ldquo;NCI&rdquo;), with additional support from us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The initiation of a Phase II study with YELIVA<SUP>&reg;</SUP>&nbsp;for the treatment of advanced hepatocellular carcinoma (&ldquo;HCC&rdquo;)
was announced in October 2016. The study is being conducted at the Medical University of South Carolina (&ldquo;MUSC&rdquo;) Hollings
Cancer Center and additional clinical centers in the U.S. The study is supported by a $1.8 million grant from the NCI awarded to
MUSC, which is intended to fund a broad range of studies on the feasibility of targeting sphingolipid metabolism for the treatment
of a variety of solid tumor cancers, including the Phase II study with YELIVA<SUP>&reg;</SUP>&nbsp;for the treatment of HCC. The
Phase II HCC study is supported by additional funding from us.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A Phase I/II clinical study evaluating YELIVA<SUP>&reg;</SUP>&nbsp;in
patients with refractory/relapsed diffuse large B-cell lymphoma was initiated at the Louisiana State University Health Sciences
Center in New Orleans in June 2015 and was put on administrative hold and recently amended to address the overall recruitment prospects.
The study,&nbsp;which will now also include Kaposi sarcoma patients, is expected to resume in the first quarter of 2017, pending
regulatory approval. The study is supported by a grant from the NCI, as well as additional support from us.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A Phase Ib clinical study to evaluate YELIVA<SUP>&reg;</SUP>
as a radioprotectant to prevent mucositis in head and neck cancer patients undergoing therapeutic radiotherapy is planned to be
initiated in the first half of 2017.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the successful completion of a Phase I study with
YELIVA<SUP>&reg;</SUP> in cancer patients with advanced solid tumors, and in light of the drug&rsquo;s mechanism of action, we
are evaluating potential clinical studies for additional oncology and inflammatory indications for YELIVA<SUP>&reg;</SUP>, as well
as potential collaboration opportunities to evaluate YELIVA<SUP>&reg;</SUP> as an add-on therapy.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>RIZAPORT</I></B><SUP>&reg;</SUP> <B><I>(RHB-103)</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2016, we, together with IntelGenx Corp., entered into
an exclusive license agreement with Grupo JUSTE S.A.Q.F (&ldquo;Grupo JUSTE&rdquo;), pursuant to which Grupo JUSTE was granted
an exclusive license to commercialize RIZAPORT<SUP>&reg; </SUP>in Spain and a right of first refusal for the commercialization
rights in certain additional territories. Under the terms of the agreement, we granted Grupo JUSTE the exclusive rights to register
and commercialize RIZAPORT<SUP>&reg; </SUP>in Spain and a right of first refusal for a predetermined term for the territories of
Belize, the Caribbean, Chile, Colombia, Costa Rica, Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama,
the Middle East and Morocco. An upfront payment has been paid by Group JUSTE, and we and IntelGenx Corp. are entitled to receive
additional milestone payments upon the achievement of certain predefined regulatory and commercial targets, as well as tiered royalties.
The initial term of the agreement is for ten years from the date of the first commercial sale and shall automatically renew for
an additional two-year term. Commercial launch of RIZAPORT<SUP>&reg;</SUP> in Spain is expected to take place in the second half
of 2017.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 13, 2016, we, together with IntelGenx Corp., entered
into an exclusive license agreement with Pharmatronic Co., pursuant to which Pharmatronic Co. was granted an exclusive license
to commercialize RIZAPORT<SUP>&reg;</SUP>&nbsp;in the Republic of Korea (South Korea). Under the terms of the agreement, we and
IntelGenx Corp. are entitled to receive an upfront payment and are entitled to receive additional milestone payments upon the achievement
of certain predetermined regulatory and commercial targets, as well as tiered royalties. The initial term of the agreement is for
ten years from the date of the first commercial sale and shall automatically renew for an additional two-year term. Commercial
launch of RIZAPORT<SUP>&reg;</SUP> in South Korea is expected to take place in the first quarter of 2019.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Following the receipt of a complete response letter from the FDA
as announced on February 4, 2014, we, together with IntelGenx Corp., expect to re-submit the NDA for RIZAPORT<SUP>&reg; </SUP>to
the FDA in the first half of 2017 and subsequently receive a new Prescription Drug User Fee Act date.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Ebola Virus Disease Therapy</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect to initiate a nonclinical research collaboration with
the U.S. National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, in the first quarter
of 2017. The study is intended to evaluate our proprietary experimental therapy for the treatment of the Ebola virus disease. Top-line
results from the nonclinical research are expected in 2017.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Potential Commercial Activities in the U.S.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are in the process of establishing commercial presence and
capabilities in the U.S., and we plan to leverage such presence and capabilities to support, among others, potential future commercial
launch of our GI-related products under development (RHB-104, RHB-105 and BEKINDA<SUP>&reg;</SUP>) in the U.S.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">On October 3, 2016, we entered into a non-binding term sheet with
a pharmaceutical company, as part of our strategic vertical integration plan to build a U.S. specialty pharmaceutical company by
establishing a commercial presence and capabilities. Under the term sheet, we would be granted the right to exclusively promote
a specialty GI product in certain territories in the U.S. The parties would share revenues generated in such territories, based
on an agreeable split between the parties. We are not required to make any upfront or milestone payments under the term sheet.
Although our goal is to complete the transaction pertaining to the commercial asset in the fourth quarter of 2016, the term sheet
is non-binding and there is no certainty as to the execution and timing of the execution of a definitive agreement between us and
our potential partner. There is no assurance that satisfactory due diligence will be completed or the parties will obtain all necessary
corporate approvals.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We were incorporated as a limited liability company under the laws
of the State of Israel on August 3, 2009. Our principal executive offices are located at 21 Ha&rsquo;arba&rsquo;a Street, Tel Aviv,
Israel and our telephone number is +972 (3) 541-3131. Our web site address is http://www.redhillbio.com. The information on our
web site does not constitute part of this prospectus. Our registered agent in the U.S. is Puglisi &amp; Associates. The address
of Puglisi &amp; Associates is 850 Library Avenue, Suite 204, Newark Delaware 19715.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>THE OFFERING</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 29%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ADSs offered by us in the offering</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrants offered by us</P></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 70%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADSs
        representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ordinary Shares (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs
        representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ordinary Shares if the underwriters exercise their
        option to purchase additional ADSs in full).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrants to purchase ADSs Each warrant will have a per ADS exercise
        price of $ and will be exercisable upon issuance and will expire three years from the date of issuance.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ADSs and warrants will be issued separately, but the ADSs
        and warrants will be issued and sold to purchasers in a fixed combination of one ADS and one warrant to purchase 0.5 of an ADS.
        The warrants may only be exercised to purchase whole ADSs.</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Total Ordinary Shares outstanding immediately after this offering</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ordinary Shares, or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ordinary Shares if the warrants offered in this offering are exercised in full. If the underwriters exercise their option in full, the total ordinary shares outstanding immediately after this offering will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ordinary Shares.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">The ADSs</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each ADS represents 10 Ordinary Shares.&nbsp;The ADSs initially
        will be evidenced by American Depositary Receipts (&ldquo;ADRs&rdquo;), executed and delivered by The Bank of New York Mellon,
        as depositary (the &ldquo;Depositary&rdquo;).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Depositary, as depositary, will be the holder of the Ordinary
        Shares underlying your ADSs and you will have rights as provided in the Deposit Agreement dated as of December 26, 2012, among
        us, The Bank of New York Mellon, as Depositary, and all owners and holders from time to time of ADSs issued thereunder (the &ldquo;Deposit
        Agreement&rdquo;), a form of which has been filed as Exhibit 1 to the Registration Statement on Form F-6 filed by the Depositary
        with the SEC on December 6, 2012.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to compliance with the relevant requirements set out
        in the prospectus, you may turn in your ADSs to the Depositary in exchange for Ordinary Shares underlying your ADSs.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Depositary will charge you fees for such exchanges pursuant
        to the Deposit Agreement.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should carefully read the &ldquo;Description of American
        Depositary Shares&rdquo; section of the accompanying prospectus and the Deposit Agreement to better understand the terms of the
        ADSs.</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Offering Price</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">The public offering price is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per a fixed combination of one ADS and one warrant to purchase 0.5 of an ADS.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Option to purchase additional ADSs </FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have granted the underwriters an option to purchase up to
        an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADSs representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        Ordinary Shares.</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Right to Nominate Director</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will grant to any investor purchasing, together with its
        affiliates, as such term is defined in Rule 405 of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), at
        least $15 million of ADSs and warrants in this offering (excluding the proceeds, if any, from the exercise of warrants) the right
        to nominate one person for election to our board of directors at our next annual meeting of shareholders (&quot;upcoming shareholder
        meeting&quot;), subject to meeting applicable legal and stock exchange requirements and subject to the consent of our board of
        directors, which consent shall, subject to our directors&rsquo; fiduciary duties under applicable law, not be unreasonably withheld.
        The nomination right is also subject to shareholder approval of amendments to our articles of association (i) increasing the maximum
        number of directors that may serve on our board of directors and (ii) providing that the term of office of any director elected
        to our board of directors, and originally nominated for election by an investor by virtue of the nomination right in this prospectus,
        shall automatically expire at the first annual meeting of shareholders following the upcoming shareholder meeting unless such investor,
        at least 75 days prior to such first following annual meeting of shareholders evidences to us its beneficial ownership, together
        with its affiliates, of at least 5% of our outstanding shares.&nbsp; If not so expired at the first annual meeting following the
        upcoming shareholder meeting, the term of office of such director shall automatically expire at the second annual meeting of shareholders
        following the upcoming shareholder meeting unless such investor, at least 75 days prior to such second annual meeting following
        this offering, evidences to us its beneficial ownership, together with its affiliates, of at least 5% of our outstanding shares.
        In any event, the term of office of such director shall automatically expire at the third annual meeting of shareholders following
        the upcoming shareholder meeting unless re-elected by the Company shareholders.&nbsp;There is no guarantee that our shareholders
        will approve such an amendments. Upon the selection of this director nominee, and the approval of this director nominee by our
        board of directors, our board shall recommend to our shareholders the election of the director nominee to our board of directors.</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Options: NewSection; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 29%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Use of Proceeds</P></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 70%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We currently intend to use the net proceeds from the sale of
        our ADSs and warrants and any proceeds from the exercise of the warrants to fund clinical development programs, for potential acquisitions,
        to support commercial operations and for general corporate purposes.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See &ldquo;Use of Proceeds&rdquo; for additional information.</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Listing </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Our ADSs are listed on The NASDAQ under the symbol &ldquo;RDHL&rdquo; and our Ordinary Shares currently trade on the TASE in Israel under the symbol &ldquo;RDHL&rdquo;. There is no established trading market for the warrants, and we do not expect a market to develop. In addition, we do not intend to list the warrants on The NASDAQ, the TASE or any other national securities exchange or any other recognized trading system. Warrant holders are prohibited from listing any warrants on any such exchange or trading system or on any other trading platform.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Risk factors</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Before deciding to invest in our ADSs and warrants, you should carefully consider the risks related to our business, the offering and our securities, and our location in Israel. See &ldquo;Risk Factors&rdquo; on <FONT STYLE="background-color: white">page&nbsp;S-11 of this</FONT> prospectus supplement.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Dividend Policy</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">We have never declared or paid any cash dividends to our shareholders, and we currently do not expect to declare or pay any cash dividends in the foreseeable future. See &ldquo;Dividend Policy.&rdquo;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Depositary </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">The Bank of New York Mellon</FONT></TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The number of Ordinary Shares to be outstanding immediately
after the offering as shown above is based on 127,840,084 Ordinary Shares outstanding as of December 19, 2016. This number does
not include, as of December 19, 2016 (i) 22,065,548 Ordinary Shares issuable upon the exercise of outstanding options to purchase
22,065,548 Ordinary Shares at a weighted average exercise price of $0.95 per share (equivalent to 2,206,554 ADSs at a weighted
average exercise price of $9.50 per ADS), (ii) 4,183,496 Ordinary Shares issuable upon the exercise of outstanding non-tradable
warrants to purchase 4,183,496 Ordinary Shares at an exercise price of $1.40 per share (equivalent to 418,349 ADSs at an exercise
price of $14.00 per ADS) and (iii) <FONT STYLE="background-color: white">3,578,960</FONT> Ordinary Shares issuable upon the exercise
of outstanding non-tradable warrants to purchase <FONT STYLE="background-color: white">3,578,960</FONT> Ordinary Shares at an exercise
price of $1.10 per share (equivalent to 357,896 ADSs at an exercise price of $11.00 per ADS).</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise stated, outstanding share information throughout
this prospectus supplement excludes such outstanding securities. Except as otherwise indicated, all information in this prospectus
supplement assumes no exercise by the underwriters of their option to purchase an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
ADSs and no exercise of the warrants issued in this offering.</P>




<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain of our directors have indicated an interest in purchasing
(or having their affiliates purchase) approximately $1,000,000 of our ADSs and warrants in this offering. Because indications of
interest are not binding agreements or commitments to purchase, these persons may decide to buy, or the underwriters may decide
to sell to them, a greater or lesser amount of ADSs and warrants or no ADSs or warrants at all. The underwriters will receive the
same underwriting discount on any ADSs and warrants purchased by these persons as they will on the other ADSs and warrants sold
to the public in this offering.&nbsp;</P>



<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
<!-- Field: Page; Sequence: 11; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"><A NAME="a_004"></A><B>SUMMARY FINANCIAL DATA</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We derived the summary financial statement data for the years
ended December&nbsp;31, 2013, 2014 and 2015 set forth below from our audited financial statements and related notes incorporated
by reference in this prospectus supplement and the accompanying prospectus. We derived the summary financial statement data as
of September 30, 2016 and for the nine months ended September 30, 2015 and 2016 from our unaudited condensed interim financial
statements and related notes incorporated by reference in this prospectus supplement and the accompanying prospectus. Our results
for interim periods are not necessarily indicative of the results that may be expected for the entire year. You should read the
information presented below together with our financial statements, the notes to those statements and the other financial information
incorporated by reference in this prospectus supplement and the accompanying prospectus.</P>




<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months ended September 30,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(<B>unaudited</B>)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="11" STYLE="text-align: center">(U.S. Dollars, in thousands, except per share and weighted average shares data)</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Statement of Comprehensive Loss</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="11">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%">Revenues&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">12</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">7,014</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">3</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">3</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Cost of Revenues&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,050</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Research and development expenses, net&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,100</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,700</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,771</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,820</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,745</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">General and administrative expenses&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,684</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,011</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,134</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,420</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,807</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating loss&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,772</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,647</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,002</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,237</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(21,551</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Financial income&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">158</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">319</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,124</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">889</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">548</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Financial expenses&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(383</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(212</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(182</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Financial expenses, net&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(144</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(64</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(912</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(707</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(531</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss and comprehensive loss&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,628</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,711</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(21,090</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14,530</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(21,020</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss per ordinary share (in U.S. dollars):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Basic -&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.17</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.12</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.19</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.14</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.17</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Diluted -&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.17</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.13</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.19</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.14</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.17</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Number of Ordinary Shares used in computing Loss per ordinary share (in thousands):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Basic -&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,379</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">86,610</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,814</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">105,328</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127,317</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Diluted -&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,379</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">87,222</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,715</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106,334</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127,615</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of September 30, 2016</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Actual</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As Adjusted</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(<B>unaudited</B>)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center">(U.S. Dollars, in thousands)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Balance Sheet Data</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left">Cash and short term investments&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">40,503</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Working capital&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,245</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total assets&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,880</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total liabilities&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,395</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accumulated deficit&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81,646</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Equity&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,485</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; margin: 0pt 0"></P>









<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;______________________</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(1)</B> See Note 2(P) of the notes to the financial statements
incorporated by reference in this prospectus supplement and the accompanying prospectus for an explanation of the determination
of the number of shares used to compute basic and dilutive per share amounts for the years ended December&nbsp;31, 2013, 2014 and
2015 and the nine months ended September 30, 2015 and 2016. Due to the anti-dilutive effect, basic loss per share was equal to
diluted loss per share for the year ended December 31, 2013.</P>




<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The as adjusted balance sheet data above reflects the application
of the net proceeds from the sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADSs representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Ordinary Shares and the sale of warrants to purchase ADSs, assuming that none of the warrants issued in this offering is exercised,
after deducting estimated underwriting discounts and commissions and estimated offering expenses.</P>




<P STYLE="font-size: 10pt; margin: 0pt 0"></P>


<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><A NAME="a_005"></A><B>RISK FACTORS</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>You should carefully consider the risks described below and in
our annual report on Form&nbsp;20-F for the year ended December&nbsp;31, 2015, as well as the other information included or incorporated
by reference in this prospectus supplement and the accompanying prospectus, including our financial statements and the related
notes, before you decide to buy our securities. The risks and uncertainties described below and incorporated by reference in this
prospectus supplement are not the only risks facing us. We may face additional risks and uncertainties not currently known to us
or that we currently deem to be immaterial. Any of the risks described below or incorporated by reference in this prospectus supplement,
and any such additional risks, could materially adversely affect our business, financial condition or results of operations. In
such case, you may lose all or part of your original investment.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Risks Related to Our Financial Condition and Capital Requirements</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We are a clinical development-stage biopharmaceutical company
with a history of operating losses. We expect to incur additional losses in the future and may never be profitable.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a clinical development-stage biopharmaceutical company.
Since our incorporation in 2009, we have been focused primarily on the development and acquisition of late clinical-stage therapeutic
candidates. All of our therapeutic candidates are in the clinical development stage, and, except for RIZAPORT<SUP>&reg;</SUP> which
has been approved for marketing in Germany but has yet to be marketed, none has been approved for marketing or is being marketed
or commercialized. Most of our therapeutic candidates require additional clinical trials before we can obtain the regulatory approvals
in order to initiate commercial sales. We have incurred losses since inception, principally as a result of research and development
and general and administrative expenses in support of our operations. We experienced net losses of approximately $21.1 million
in 2015 and $10.7 million in 2014. As of September 30, 2016, we had an accumulated deficit of approximately $81.6 million. We may
incur significant additional losses as we continue to focus our resources on prioritizing, selecting and advancing our therapeutic
candidates. Our ability to generate revenue and achieve profitability depends mainly upon our ability, alone or with others, to
successfully develop our therapeutic candidates, obtain the required regulatory approvals in various territories and commercialize
our therapeutic candidates. We may be unable to achieve any or all of these goals with regard to our therapeutic candidates. As
a result, we may never be profitable or achieve significant and/or sustained revenues.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Our limited operating history makes it difficult to evaluate
our business and prospects.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have a limited operating history and our operations to date
have been limited primarily to acquiring and in-licensing therapeutic candidates, research and development, raising capital and
recruiting scientific and management personnel and third party partners. Except with respect to RHB-106 and related rights, which
is out-licensed to Valeant Pharmaceutical International, Inc. (&ldquo;Valeant&rdquo;), and with respect to RIZAPORT<SUP>&reg;</SUP>,
for which we have received marketing approval in Germany and which was out-licensed in July 2016 to Grupo JUSTE for the commercialization
in Spain, and a right of first refusal for additional territories, and which was out-licensed in December 2016 to Pharmatronic
Co. for commercialization in South Korea, we have not yet demonstrated an ability to commercialize or obtain regulatory approval
for any of our therapeutic candidates. Consequently, any predictions about our future performance may not be accurate, and you
may not be able to fully assess our ability to complete development and/or commercialize our therapeutic candidates, obtain regulatory
approvals, or achieve market acceptance or favorable pricing for our therapeutic candidates.&nbsp;</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Our current working capital is not sufficient to complete
our research and development with respect to all of our therapeutic candidates. We will need to raise additional capital to achieve
our strategic objectives of acquiring, developing and commercializing therapeutic candidates, and our failure to raise sufficient
capital would significantly impair our ability to fund our operations, develop our therapeutic candidates, attract development
and/or commercial partners and retain key personnel.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We have funded our operations primarily through public and private offerings of our securities. We plan to
fund our future operations through commercialization and out-licensing of our therapeutic candidates and raising additional capital.
As of September 30, 2016, we had cash and short-term investments of approximately $40.5 million, and as of December 31, 2015, we
had cash and short-term investments of approximately $58.1 million. These amounts are not sufficient to complete the research and
development of all of our therapeutic candidates, and accordingly we may need to raise additional capital in the coming year.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">To date, our business generated limited revenues. As we plan to
continue expending substantial funds in research and development, including clinical trials, as well as to acquire additional products,
we will need to raise additional capital in the future through either debt or equity financing or pursuant to development or commercialization
agreements with third parties with respect to particular therapeutic candidates. However, we cannot be certain that we will be
able to raise capital on commercially reasonable terms or at all, or that our actual cash requirements will not be greater than
anticipated. We may have difficulty raising needed capital or securing a development or commercialization partner in the future
as a result of, among other factors, our lack of revenues from commercialization of the therapeutic candidates, as well as the
inherent business risks associated with our company, our therapeutic candidates and present and future market conditions. In addition,
global and local economic conditions may make it more difficult for us to raise needed capital or secure a development or commercialization
partner in the future and may impact our liquidity. If we are unable to obtain future financing or obtain sufficient future financing,
we may be forced to delay, reduce the scope of, or eliminate one or more of our research, development or commercialization programs
for our therapeutic candidates, any of which may have material adverse effect on our business, financial condition and results
of operations. Moreover, to the extent we are able to raise capital through the issuance of debt or equity securities, it could
result in substantial dilution to existing shareholders.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Our long term capital requirements are subject to numerous risks.</I></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Our long term capital requirements are expected to depend on many potential factors,
including:&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the number of therapeutic candidates in development;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the regulatory clarity and path of each of our therapeutic candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the progress, success and cost of our clinical trials and research and development programs including manufacturing;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the identification and acquisition of additional therapeutic candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the costs, timing and outcome of regulatory review and obtaining regulatory clarity and approval of our therapeutic candidates and addressing regulatory and other issues that may arise post-approval;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the costs of enforcing our issued patents and defending intellectual property-related claims;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the costs of manufacturing, developing sales, marketing and distribution channels;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our ability to successfully commercialize our therapeutic candidates, including through securing commercialization agreements with third parties and favorable pricing and market share or through securing our own commercialization capabilities; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our consumption of available resources more rapidly than currently anticipated, resulting in the need for additional funding sooner than anticipated.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Risks Related to Our Business and Regulatory Matters</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify"><B><I>If we and/or our commercialization partners are unable to
obtain FDA and/or other foreign regulatory authority clearance and approval for our therapeutic candidates, we and/or our commercialization
partners will be unable to commercialize our therapeutic candidates.</I></B></P>



<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, we have not marketed, distributed or sold any therapeutic
candidate or other product. Currently, we have eight therapeutic candidates, which include one therapeutic candidate (RP101) for
which we have an option to acquire, in various programs and clinical development stages, RHB-105 for the eradication of <I>H. pylori</I>
infection; RHB-104 for the treatment of Crohn&rsquo;s disease and potentially other diseases; RHB-106 (out-licensed to Valeant)
for bowel preparation; BEKINDA<SUP>&reg;</SUP> (RHB-102) for acute gastroenteritis and gastritis, IBS-D and for the prevention
of chemotherapy and radiotherapy induced nausea and vomiting; YELIVA<SUP>&reg;</SUP> (ABC294640), a sphingosine kinase-2 selective
inhibitor targeting multiple oncology, GI and inflammatory indications; MESUPRON targeting GI and other solid tumor cancers; RP101
(currently subject to an option-to-acquire by us) targeting pancreatic and other GI cancers; and RIZAPORT<SUP>&reg;</SUP> (RHB-103)
for the treatment of acute migraine headaches. Our therapeutic candidates are subject to extensive governmental laws, regulations
and guidelines relating to development, clinical trials, manufacturing and commercialization of drugs. Other than RIZAPORT<SUP>&reg;</SUP>
which has received marketing approval to date only in Germany, we may not be able to obtain marketing approval for any of our therapeutic
candidates in a timely manner or at all.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Any material delay in obtaining, or the failure to obtain, required
regulatory clarity and approvals will increase our costs and materially and adversely affect our ability to generate future revenues.
Any regulatory approval to market a therapeutic candidate may be subject to limitations on the indicated uses for marketing the
therapeutic candidate or may impose restrictive conditions of use, including cautionary information, thereby limiting the size
of the market for the therapeutic candidate. We also are, and will be, subject to numerous regulatory requirements from both the
FDA and foreign state agencies that govern the conduct of clinical trials, manufacturing and marketing authorization, pricing and
third-party reimbursement. Moreover, approval by one regulatory authority does not ensure approval by other regulatory authorities
in separate jurisdictions. Each jurisdiction may have different approval processes and may impose additional testing, development
and manufacturing requirements for our therapeutic candidates than other jurisdictions. Additionally, the FDA or other foreign
regulatory bodies may change their approval policies or adopt new laws, regulations or guidelines in a manner that materially delays
or impairs our ability to obtain the necessary regulatory approvals or our ability to commercialize our therapeutic candidates.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Clinical trials and related non-clinical studies may involve
a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future
trial results. We and/or commercialization partners will not be able to commercialize our therapeutic candidates without completing
such trials.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We have limited experience in conducting and managing the clinical
trials that are required to commence commercial sales of our therapeutic candidates. Clinical trials and related non-clinical studies
are expensive, complex, can take many years and have uncertain outcomes. We cannot predict whether we, independently or through
third parties, will encounter problems with any of the completed, ongoing or planned clinical trials that will cause delays, including
suspension of a clinical trial, delay of data analysis or release of the final report. The clinical trials of our therapeutic candidates
may take significantly longer to complete than is estimated. Failure can occur at any stage of the testing and we may experience
numerous unforeseen events during, or as a result of, the clinical trial process that could materially delay or prevent commercialization
of our current or future therapeutic candidates.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In connection with the clinical trials for our therapeutic candidates
and other therapeutic candidates that we may seek to develop in the future, either on our own or through licensing or partnering
agreements, we face various risks and uncertainties, including but not limited to:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">delays in securing clinical investigators or trial sites for the clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">delays in receiving import or other government approvals to ensure appropriate drug supply;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">delays in obtaining institutional review board and other regulatory approvals to commence a clinical trial;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">expiration of clinical trial material before or during our trials as a result of degradation of, or other damage to, the clinical trial material;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">negative or inconclusive results from clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the FDA or other foreign regulatory authorities may disagree with the number, design, size, conduct or implementation of our clinical studies;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the FDA or other foreign regulatory authorities may require us to conduct additional clinical trials and/or studies;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">inability to monitor patients adequately during or after treatment;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">problems with investigator or patient compliance with the trial protocols;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a therapeutic candidate may not prove safe or efficacious; there may be unexpected or even serious adverse events and side effects from the use of a therapeutic candidate;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the results with respect to any therapeutic candidate may not confirm the positive results from earlier preclinical studies or clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the results may not meet the level of statistical significance required by the FDA or other foreign regulatory authorities;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the results may justify only limited and/or restrictive uses, including the inclusion of warnings and contraindications, which could significantly limit the marketability and profitability of a therapeutic candidate;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the clinical trials may be delayed or not completed due to the failure to recruit suitable candidates or if there is a lower rate of suitable candidates than anticipated or if there is a delay in recruiting suitable candidates; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes to the current regulatory requirements related to clinical trials which can delay, hinder or lead to unexpected costs in connection with our receiving the applicable regulatory approvals.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">A number of companies in the pharmaceutical and biotechnology industries,
including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials,
even after seeing promising results in earlier clinical trials. As such, despite the results reported in earlier clinical trials
of our therapeutic candidates, we do not know if the clinical trials we conduct will demonstrate adequate efficacy and safety sufficient
to obtain regulatory approval to market our therapeutic candidates. If any of the clinical trials of any therapeutic candidate
do not produce favorable results, our ability to obtain regulatory approval for the therapeutic candidate may be adversely impacted,
which will have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>














<!-- Field: Page; Sequence: 16; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>If we do not establish collaborations for our therapeutic
candidates or otherwise raise substantial additional capital, we will likely need to alter our development and any commercialization
plans.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our drug development programs and the potential commercialization
of our therapeutic candidates will require additional cash to fund expenses. As such, our strategy includes either selectively
partnering or collaborating with multiple pharmaceutical and biotechnology companies to assist us in furthering development and/or
potential commercialization of our therapeutic candidates, in whole or in part, in some or all jurisdictions or through securing
our own commercialization capabilities. Although we are currently aware of numerous potential new third party partners for the
development or commercialization of our therapeutic candidates, we may not be successful in entering into new collaborations with
third parties on acceptable terms, or at all. In addition, if we fail to negotiate and maintain suitable development and/or commercialization
agreements or otherwise raise substantial additional capital to secure our own commercialization capabilities, we may have to limit
the size or scope of our activities or we may have to delay one or more of our development or commercialization programs. Any failure
to enter into development or commercialization agreements with respect to the development, marketing and commercialization of any
therapeutic candidate or failure to develop, market and commercialize such therapeutic candidate independently will have an adverse
effect on our business, financial condition and results of operations.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Any collaborative arrangements that we have established or may establish may not be successful or we may otherwise
not realize the anticipated benefits from these collaborations, including our out-license of RHB-106. We do not control third parties
with whom we have or may have collaborative arrangements, and we rely on them to achieve results which may be significant to us.
In addition, any future collaborative arrangements may place the development and commercialization of our therapeutic candidates
outside our control, may require us to relinquish important rights or may otherwise be on terms unfavorable to us.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Each of our collaborative arrangements requires us to rely on external
consultants, advisors, and experts for assistance in several key functions, including clinical development, manufacturing, regulatory,
market research, intellectual property and commercialization. We do not control these third parties, but we rely on them to achieve
results which may be significant to us. To date, we have out-licensed one of our therapeutic candidates, RHB-106 and related rights
to Valeant. We do not control Valeant, but we rely on Valeant to clinically develop and commercialize the product based on the
license agreement.&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Relying upon collaborative arrangements to develop and commercialize
our therapeutic candidates, such as our out-license of RHB-106 and related rights, subjects us to a number of risks, including&nbsp;but
not limited to:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may not be able to control the amount and timing of resources that our collaborators may devote to our therapeutic candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">should a collaborator fail to comply with applicable laws, rules, or regulations when performing services for us, we could be held liable for such violations;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our collaborators may experience financial difficulties or changes in business focus;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">our collaborators&rsquo; partners may fail to secure adequate commercial supplies of our therapeutic candidates upon marketing
approval, if at all;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">our collaborators&rsquo; partners may have a shortage of qualified personnel;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may be required to relinquish important rights, such as marketing and distribution rights;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">business combinations or significant changes in a collaborator&rsquo;s business or business strategy may adversely affect a collaborator&rsquo;s willingness or ability to complete its obligations under any arrangement;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">under certain circumstances, a collaborator could move forward with a competing therapeutic candidate developed either independently or in collaboration with others, including our competitors; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">collaborative arrangements are often terminated or allowed to expire, which could delay the development and may increase the cost of developing our therapeutic candidates.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">If any of these scenarios materialize, they could have an adverse
effect on our business, financial condition or results of operations.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>
<!-- Field: Page; Sequence: 17; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We may not be successful in acquiring products and/or companies
that own the rights to FDA-approved products (approved for marketing in the U.S.) that achieve commercial success or building our
own marketing and commercialization capabilities.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Part of our strategy is to identify and acquire rights to products
that have been approved for marketing in the U.S. Specifically, we seek to acquire rights to products that are already commercialized
in the U.S., which would enable us to commercialize such products independently and build our own marketing and commercialization
capabilities. However, there can be no assurance as to our ability to identify and acquire rights to such products, in particular
those with a therapeutic focus on GI, inflammation and/or cancer. If we are not successful in acquiring any such products, we may
not be able to build our own marketing and commercialization capabilities. This may limit our ability to commercialize our products
on our own or require us to contract with third party commercialization partners which may not be on commercially favorable terms
and which may result in additional commercialization and marketing expenses.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In addition, there can be no assurance as to our ability to accurately
or consistently identify products approved for marketing in the U.S. that will achieve commercial success or that we will successfully
commercialize these products in the U.S.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We may encounter difficulties successfully expanding our operations
to build our own marketing and commercialization capabilities.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">To build our own marketing and commercialization
capabilities, we would need to expand our development, regulatory, manufacturing, marketing and sales capabilities and to increase
our personnel to accommodate sales, including establishing a direct sales force and a complete commercial team. Expanding our operations
would also impose significant added responsibilities on our management. We must be able to manage our independent commercialization
efforts effectively; hire, train and integrate additional management, development, administrative and sales and marketing personnel;
improve our managerial, development, operational and finance systems, all of which may impose a strain on our administrative and
operational infrastructure and adversely affect our research and development activities. We may also not have sufficient funds
to finance the hiring of the additional personnel and the expansion of our marketing and commercialization activities. If we are
not able to effectively expand our operations to build our own marketing and commercialization capabilities, our revenues and growth
may be adversely affected, which will have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We have no history of independently commercializing therapeutic
candidates and may have difficulty commercializing products on our own.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We have no prior experience in commercializing therapeutic candidates
on our own, which may materially increase marketing and sales expenses. There can be no assurance we will successfully commercialize
our products or the products we acquire.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">In addition, many companies, both public
and private, including well-known pharmaceutical companies and smaller niche-focused companies, are currently distributing drug
products that directly compete with the therapeutic candidates that we may seek to commercialize. Many of these companies have
significantly greater financial, marketing and sales experience and resources than us. As a result, our competitors may be more
successful than we are in commercializing their products to consumers.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><B><I>We rely on third parties to conduct
our clinical trials and related non-clinical studies and those third parties may not perform satisfactorily, including but not
limited to failing to meet established deadlines for the completion of such clinical trials.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We currently do not have the ability to independently conduct clinical
trials and related non-clinical studies for our therapeutic candidates, and we rely on third parties, such as contract research
organizations, medical institutions, contract laboratories, development and commercialization partners, clinical investigators
and independent study monitors to perform these functions. Our reliance on these third parties for clinical development activities
reduces our control over these activities. Furthermore, these third parties may also have relationships with other entities, some
of which may be our competitors. Although we have, in the ordinary course of business, entered into agreements with such third
parties, other than with respect to RHB-106 and related rights, which we have out-licensed to Valeant, we continue to be responsible
for confirming that each of our clinical trials is conducted in accordance with its general investigational plan and protocol.
Moreover, the FDA requires us to comply with regulations and standards, commonly referred to as good clinical practices, for conducting,
recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that
the trial participants are adequately protected. Our reliance on third parties does not relieve us of these responsibilities and
requirements. To date, we believe our contract research organizations and other similar entities with which we are working have
performed well. However, if these third parties do not successfully carry out their contractual duties or meet expected deadlines,
we may be required to replace them or perform such functions independently. Although we believe that there are a number of other
third-party contractors we could engage to continue these activities, it may result in a delay of the affected trial and additional
costs. Accordingly, we may be materially delayed in obtaining regulatory approvals for our therapeutic candidates and may be materially
delayed in our efforts to successfully commercialize our therapeutic candidates for targeted diseases.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In addition, our ability to bring our therapeutic candidates to
market depends on the quality and integrity of data that we present to regulatory authorities in order to obtain marketing authorizations.
Although we attempt to audit and control the quality of third party data, we cannot guarantee the authenticity or accuracy of such
data, nor can we be certain that such data has not been fraudulently generated.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>If third parties do not manufacture our therapeutic candidates
with sufficient quality, in sufficient quantities, in the required timeframe, and at an acceptable cost, clinical development and
commercialization of our therapeutic candidates would be delayed.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We do not currently own or operate manufacturing facilities, and
we rely, and expect to continue to rely, on third parties to manufacture clinical and commercial quantities of our therapeutic
candidates. Our reliance on third parties includes our reliance on them for quality assurance related to regulatory compliance.
Our current and anticipated future reliance upon others for the manufacture of our therapeutic candidates may adversely affect
our future profit margins, if any, and our ability to develop therapeutic candidates and commercialize any therapeutic candidates
on a timely and competitive basis.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We may not be able to maintain our existing or future third-party
manufacturing arrangements on acceptable terms, if at all. If for some reason our manufacturers do not perform as agreed or expected,
we may be required to replace them. Although we are not substantially dependent upon our existing manufacturing agreements since
we could replace them with other third party manufacturers, we may incur added costs and delays in identifying, engaging, qualifying
and training any such replacements.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We rely on third-party-contract vendors to manufacture and
supply us with high quality active pharmaceutical ingredients in the quantities we require on a timely basis.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We currently do not manufacture any active pharmaceutical ingredients
ourselves. Instead, we rely on third-party vendors for the manufacture and supply of our active pharmaceutical ingredients that
are used to formulate our therapeutic candidates. While there are many potential active pharmaceutical ingredient suppliers in
the market, if these suppliers are incapable or unwilling to meet our current or future needs on acceptable terms or at all, we
could experience a delay in obtaining regulatory approval for our therapeutic candidates or conducting additional clinical trials
of our therapeutic candidates and incur additional costs.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For example, our supplier of raw materials for RIZAPORT<SUP>&reg;</SUP>
has been sending updates to the FDA regarding progress of corrective actions in regard to compliance issues at its manufacturing
facility and subsequently invited the FDA for re-inspection, which are independent of us and not specific to RIZAPORT<SUP>&reg;</SUP>.
Although we were informed that the supplier recently resolved these compliance issues and although we have been working to ensure
continued supply of the necessary raw materials for RIZAPORT<SUP>&reg;</SUP> from an alternative supplier, our ability to obtain
FDA approval for RIZAPORT<SUP>&reg;</SUP> may be delayed until we are able to successfully manufacture new batches with the new
active pharmaceutical ingredient secured from a compliant source of active pharmaceutical ingredient.</P>






<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">While there may be several alternative suppliers of active pharmaceutical
ingredient on the market, we have yet to conclude extensive investigations into the quality or availability of their active pharmaceutical
ingredients. As a result, we can provide no assurances that supply sources will not be interrupted from time to time. Changing
active pharmaceutical ingredient suppliers or finding and qualifying new active pharmaceutical ingredient suppliers can be costly
and take a significant amount of time. Many active pharmaceutical ingredients require significant lead time to manufacture. There
can also be challenges in maintaining similar quality or technical standards from one manufacturing batch to the next.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;<BR>
If we are not able to find stable, affordable, high quality, or reliable supplies of our active pharmaceutical ingredients, we
may not be able to produce enough supplies of our therapeutic candidates, which could materially adversely affect our business,
financial condition or results of operations.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We anticipate continued reliance on third-party manufacturers
if we are successful in obtaining marketing approval from the FDA and other regulatory agencies for any of our therapeutic candidates.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">To date, our therapeutic candidates have been manufactured in relatively
small quantities for preclinical testing and clinical trials as well as for other regulatory purposes by third-party manufacturers.
If the FDA or other regulatory agencies approve any of our therapeutic candidates for commercial sale, we expect that we would
continue to rely, at least initially, on third-party manufacturers to produce commercial quantities of our approved therapeutic
candidates. These manufacturers may not be able to successfully increase the manufacturing capacity for any of our approved therapeutic
candidates in a timely or economic manner, or at all. Significant scale-up of manufacturing may require additional validation studies,
which the FDA or other foreign regulatory agencies must review and approve. If they are unable to successfully increase the manufacturing
capacity for a therapeutic candidate, or we are unable to establish our own manufacturing capabilities or secure replacement manufacturers,
the commercial launch of any approved products may be delayed or there may be a shortage in supply.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We and our third-party manufacturers are, and will be, subject
to regulations of the FDA and other foreign regulatory authorities.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We and our contract manufacturers are, and will be, required to
adhere to laws, regulations and guidelines of the FDA or other foreign regulatory authorities setting forth current good manufacturing
practices. These laws, regulations and guidelines cover all aspects of the manufacturing, testing, quality control and recordkeeping
relating to our therapeutic candidates. We and our manufacturers may not be able to comply with applicable laws, regulations and
guidelines. We and our manufacturers are and will be subject to unannounced inspections by the FDA, state regulators and similar
foreign regulatory authorities outside the U.S. Our failure, or the failure of our third-party manufacturers, to comply with applicable
laws, regulations and guidelines could result in the imposition of sanctions on us, including fines, injunctions, civil penalties,
failure of regulatory authorities to grant marketing approval of our therapeutic candidates, delays, suspension or withdrawal of
approvals, license revocation, seizures or recalls of our therapeutic candidates, operating restrictions and criminal prosecutions,
any of which could significantly and adversely affect regulatory approval and supplies of our therapeutic candidates, and materially
and adversely affect our business, financial condition and results of operations.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Even if we obtain regulatory approvals, our therapeutic candidates
will be subject to ongoing regulatory review. If we fail to comply with continuing U.S. and applicable foreign laws, regulations
and guidelines, we could lose those approvals, and our business may be seriously harmed.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Even if our therapeutic candidates receive regulatory approval,
we or our commercialization partners, as applicable, will be subject to ongoing reporting obligations, including pharmacovigilance,
and the therapeutic candidates and the manufacturing operations will be subject to continuing regulatory review, including inspections
by the FDA or other foreign regulatory authorities. The results of this ongoing review may result in the withdrawal of a therapeutic
candidate from the market, the interruption of the manufacturing operations and/or the imposition of labeling and/or marketing
limitations. Since many more patients are exposed to drugs following their marketing approval, serious but infrequent adverse reactions
that were not observed in clinical trials may be observed during the commercial marketing of the therapeutic candidate. As we develop
our product candidates, we may also periodically discuss with the FDA certain clinical, regulatory and manufacturing matters and
our views may, at times, differ from those of the FDA. For example, the FDA may seek to regulate our therapeutic candidates that
consist of two or more active ingredients as combination drugs under its Combination Drug Policy. The Combination Drug Policy requires
that we demonstrate that each active ingredient in a drug product contributes to the product&rsquo;s claimed effect. If the FDA
raises questions regarding whether available data and information provided to the FDA demonstrate the contribution of each active
ingredient in such combination drug products, we may be required to provide additional information, which may include the results
of additional preclinical studies or clinical trials. If we are required to conduct additional clinical trials or other testing
of our product candidates, we may face substantial additional expenses, be delayed in obtaining marketing approval for our product
candidates or may never obtain marketing approval.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In addition, the manufacturer and the manufacturing facilities that
we or our commercialization partners use to produce any therapeutic candidate will be subject to periodic review and inspection
by the FDA and other foreign regulatory authorities. Later discovery of previously unknown problems with any therapeutic candidate,
manufacturer or manufacturing process, or failure to comply with rules and regulatory requirements, may result in actions, including
but not limited to the following:</P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">restrictions on such therapeutic candidate, manufacturer or manufacturing process;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">warning letters from the FDA or other foreign regulatory authorities;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">withdrawal of the therapeutic candidate from the market;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">suspension or withdrawal of regulatory approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">refusal to approve pending applications or supplements to approved applications that we or our commercialization partners&nbsp;submit;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">voluntary or mandatory recall;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">fines;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">refusal to permit the import or export of our therapeutic candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">product seizure or detentions;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">injunctions or the imposition of civil or criminal penalties; or</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">adverse publicity.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">If we, or our commercialization partners, suppliers, third party
contractors or clinical investigators are slow to adapt, or are unable to adapt, to changes in existing regulatory requirements
or the adoption of new regulatory requirements or policies, we or our commercialization partners may lose marketing approval for
any of our therapeutic candidates if any of our therapeutic candidates are approved, resulting in decreased or lost revenue from
milestones, product sales or royalties.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Modifications to our therapeutic candidates, or to any other
therapeutic candidates that we may acquire or develop in the future, may require new regulatory clearances or approvals or may
require us or our development and/or commercialization partners, as applicable, to recall or cease marketing of these therapeutic
candidates until clearances are obtained.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Modifications to our therapeutic candidates, after they have been
approved for marketing, if at all, or to any other pharmaceutical product or medical device that we may acquire or develop in the
future, may require new regulatory clearance or approvals, and, if necessitated by a problem with a marketed product, may result
in the recall or suspension of marketing of the previously approved and marketed product until clearances or approvals of the modified
product are obtained. The FDA and other foreign regulatory authorities require pharmaceutical products and device manufacturers
to initially make and document a determination of whether or not a modification requires a new approval, supplement or clearance.
A manufacturer may determine in conformity with applicable laws, regulations and guidelines that a modification may be implemented
without pre-clearance by the FDA or other foreign regulatory authorities. However, the FDA or other foreign regulatory authorities
can review a manufacturer&rsquo;s decision and may disagree. The FDA or other foreign regulatory authorities may also on their
own initiative determine that a new clearance or approval is required. If the FDA or other foreign regulatory authorities require
new clearances or approvals of any pharmaceutical product for which we or our partners, including development and/or commercialization
partners previously received marketing approval, we or our partners, including development and/or commercialization partners may
be required to recall such therapeutic candidate and to stop marketing the therapeutic candidate as modified, which could require
us or our partners, including development and/or commercialization partners to redesign the therapeutic candidate and may cause
a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We depend on our ability to identify and in-license or acquire
therapeutic candidates to achieve commercial success, including products approved for marketing in the U.S.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our eight therapeutic candidates were all acquired by us from or
licensed to us by third parties, other than RP101 for which we have an option to acquire. We evaluate internally and with external
consultants each therapeutic candidate. However, there can be no assurance as to our ability to accurately or consistently identify
therapeutic candidates that are likely to achieve commercial success, specifically therapeutic candidates that have been approved
for marketing in the U.S. In addition, even if we identify additional therapeutic candidates that are likely to achieve commercial
success, there can be no assurance as to our ability to in-license or acquire such therapeutic candidates under favorable terms
or at all.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We compete with other entities for some of our in-license
or acquisition opportunities.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">As part of our overall strategy, we pursue opportunities to in-license
or acquire therapeutic candidates. We may compete for in-license and acquisition opportunities with other, established and well-capitalized
companies. As a result, we may be unable to in-license or acquire additional therapeutic candidates at all or on favorable terms.
Our failure to further in-license or acquire therapeutic candidates in the future may materially hinder our ability to grow and
could materially harm our business, financial condition and results of operations.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>If we cannot meet our obligations under our acquisition or
in-license agreements or we cannot renegotiate our obligations, or if other events occur that are not within our control such as
bankruptcy of a licensor, we could lose the rights to our therapeutic candidates and/or experience delays in developing and/or
commercializing our therapeutic candidates, or incur additional costs, which could have a material adverse effect on our business.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We acquired our rights to three of our therapeutic candidates,
RHB-105, RHB-104 and RHB-106, from a third party pursuant to an asset and purchase agreement. In addition, we in-licensed our rights
to four other therapeutic candidates, BEKINDA<SUP>&reg;</SUP>, YELIVA<SUP>&reg;</SUP>, MESUPRON and RIZAPORT<SUP>&reg;</SUP> pursuant
to license agreements under which we received exclusive perpetual licenses to certain patent rights and know-how related to these
therapeutic candidates. We have also obtained an option-to-acquire for RP101. These agreements require us to make payments and
satisfy various performance obligations in order to maintain our rights and licenses with respect to these therapeutic candidates.
If we do not meet our obligations under these agreements, or if other events occur that are not within our control such as the
bankruptcy of a licensor, we could lose the rights to our therapeutic candidates, experience delays in developing and/or commercializing
our therapeutic candidates and/or incur additional costs, any of which could have a material adverse effect on our business, financial
condition and results of operations. In addition, our agreement with IntelGenx Corp. requires us to renegotiate certain provisions
of the agreement in the event the agreed-to budget is exceeded by a certain amount. In the event we are required to renegotiate
this agreement, there is no guarantee that we will agree upon new terms promptly, or at all, which could delay the development
and/or commercialization of RIZAPORT<SUP>&reg;</SUP>. Moreover, if we elect not to exercise the option-to-acquire RP101, the term
of which was extended in August 2016 for an additional nine months period, we may lose all of our rights in relation to RP101.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In addition, we are responsible for the cost of filing and prosecuting
certain patent applications and maintaining certain issued patents licensed to us. If we do not meet our obligations under these
agreements in a timely manner&nbsp;and/or if other events occur that are not within our control, such as the bankruptcy of a licensor,
which impacts our ability to prosecute certain patent applications and maintain certain issued patents licensed to us, we could
lose the rights to our therapeutic candidates which could have a material adverse effect on our business, financial condition and
results of operations. We manage a large portfolio of patents and may decide to discontinue maintaining certain patents in certain
territories for various reasons, such as a current belief that the commercial market for the therapeutic candidate will not be
large or that there is a near-term patent expiration that may reduce the value of the therapeutic candidate. In the event we discontinue
maintaining such patents, we may not be able to enforce rights for our therapeutic candidates or protect our therapeutic candidates
from competition in those territories.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Our business could suffer if we are unable to attract and
retain key employees.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The loss of the services of members of senior management or other
key personnel could delay or otherwise adversely impact the successful completion of our planned clinical trials or the commercialization
of our therapeutic candidates or otherwise affect our ability to manage our company effectively and to carry out our business plan.
These key personnel are Dror Ben-Asher, our chief executive officer, and Reza Fathi PhD, our senior vice president for research
and development. We do not maintain key-man life insurance. Although we have entered into employment or consultancy agreements
with all of the members of our senior management team, members of our senior management team may resign at any time. High demand
exists for senior management and other key personnel in the pharmaceutical industry. There can be no assurance that we will be
able to continue to retain and attract such personnel.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Our growth and success also depend
on our ability to attract and retain additional highly qualified scientific, technical, business development, marketing, managerial
and finance personnel. We experience intense competition for qualified personnel, and the existence of non-competition agreements
between prospective employees and their former employers may prevent us from hiring those individuals or subject us to liability
from their former employers. In addition, if we elect to independently commercialize any therapeutic candidate or if we acquire
rights to therapeutic candidates which are already approved for marketing and/or are already commercialized, we will need to build
and expand our marketing and sales capabilities. While we attempt to provide competitive compensation packages to attract and retain
key personnel, many of our competitors are likely to have greater resources and more experience than we have, making it difficult
for us to compete successfully for key personnel. If we cannot attract and retain sufficiently qualified suitable employees on
acceptable terms, we may not be able to develop and commercialize competitive therapeutic candidates. Further, any failure to effectively
integrate new personnel could materially prevent us from successfully growing our company.</FONT>&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We face several risks associated with international business</I>.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We operate our business in multiple international jurisdictions.
Such operations could be materially affected by changes in foreign exchange rates, capital and exchange controls, expropriation
and other restrictive government actions, changes in intellectual property legal protections and remedies, trade regulations and
procedures and actions affecting approval, production, pricing, and marketing of, reimbursement for and access to, our therapeutic
candidates, as well as by political unrest, unstable governments and legal systems and inter-governmental disputes. Any of these
changes could materially adversely affect our business.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Risks Related to Our Industry</B></FONT>&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Even if our therapeutic candidates receive regulatory approval
or do not require regulatory approval, they may not become commercially viable products.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except for RIZAPORT<SUP>&reg;</SUP>, which has been approved
for marketing in Germany and which was out-licensed in July 2016 to Grupo JUSTE for the commercialization in Spain, and a right
of first refusal for additional territories, and which was out-licensed in December 2016 to Pharmatronic Co. for commercialization
in South Korea, none of our therapeutic candidates has been approved for marketing or is being marketed or commercialized. Even
if our therapeutic candidates are approved for commercialization, they may not become commercially viable products. For example,
if we or our commercialization partners receive regulatory approval to market a therapeutic candidate, approval may be subject
to limitations on the indicated uses or subject to labeling or marketing restrictions which could materially and adversely affect
the marketability and profitability of the therapeutic candidate. In addition, a new therapeutic candidate may appear promising
at an early stage of development or after clinical trials but never reach the market, or it may reach the market but not result
in sufficient product sales, if any. A therapeutic candidate may not result in commercial success for various reasons, including
but not limited to:</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">difficulty in large-scale manufacturing, including yield and quality;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">low market acceptance by physicians, healthcare payors, patients and the medical community as a result of lower demonstrated clinical safety or efficacy compared to other products, prevalence and severity of adverse side effects, or other potential disadvantages relative to alternative treatment methods;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">insufficient or unfavorable levels of reimbursement from government or third-party payors, such as insurance companies, health maintenance organizations and other health plan administrators;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">infringement on proprietary rights of others for which we or our commercialization partners have not received licenses;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">incompatibility with other therapeutic products;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">other potential advantages of alternative treatment methods and competitive forces that may make it more difficult for us to penetrate a particular market segment, if at all;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ineffective marketing and distribution support;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">lack of significant competitive advantages over existing products on the market;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">lack of cost-effectiveness or unfavorable pricing compared to other alternatives available on the market;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">inability to establish collaborations with third party commercialization partners on acceptable terms, or at all, and our inability or unwillingness for cost or other reasons to commercialize the therapeutic candidates on our own; or</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">timing of market introduction of competitive products.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Physicians, various other health care
providers, patients, payors or the medical community in general may be unwilling to accept, utilize or recommend any of our approved
therapeutic candidates. If we are unable, either on our own or through third parties, to manufacture, commercialize and market
our proposed formulations or therapeutic candidates when planned, or to develop commercially viable therapeutic candidates, we
may not achieve any market acceptance or generate revenue.</FONT>&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>The market for our therapeutic candidates is rapidly changing
and competitive, and new drug delivery mechanisms, drug delivery technologies, new drugs and new treatments which may be developed
by others could impair our ability to maintain and grow our business and remain competitive.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The pharmaceutical and biotechnology industry is highly competitive,
and we face significant competition from many pharmaceutical, biopharmaceutical and biotechnology companies that are researching
and marketing products designed to address the indications for which we are currently developing therapeutic candidates or for
which we may develop therapeutic candidates in the future. There are various other companies that currently market, are in the
process of developing or may develop in the future products that address all of the indications or diseases treated by our therapeutic
candidates.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">New drug delivery mechanisms, drug delivery technologies, new drugs
and new treatments that have been developed or that are in the process of being developed or will be developed by others may render
our therapeutic candidates noncompetitive or obsolete, or we may be unable to keep pace with technological developments or other
market factors. Some of these technologies may have an entirely different approach or means of accomplishing similar therapeutic
effects compared to our therapeutic candidates. Technological competition from pharmaceutical and biotechnology companies, universities,
governmental entities and others is intense and is expected to increase. Many of these entities have significantly greater research
and development capabilities, human resources and budgets than we do, as well as substantially more marketing, manufacturing, financial
and managerial resources. These entities represent significant competition for us. Acquisitions of, or investments in, competing
pharmaceutical or biotechnology companies by large corporations could increase such competitors&rsquo; financial, marketing, manufacturing
and other resources.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The potential widespread acceptance of therapies that are alternatives
to ours may limit market acceptance of our formulations or therapeutic candidates, even if commercialized. Many of our targeted
diseases and conditions can also be treated by other medications or drug delivery technologies. These treatments may be widely
accepted in medical communities and have a longer history of use. The established use of these competitive drugs may limit the
potential for our therapeutic candidates to receive widespread acceptance if commercialized.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We could be adversely affected if healthcare reform measures
substantially change the market for medical care or healthcare coverage in the U.S.</I></B></P>





<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 23, 2010, President Obama signed the &ldquo;Patient
Protection and Affordable Care Act&rdquo; (P.L. 111-148) and on March 30, 2010, the President signed the &ldquo;Health Care and
Education Reconciliation Act&rdquo; (P.L. 111-152), collectively commonly referred to as the &ldquo;Healthcare Reform Law.&rdquo;
The Healthcare Reform Law included a number of new rules regarding health insurance, the provision of health care, and conditions
to reimbursement for healthcare services provided to Medicare and Medicaid patients. Through the law making process, substantial
changes have been and continue to be made to the current system for paying for healthcare in the U.S., including changes made in
order to extend medical benefits to tens of millions of Americans who lacked insurance coverage and to contain healthcare costs.
Extending coverage to a large population could substantially change the structure of the health insurance system and the methodology
for reimbursing medical services and drugs. This legislation is one of the most comprehensive and significant reforms ever experienced
by the U.S. in the healthcare industry and has significantly changed the way healthcare is financed by both governmental and private
insurers. This legislation has impacted the scope of healthcare insurance and the insurance refunds from the insurance companies,
among others.&nbsp;Additionally, the Healthcare Reform Law&rsquo;s provisions are designed to encourage providers to find cost
savings in their clinical operations. Pharmaceuticals represent a significant portion of the cost of providing care. Through modified
reimbursement rates and other incentives, the U.S. government is requiring that providers identify the most cost-effective services,
supplies and pharmaceuticals. This environment has caused changes in the purchasing habits of providers and resulted in specific
attention to the pricing negotiation, product selection and utilization review surrounding pharmaceuticals. To the extent that
our therapeutic candidates may at some point be reimbursable by U.S. federal government programs, this attention may result in
our therapeutic candidates being chosen less frequently or the pricing being substantially lowered. Some of the provisions of the
Healthcare Reform Law have not yet been fully implemented, and the effect of the legislation is difficult to predict. At this stage,
we are unable to estimate the full extent of the direct and/or indirect impact of the legislation on us.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These structural changes could entail further modifications
to the existing system of private payors and government programs (such as Medicare, Medicaid and state Children&rsquo;s Health
Insurance Program), creation of a government-sponsored healthcare insurance source, or some combination of both, as well as other
changes. Restructuring the coverage of medical care in the U.S. could impact the reimbursement for prescribed drugs and pharmaceuticals,
such as those we and our development and/or commercialization partners are currently developing. If reimbursement for our approved
therapeutic candidates, if any, is substantially reduced in the future, or rebate obligations associated with them are substantially
increased, our business could be materially and adversely impacted.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Extending medical benefits to those who currently lack coverage
will likely result in substantial cost to the U.S. federal government, which may force significant additional changes to the healthcare
system in the U.S. Much of the funding for expanded healthcare coverage may be sought through cost savings. While some of these
savings may come from realizing greater efficiencies in delivering care, improving the effectiveness of preventive care and enhancing
the overall quality of care, much of the cost savings may come from reducing the cost of care and increased enforcement activities.
Cost of care could be reduced by decreasing the level of reimbursement for medical services or products (including those therapeutic
candidates currently being developed by us or our development and/or commercialization partners), or by restricting coverage (and,
thereby, utilization) of medical services or products. In either case, a reduction in the utilization of, or reimbursement for,
any therapeutic candidate for which we receive marketing approval in the future could have a materially adverse effect on our financial
performance.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Several states and private entities initially mounted legal
challenges to the Healthcare Reform Law, and they continue to litigate various aspects of the legislation. On July 26, 2012, the
U.S. Supreme Court generally upheld the healthcare reform legislation as constitutional. However, the Supreme Court held that the
legislation improperly required the states to expand their Medicaid programs to cover more individuals. As a result, the states
have a choice as to whether they will expand the numbers of individuals covered by their respective state Medicaid programs. Some
states have determined that they will not expand their Medicaid programs and will develop other cost saving and coverage measures
to provide care to currently uninsured residents. Many of these efforts to date have included the institution of Medicaid managed
care programs. The manner in which these cost saving measures are implemented could have a materially adverse effect on our financial
performance. Further, the healthcare regulatory environment has seen significant changes in recent years and is still in flux.
Legislative initiatives to modify or repeal the Healthcare Reform Law and judicial challenges continue, and may increase in light
of the change in administrations following the presidential election. We cannot predict the impact on our business of future legal
challenges to the Healthcare Reform Legislation or other changes to the current laws and regulations.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>If third-party payors do not adequately reimburse customers
for any of our therapeutic candidates that are approved for marketing, they might not be purchased or used, and our revenues and
profits will not develop or increase.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our revenues and profits will depend heavily upon the availability
of adequate reimbursement for the use of our approved therapeutic candidates, if any, from governmental or other third-party payors,
both in the U.S. and in foreign markets. Reimbursement by a third-party payor may depend upon a number of factors, including but
not limited to the third-party payor&rsquo;s determination that the use of an approved therapeutic candidate is:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a covered benefit under its health plan;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">safe, effective and medically necessary;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">appropriate for the specific patient;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">cost-effective; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">neither experimental nor investigational.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Obtaining reimbursement approval for a therapeutic candidate from
each government or other third-party payor is a time-consuming and costly process that could require us or our development and/or
commercialization partners to provide supporting scientific, clinical and cost-effectiveness data for the use of our therapeutic
candidates to each payor. Even when a payor determines that a therapeutic candidate is eligible for reimbursement, the payor may
impose coverage limitations that preclude payment for some uses that are approved by the FDA or other foreign regulatory authorities.
Reimbursement rates may vary according to the use of the therapeutic candidate and the clinical setting in which it used, may be
based on payments allowed for lower-cost products that are already reimbursed, may be incorporated into existing payments for other
products or services, and may reflect budgetary constraints and/or imperfections in Medicare, Medicaid or other data used to calculate
these rates.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the U.S., there have been, and we expect that there will
continue to be, federal and state proposals to constrain expenditures for medical products and services, which may affect payments
for our therapeutic candidates in the U.S. In addition, there is a growing emphasis on comparative effectiveness research, both
by private payors and by government agencies. To the extent other drugs or therapies are found to be more effective than our products,
payors may elect to cover such therapies in lieu of our products and/or reimburse our products at a lower rate.&nbsp;&nbsp;We believe
that legislation that reduces reimbursement for our therapeutic candidates could adversely impact how much or under what circumstances
healthcare providers will prescribe or administer our therapeutic candidates, if approved. This could materially and adversely
impact our business by reducing our ability to generate revenue, raise capital, obtain additional collaborators and market our
therapeutic candidates, if approved. At this stage, we are unable to estimate the extent of the direct and/or indirect impact of
any such federal and state proposals.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Furthermore, the Centers for Medicare
and Medicaid Services frequently change product descriptors, coverage policies, product and service codes, payment methodologies
and reimbursement values. Third-party payors often follow Medicare coverage policy and payment limitations in setting their own
reimbursement rates, and both the Centers for Medicare and Medicaid Services and other third-party payors may have sufficient market
power to demand significant price reductions.</FONT>&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>


<P STYLE="font-size: 10pt; margin: 0pt 0"></P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><B><I>We are subject to additional federal
and state laws and regulations relating to our business, and our failure to comply with those laws could have a material adverse
effect on our results of operations and financial conditions.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">In the event that we were to market products
in the U.S., we would be subject to additional healthcare regulation and enforcement by the federal government and the states in
which we conduct or will conduct our business. The laws that may affect our ability to operate include, but are not limited to,
the following:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under government healthcare programs such as the Medicare and Medicaid programs;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the federal Anti-Inducement Law (also known as the Civil Monetary Penalties Law), which prohibits a person from offering or transferring remuneration to a Medicare or State healthcare program beneficiary that the person knows or should know is likely to influence the beneficiary&rsquo;s selection of a particular provider, practitioner or supplier of any item or service for which payment may be made, in whole or in part, by Medicare or a State healthcare program;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Ethics in Patient Referrals Act of 1989, commonly referred to as the Stark Law, which prohibits physicians from referring Medicare or Medicaid patients for certain designated health services where that physician or family member has a financial relationship with the entity providing the designated health service, unless an exception applies;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">federal false claims laws that prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other government healthcare programs that are false or fraudulent;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Further, the Healthcare Reform Law,
among other things, amends the intent requirement of the federal anti-kickback and criminal healthcare fraud statutes. A person
or entity can now be found guilty of fraud or an anti-kickback violation without actual knowledge of the statute or specific intent
to violate it. In addition, the Healthcare Reform Law provides that the government may assert that a claim including items or services
resulting from a violation of the federal Anti-Kickback Statue constitutes a false or fraudulent claim for purposes of the False
Claims Act. Possible sanctions for violation of these anti-kickback laws include monetary fines, civil and criminal penalties,
exclusion from Medicare, Medicaid and other government programs and forfeiture of amounts collected in violation of such prohibitions.
Any violations of these laws, or any action against us for violation of these laws, even if we successfully defend against it,
could result in a material adverse effect on our reputation, business, results of operations and financial condition.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">The Healthcare Reform Law also imposes
reporting requirements on certain medical device and pharmaceutical manufacturers, among others, to make annual public disclosures
of certain payments and other transfers of value to physicians and teaching hospitals and ownership or investment interests held
by physicians or their immediate family members. Failure to submit required information may result in civil monetary penalties
of up to an aggregate of $150,000 per year (or up to an aggregate of $1 million per year for &ldquo;knowing failures&rdquo;), for
all payments, transfers of value or ownership or investment interests that are not reported. Manufacturers were required to begin
data collection on August 1, 2013 and report such data to CMS by March 31 each year.&nbsp;&nbsp;CMS made the data publicly available
on its searchable database beginning in September 2014.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">In addition, there has been a recent trend
of increased federal and state regulation of payments made to physicians for marketing, medical directorships, and other purposes.
Some states, such as California, Massachusetts and Vermont, mandate implementation of corporate compliance programs, along with
the tracking and reporting of gifts, compensation and other remuneration to physicians, and some states limit or prohibit such
gifts.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 26; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Most recently, there has been a trend
in federal and state legislation aimed at requiring pharmaceutical manufacturers to disclose information about their production
and marketing costs. Several states have introduced bills that would require disclosure of certain pricing information for prescription
drugs that have no threshold amount or are above a certain annual wholesale acquisition cost, and in June 2016 Vermont became the
first state to pass legislation requiring certain drug manufacturers to disclose information relating to justification of certain
price increases. The U.S. Congress has also introduced bills targeting prescription drug price transparency.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">Any such implementation of this type of
legislation requiring publication of drug costs could materially and adversely impact our business by promoting a reduction in
drug prices. As such, patients may choose to use other low-cost, established drugs or therapies.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">The scope and enforcement of these laws
is uncertain and subject to change in the current environment of healthcare reform, especially in light of the lack of applicable
precedent and regulations. We cannot predict the impact on our business of any changes in these laws. Federal or state regulatory
authorities may challenge our current or future activities under these laws. Any such challenge could have a material adverse effect
on our reputation, business, results of operations, and financial condition. Any state or federal regulatory review of us, regardless
of the outcome, would be costly and time-consuming.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We could be exposed to significant drug product liability
claims which could be time consuming and costly to defend, divert management attention and adversely impact our ability to obtain
and maintain insurance coverage.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The clinical trials that we conduct, and the testing, manufacturing,
marketing and commercial sale of our therapeutic candidates, involve and will involve an inherent risk that significant liability
claims may be asserted against us. We currently have a product liability policy that includes coverage for our clinical trials.
Should we decide to seek additional insurance against such risks before our product sales commence, there is a risk that such insurance
will be unavailable to us, or if it can be obtained at such time, that it will be available at an unaffordable cost. Even if we
obtain insurance, it may prove inadequate to cover claims and/or litigation costs, especially in the case of wrongful death claims.
Product liability claims or other claims related to our therapeutic candidates, regardless of their outcome, could require us to
spend significant time and money in litigation or to pay significant settlement amounts or judgments. Any successful product liability
or other claim may prevent us from obtaining adequate liability insurance in the future on commercially desirable or reasonable
terms. An inability to obtain sufficient insurance coverage at an acceptable cost or otherwise to protect against potential product
liability claims could prevent or inhibit the commercialization of our products and therapeutic candidates. A product liability
claim could also significantly harm our reputation and delay market acceptance of our therapeutic candidates.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Global economic conditions may make it more difficult for
us to commercialize our therapeutic candidates.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The pharmaceutical industry, like other industries and businesses,
continues to face the effects of the challenging economic environment. Patients experiencing the effects of the challenging economic
environment, including high unemployment levels and increases in co-pays, may switch to generic products, delay treatments, skip
doses or use other less effective treatments to reduce their costs. Challenging economic conditions in the U.S. include the demands
by payors for substantial rebates and formulary restrictions limiting access to brand-name drugs. In addition, in Europe and in
a number of emerging markets there are government-mandated reductions in prices for certain pharmaceutical products, as well as
government-imposed access restrictions in certain countries. All of the aforesaid may make it more difficult for us to commercialize
our therapeutic candidates.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Our business involves risks related to handling regulated
substances which could severely affect our ability to conduct research and development of our therapeutic candidates.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In connection with our development and/or commercialization partners&rsquo;
research and clinical development activities, as well as the manufacture of materials and therapeutic candidates, we and our development
and/or commercialization partners are subject to federal, State and local laws, rules, regulations and policies governing the use,
generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain materials, biological specimens
and waste. We and our development and/or commercialization partners may be required to incur significant costs to comply with environmental
and health and safety regulations in the future. Our research and clinical development, as well as the activities of our manufacturing
and commercialization partners, both now and in the future, may involve the controlled use of hazardous materials, including but
not limited to certain hazardous chemicals. We cannot completely eliminate the risk of accidental contamination or injury from
these materials. In the event of such an occurrence, we could be held liable for any damages that result and any such liability
could exceed our resources.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 27; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Risks Related to Intellectual Property</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We may be unable to adequately protect or enforce our rights
to intellectual property, causing us to lose valuable rights. Loss of patent rights may lead us to lose market share and anticipated
profits.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our success depends, in part, on our ability, and the ability of
our commercialization partners to obtain patent protection for our therapeutic candidates, maintain the confidentiality of our
trade secrets and know how, operate without infringing on the proprietary rights of others and prevent others from infringing our
proprietary rights.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We try to protect our proprietary position by, among other things,
filing U.S., European, and other patent applications related to our therapeutic candidates, inventions and improvements that may
be important to the continuing development of our therapeutic candidates.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because the patent position of pharmaceutical
companies involves complex legal and factual questions, we cannot predict the validity and enforceability of patents with certainty.
Our issued patents and the issued patents of our commercialization partners may not provide us with any competitive advantages,
or may be held invalid or unenforceable as a result of legal challenges by third parties or could be circumvented. Ownership of
the patent rights we in-license from our partners may be challenged, and as a result the rights we in-license may turn out not
to be exclusive or we may not actually have rights under the patents despite receiving representations from the partner.&nbsp;
Also, our license rights may lapse for any number of reasons and we could lose our right to commercialize one or more of our products
and cause a loss of expected profits and market share. Our competitors may also independently develop drug delivery technologies
or products similar to ours or design around or otherwise circumvent patents issued to, or licensed by, us. Thus, any patents that
we own or license from others may not provide any protection against competitors. Our pending patent applications, those we may
file in the future or those we may license from third parties may not result in patents being issued. If these patents are issued,
they may not provide us with proprietary protection or competitive advantages. The degree of future protection to be afforded by
our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights
or permit us to gain or keep our competitive advantage.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Patent rights are territorial; thus, the patent protection we do
have will only extend to those countries in which we have issued patents. Even so, the laws of certain countries do not protect
our intellectual property rights to the same extent as do the laws of the U.S. and the European Union. Competitors may successfully
challenge our patents, produce similar drugs or products that do not infringe our patents, or produce drugs in countries where
we have not applied for patent protection or that do not respect our patents. Furthermore, it is not possible to know the scope
of claims that will be allowed in published applications and it is also not possible to know which claims of granted patents, if
any, will be deemed enforceable in a court of law.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">After the completion of development and registration of our patents,
third parties may still manufacture and/or market therapeutic candidates in infringement of our patent protected rights. Such manufacture
and/or market of our therapeutic candidates in infringement of our patent protected rights is likely to cause us damage and lead
to a reduction in the prices of our therapeutic candidates, thereby reducing our anticipated profits.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In addition, due to the extensive time needed to develop, test and
obtain regulatory approval for our therapeutic candidates, any patents that protect our therapeutic candidate may expire early
during commercialization. This may reduce or eliminate any market advantages that such patents may give us. Following patent expiration,
we may face increased competition through the entry of generic products into the market and a subsequent decline in market share
and profits.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In addition, in some cases we may rely on our licensors to conduct
patent prosecution, patent maintenance or patent defense on our behalf. Therefore, our ability to ensure that these patents are
properly prosecuted, maintained, or defended may be limited, which may adversely affect our rights in our therapeutic candidates.
Any failure by our licensors or development partners to properly conduct patent prosecution, patent maintenance, patent enforcement,
or patent defense could materially harm our ability to obtain suitable patent protection covering our products and/or ensure freedom
to commercialize the products in view of third party patent rights, thereby materially reducing our anticipated profits.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>If we are unable to protect the confidentiality of our trade
secrets or know-how, such proprietary information may be used by others to compete against us.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In addition to filing patents, we generally try to protect our trade
secrets, know-how and technology by entering into confidentiality or non-disclosure agreements with parties that have access to
it, such as our development and/or commercialization partners, employees, contractors and consultants. We also enter into agreements
that purport to require the disclosure and assignment to us of the rights to the ideas, developments, discoveries and inventions
of our employees, advisors, research collaborators, contractors and consultants while we employ or engage them. However, these
agreements can be difficult and costly to enforce or may not provide adequate remedies. Any of these parties may breach the confidentiality
agreements and willfully or unintentionally disclose our confidential information, or our competitors might learn of the information
in some other way. The disclosure to, or independent development by, a competitor of any trade secret, know-how or other technology
not protected by a patent could materially adversely affect any competitive advantage we may have over any such competitor.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 28; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">To the extent that any of our employees, advisors, research collaborators,
contractors or consultants independently develop, or use independently developed, intellectual property in connection with any
of our projects, disputes may arise as to the proprietary rights to this type of information. If a dispute arises with respect
to any proprietary right, enforcement of our rights can be costly and unpredictable and a court may determine that the right belongs
to a third party.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Legal proceedings or third-party claims of intellectual property
infringement and other challenges may require us to spend substantial time and money and could prevent us from developing or commercializing
our therapeutic candidates.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The development, manufacture, use, offers for sale, sale or importation
of our therapeutic candidates may infringe on the claims of third-party patents or other intellectual property rights. The nature
of claims contained in unpublished patent filings around the world is unknown to us and it is not possible to know which countries
patent holders may choose for the extension of their filings under the Patent Cooperation Treaty, or other mechanisms. We may also
be subject to claims based on the actions of employees and consultants with respect to the usage or disclosure of intellectual
property learned at other employers. The cost to us of any intellectual property litigation or other infringement proceeding, even
if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the costs of such litigation or
proceedings more effectively because of their substantially greater financial resources. Uncertainties resulting from the initiation
and continuation or defense of intellectual property litigation or other proceedings could have a material adverse effect on our
ability to compete in the marketplace. Intellectual property litigation and other proceedings may also absorb significant management
time. Consequently, we are unable to guarantee that we will be able to manufacture, use, offer for sale, sell or import our therapeutic
candidates in the event of an infringement action.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In the event of patent infringement claims, or to avoid potential
claims, we may choose or be required to seek a license from a third party and would most likely be required to pay license fees
or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license,
the rights may be non-exclusive, which could potentially limit our competitive advantage. Ultimately, we could be prevented from
commercializing a therapeutic candidate or be forced to cease some aspect of our business operations if, as a result of actual
or threatened patent infringement or other claims, we are unable to enter into licenses on acceptable terms. This inability to
enter into licenses could harm our business significantly.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We may be subject to other patent-related litigation or proceedings
that could be costly to defend and uncertain in their outcome.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In addition to infringement claims against us, we may in the future
become a party to other patent litigation or proceedings before regulatory agencies, including interference or re-examination proceedings
filed with the U.S. Patent and Trademark Office or opposition proceedings in other foreign patent offices regarding intellectual
property rights with respect to our therapeutic candidates, as well as other disputes regarding intellectual property rights with
development and/or commercialization partners, or others with whom we have contractual or other business relationships. Post-issuance
oppositions are not uncommon and we, our development and/or commercialization partners will be required to defend these opposition
procedures as a matter of course. Opposition procedures may be costly, and there is a risk that we may not prevail which could
harm our business significantly.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Risks Related to our Ordinary Shares and American Depositary
Shares.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We may be a &ldquo;passive foreign investment company&rdquo;
for U.S. federal income tax purposes, which could result in adverse U.S. federal income tax consequences to U.S. investors.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While the determination of passive foreign
investment company, or PFIC, status is fact specific, and generally cannot be made until the close of the taxable year in question,
based on the value and composition of our assets, we may be a PFIC for U.S. federal income tax purposes for our current taxable
year and future taxable years. A non-U.S. corporation will be considered a PFIC for any taxable year if either (1) at least 75%
of its gross income for such year is passive income or (2) at least 50% of the value of its assets (based on an average of the
quarterly values of the assets during such year) is attributable to assets that produce or are held for the production of passive
income. Because the value of our assets for purposes of this determination will generally be determined by reference to the market
price of the ADSs, our PFIC status will depend in large part on the market price of the ADSs. A separate determination must be
made each taxable year as to whether we are a PFIC (after the close of each such taxable year). If we are a PFIC for any taxable
year during which a U.S. Holder (as defined in &ldquo;Taxation&mdash;U.S. Federal Income Tax Considerations &ndash; Passive Foreign
Investment Companies&rdquo;) holds ordinary shares or ADSs, the U.S. Holder may be subject to adverse tax consequences, including
(i) the treatment of all or a portion of any gain on disposition as ordinary income, (ii) the application of an interest charge
with respect to such gain and certain dividends and (iii) compliance with certain reporting requirements. Each U.S. Holder is strongly
urged to consult its own tax advisor regarding these issues. For more information, see &ldquo;Taxation &ndash; U.S. Federal Income
Tax Considerations &ndash; Passive Foreign Investment Companies.&rdquo;</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>The market price of our Ordinary Shares and our ADSs are subject
to fluctuation, which could result in substantial losses by our investors.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The stock market in general and the market price of our Ordinary
Shares on the TASE and our ADSs on The NASDAQ in particular, are subject to fluctuation, and changes in the price of our securities
may be unrelated to our operating performance. The market price of our Ordinary Shares on the TASE and the market price of our
ADSs on The NASDAQ have fluctuated in the past, and we expect they will continue to do so. The market price of our Ordinary Shares
and ADSs are and will be subject to a number of factors, including&nbsp;but not limited to:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">announcements of technological innovations or new therapeutic candidates by us or others;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">announcements by us of significant acquisitions, strategic partnerships, in-licensing, out-licensing, joint ventures or capital commitments;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">expiration or terminations of licenses, research contracts or other development or commercialization agreements;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">public concern as to the safety of drugs we, our development or commercialization partners or others develop;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the volatility of market prices for shares of biotechnology companies generally;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">success or failure of research and development projects;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">departure of key personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">developments concerning intellectual property rights or regulatory approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">variations in our and our competitors&rsquo; results of operations;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in earnings estimates or recommendations by securities analysts, if our Ordinary Shares or ADSs are covered by analysts;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in government regulations or patent decisions;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">developments by our development and/or commercialization partners; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">general market conditions and other factors unrelated to our operating performance.</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">These factors and any corresponding price fluctuations may materially
and adversely affect the market price of our Ordinary Shares and/or ADSs and result in substantial losses by our investors.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Additionally, market prices for securities of biotechnology and
pharmaceutical companies historically have been very volatile. The market for these securities has from time to time experienced
significant price and volume fluctuations for reasons unrelated to the operating performance of any one company. In the past, following
periods of market volatility, shareholders have often instituted securities class action litigation. If we were involved in securities
litigation, it could have a substantial cost and divert resources and attention of management from our business, even if we are
successful.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Future sales of our Ordinary Shares or ADSs could reduce the
market price of our Ordinary Shares and ADSs</I></B>.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 19, 2016, we had non-tradable warrants to purchase
an aggregate of 4,183,496 Ordinary Shares and non-tradable warrants to purchase an aggregate of 357,896 ADSs (each representing
10 Ordinary Shares) and options to purchase 22,065,548 Ordinary Shares under our 2010 Stock Option Plan. In addition, our Board
of Directors reserved up to 30,000,000 Ordinary Shares for issuance under our 2010 Stock Option Plan. Substantial sales of our
Ordinary Shares or ADSs, or the perception that such sales may occur in the future, including sales of shares issuable upon the
exercise of options and warrants, may cause the market price of our Ordinary Shares or ADSs to decline. Moreover, the issuance
of Ordinary Shares underlying our options and warrants will also have a dilutive effect on our shareholders, which could further
reduce the price of our Ordinary Shares and ADSs on their respective exchanges.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Our Ordinary Shares and our ADSs are traded on different markets
and this may result in price variations.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our Ordinary Shares have been traded on the TASE since February
2011, and our ADSs have been listed on The NASDAQ since December 27, 2012. Trading in our securities on these markets take place
in different currencies (U.S. dollars on The NASDAQ and New Israeli Shekels, or NIS, on the TASE), and at different times (resulting
from different time zones, different trading days and different public holidays in the U.S. and Israel). The trading prices of
our securities on these two markets may differ due to these and other factors. Any decrease in the price of our securities on one
of these markets could cause a decrease in the trading price of our securities on the other market.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>There has been a limited market for our ADSs. We cannot ensure
investors that an active market will continue or be sustained for our ADSs on The NASDAQ, and this may limit the ability of our
investors to sell our ADSs in the U.S.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In the past, there was limited trading in our ADSs, and there is
no assurance that an active trading market of our ADSs will continue or will be sustained. Limited or minimal trading in our ADSs
has in the past, and may in the future, lead to dramatic fluctuations in market price and investors may not be able to liquidate
their investment at all or at a price that reflects the value of the business.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">While our ADSs began trading on The NASDAQ in December 2012, we
cannot assure you that we will maintain compliance with all of the requirements for our ADSs to remain listed. Additionally, there
can be no assurance that trading of our ADSs on such market will be sustained or desirable.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We have incurred additional increased costs as a result of
the listing of our ADSs on The NASDAQ, and we may need to devote substantial time and resources to new compliance initiatives and
reporting requirements.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">As a public company in the U.S., we incur additional significant
accounting, legal and other expenses as a result of the listing of our securities on both The NASDAQ and the TASE. These include
costs associated with the reporting requirements of the SEC and the requirements of The NASDAQ Capital Market Rules, as well as
requirements under Section 404 and other provisions of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act. These rules and
regulations have increased our legal and financial compliance costs, introduced new costs such as investor relations, travel costs,
stock exchange listing fees and shareholder reporting, and made some activities more time consuming and costly. Any future changes
in the laws and regulations affecting public companies in the U.S. and Israel, including Section 404 and other provisions of the
Sarbanes-Oxley Act, the rules and regulations adopted by the SEC and the Market Rules of The NASDAQ, as well as applicable Israeli
reporting requirements, will result in increased costs to us as we respond to such changes. These laws, rules and regulations could
make it more difficult and costly for us to obtain certain types of insurance, including director and officer liability insurance,
and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar
coverage. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to
serve on our board of directors, our board committees or as executive officers and may require us to pay more for such positions.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Since we are an &ldquo;emerging growth company,&rdquo; as defined
in the JOBS Act, we may take advantage of certain temporary exemptions from various reporting requirements, including, but not
limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes Oxley Act (and
the rules and regulations of the SEC thereunder). We will remain an emerging growth company until the earliest of: (a) the last
day of our fiscal year during which we have total annual gross revenues of at least $1.0 billion; (b) the last day of our fiscal
year following the fifth anniversary of the date of the first sale of our Ordinary Shares pursuant to an effective registration
statement (in our case, December 31, 2018); (c) the date on which we have, during the previous three-year period, issued more than
$1.0 billion in non-convertible debt; or (d) the date on which we are deemed to be a &ldquo;large accelerated filer&rdquo; under
the Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), which would occur if the market value of our Ordinary Shares
held by non-affiliates is $700 million or more as of the last business day of our most recently completed fiscal quarter. When
these exemptions cease to apply, we expect to incur additional expenses and devote increased management effort toward ensuring
compliance with such reporting requirements. We cannot predict or estimate the amount of additional costs we may incur as a result
of complying with these additional reporting requirements.</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 31; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>As a foreign private issuer, we are permitted to follow certain
home country corporate governance practices instead of applicable SEC and NASDAQ Stock Market requirements, which may result in
less protection than is accorded to investors under rules applicable to domestic issuers. </I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a foreign private issuer, we are permitted to follow certain
home country corporate governance practices instead of those otherwise required under The NASDAQ Capital Market Rules for domestic
issuers. For instance, we follow home country practice in Israel with regard to, among other things, director nomination procedure
and quorum at shareholders&rsquo; meetings. In addition, we follow our home country law, instead of The NASDAQ Capital Market Rules,
which require that we obtain shareholder approval for certain dilutive events, such as for the establishment or amendment of certain
equity based compensation plans, an issuance that will result in a change of control of the company, certain transactions other
than a public offering involving issuances of a 20% or more interest in the company and certain acquisitions of the stock or assets
of another company. Following our home country governance practices as opposed to the requirements that would otherwise apply to
a U.S. domestic issuer listed on The NASDAQ may provide less protection than is accorded to investors under The Market Rules of
The NASDAQ Capital Market applicable to domestic issuers.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In addition, as a foreign private issuer, we are exempt from the
rules and regulations under the Exchange Act, related to the furnishing and content of proxy statements, and our officers, directors
and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of
the Exchange Act. In addition, we are not required under the Exchange Act, to file annual, quarterly and current reports and financial
statements with the SEC as frequently or as promptly as domestic issuers whose securities are registered under the Exchange Act.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We may fail to maintain effective internal controls over financial
reporting, which may adversely affect investor confidence in our company and, as a result, may affect the value of our Ordinary
Shares and ADSs.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We are required, pursuant to Section 404 of the Sarbanes-Oxley Act,
to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. Pursuant
to the JOBS Act, we are classified as an &ldquo;emerging growth company,&rdquo; and we are exempt from certain reporting requirements,
including the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act.&nbsp;&nbsp;Under this exemption, our auditor
will not be required to attest to and report on management&rsquo;s assessment of our internal controls over financial reporting
during a five year transition period commencing in 2013.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our management report regarding our internal control over financial
reporting must include, among other things, disclosure of any material weaknesses identified by our management in our internal
control over financial reporting. The continuous process of strengthening our internal controls and complying with Section 404
is complicated and time-consuming.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We have documented and tested our internal control systems and procedures
in order for us to comply with the requirements of Section 404. While our assessment of our internal control over financial reporting
resulted in our conclusion that as of December 31, 2015, our internal control over financial reporting was effective, we cannot
predict the outcome of our testing in future periods. If we fail to maintain the adequacy of our internal controls, we may not
be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting.&nbsp;&nbsp;Failure
to maintain effective internal control over financial reporting could result in investigation or sanctions by regulatory authorities,
and could have a material adverse effect on our operating results, investor confidence in the accuracy and completeness of our
financial reports, which would cause the price of our Ordinary Shares and ADSs to decline.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We currently do not anticipate paying cash dividends, and
accordingly, investors must rely on the appreciation in our ADSs for any return on their investment.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We currently anticipate that we will retain future earnings for
the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable
future. Therefore, the success of an investment in our ADSs will depend upon any future appreciation in their value. There is no
guarantee that our ADSs will appreciate in value or even maintain the price at which our investors have purchased their securities.</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 32; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Investors in our ADSs may not receive the same distributions
or dividends as those we make to the holders of our Ordinary Shares, and, in some limited circumstances, investors in our ADSs
may not receive dividends or other distributions on our Ordinary Shares and may not receive any value for them, if it is illegal
or impractical to make them available to investors in our ADSs.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Depositary for the ADSs has agreed to pay to investors in
our ADSs the cash dividends or other distributions it or the custodian receives on Ordinary Shares or other deposited securities
underlying the ADSs, after deducting its fees and expenses. Investors in our ADSs will receive these distributions in proportion
to the number of Ordinary Shares such ADSs represent. However, the Depositary is not responsible if it decides that it is unlawful
or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a distribution
to a holder of ADSs if it consists of securities that require registration under Securities Act, but that are not properly registered
or distributed under an applicable exemption from registration. In addition, conversion into U.S. dollars from foreign currency
that was part of a dividend made in respect of deposited Ordinary Shares may require the approval or license of, or a filing with,
any government or agency thereof, which may be unobtainable. In these cases, the Depositary may determine not to distribute such
property and hold it as &ldquo;deposited securities&rdquo; or may seek to effect a substitute dividend or distribution, including
net cash proceeds from the sale of the dividends that the Depositary deems an equitable and practicable substitute. We have no
obligation to register under U.S. securities laws any ADSs, Ordinary Shares, rights or other securities received through such distributions.
We also have no obligation to take any other action to permit the distribution of ADSs, Ordinary Shares, rights or anything else
to holders of ADSs. In addition, the Depositary may deduct from such dividends or distributions its fees and may withhold amounts
on account of taxes or other governmental charges to the extent the Depositary believes it is required to make such withholding.
This means that investors in our ADSs may not receive the same distributions or dividends as those we make to the holders of our
Ordinary Shares, and, in some limited circumstances, investors in our ADSs may not receive any value for such distributions or
dividends if it is illegal or impractical for us to make them available to investors in our ADSs. These restrictions may cause
a material decline in the value of the ADSs.</P>







<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Holders of ADSs must act through the Depositary to exercise
their rights as shareholders of our company.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of our ADSs do not have the same
rights of our shareholders and may only exercise the voting rights with respect to the underlying Ordinary Shares in accordance
with the provisions of the deposit agreement for the ADSs. Under Israeli law, the minimum notice period required to convene a shareholders&rsquo;
meeting is no less than 35 or 21 calendar days, depending on the proposals on the agenda for the shareholders&rsquo; meeting. When
a shareholder meeting is convened, holders of our ADSs may not receive sufficient notice of a shareholders&rsquo; meeting to permit
them to withdraw their Ordinary Shares to allow them to cast their vote with respect to any specific matter. In addition, the Depositary
and its agents may not be able to send voting instructions to holders of our ADSs or carry out their voting instructions in a timely
manner. We will make all reasonable efforts to cause the Depositary to extend voting rights to holders of our ADSs in a timely
manner, but we cannot assure holders that they will receive the voting materials in time to ensure that they can instruct the Depositary
to vote their ADSs. Furthermore, the Depositary and its agents are not responsible for any failure to carry out any instructions
to vote, for the manner in which any vote is cast or for the effect of any such vote. As a result, holders of our ADSs may not
be able to exercise their right to vote and they may lack recourse if their ADSs are not voted as they requested. In addition,
in the capacity as an American Depositary Share holder, they are not able to call a shareholders&rsquo; meeting.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>The Depositary for our ADSs gives us a discretionary proxy
to vote our Ordinary Shares underlying ADSs if a holder of our ADSs does not vote at shareholders&rsquo; meetings, except in limited
circumstances, which could adversely affect their interests.</I></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Under the deposit agreement for the ADSs, the Depositary gives us a discretionary proxy
to vote our Ordinary Shares underlying ADSs at shareholders&rsquo; meetings if a holder of our ADSs does not vote, unless:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">we have instructed the Depositary that we do not wish a discretionary proxy to be given;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">we have informed the Depositary that there is substantial opposition as to a matter to be voted on at the meeting; or</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">a matter to be voted on at the meeting would have a material adverse impact on shareholders.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The effect of this discretionary proxy is that a holder of our ADSs
cannot prevent our Ordinary Shares underlying such ADSs from being voted, absent the situations described above, and it may make
it more difficult for holders of our ADSs to influence the management of our company. Holders of our Ordinary Shares are not subject
to this discretionary proxy.</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 33; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Risks Related to our Operations in Israel</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We conduct our operations in Israel and therefore our results
may be adversely affected by political, economic and military instability in Israel and the region.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We are incorporated under the laws of the State of Israel, our principal
offices are located in central Israel and some of our officers, employees and directors are residents of Israel. Accordingly, political,
economic and military conditions in Israel and the surrounding region may directly affect our business. Since the establishment
of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its Arab neighbors. Any hostilities
involving Israel or the interruption or curtailment of trade within Israel or between Israel and its trading partners could adversely
affect our operations and results of operations and could make it more difficult for us to raise capital. During the summer of
2014, Israel was engaged in an armed conflict with Hamas in Gaza, which involved missile strikes against civilian targets in various
parts of Israel and negatively affected business conditions in Israel. In addition, recent political uprisings and conflicts in
various countries in the Middle East, including Egypt and Syria, are affecting the political stability of those countries. It is
not clear how this instability will develop and how it will affect the political and security situation in the Middle East. This
instability has raised concerns regarding security in the region and the potential for armed conflict. In addition, it is widely
believed that Iran, which has previously threatened to attack Israel, has been stepping up its efforts to achieve nuclear capability.
Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza and Hezbollah in Lebanon.
Additionally, the Islamic State of Iraq and Levant (&ldquo;ISIL&rdquo;), a violent jihadist group, is involved in hostilities in
Iraq and Syria. Although ISIL&rsquo;s activities have not directly affected the political and economic conditions in Israel, ISIL&rsquo;s
stated purpose is to take control of the Middle East, including Israel. The tension between Israel and Iran and/or these groups
may escalate in the future and turn violent, which could affect the Israeli economy in general and us in particular. Any armed
conflicts, terrorist activities or political instability in the region could adversely affect business conditions and could harm
our results of operations. For example, any major escalation in hostilities in the region could result in a portion of our employees
being called up to perform military duty for an extended period of time. Parties with whom we do business have sometimes declined
to travel to Israel during periods of heightened unrest or tension, forcing us to make alternative arrangements when necessary.
In addition, the political and security situation in Israel may result in parties with whom we have agreements involving performance
in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure provisions
in such agreements.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our commercial insurance does not cover losses that may occur as
a result of events associated with the security situation in the Middle East. Although the Israeli government currently covers
the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government
coverage will be maintained, or if maintained, will be sufficient to compensate us fully for damages incurred. Any losses or damages
incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region
would likely negatively affect business conditions and could harm our results of operations.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The State of Israel and Israeli companies have been subject to economic
boycotts. These restrictions and boycotts may have a material adverse impact on our operating results, financial condition or the
expansion of our business.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Our operations may be disrupted as a result of the obligation
of management or personnel to perform military service.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Many of our employees in Israel, including members of our senior
management, perform up to one month, and in some cases more, of annual military reserve duty until they reach the age of 40 or
older and, in the event of a military conflict, may be called to active duty. There have also been periods of significant call-ups
of military reservists, and it is possible that there will be military reserve duty call-ups in the future. Our operations could
be disrupted by the absence of a significant number of our employees. Such disruption could materially adversely affect our business,
financial condition and results of operations.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Because a certain portion of our expenses is incurred in currencies
other than the U.S. dollar, our results of operations may be harmed by currency fluctuations and inflation.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our reporting and functional currency is the U.S. dollar. Most of
the royalty payments from our agreements with our development and/or commercialization partners are payable in U.S. dollars, and
we expect our revenues from future licensing agreements to be denominated mainly in U.S. dollars or in Euros. We pay a substantial
portion of our expenses in U.S. dollars; however, a portion of our expenses, related to salaries of the employees in Israel and
payment to part of the service providers in Israel and other territories, are paid in NIS and in other currencies. In addition,
a portion of our financial assets is held in NIS and in other currencies. As a result, we are exposed to the currency fluctuation
risks. For example, if the NIS strengthens against the U.S. dollar, our reported expenses in U.S. dollars may be higher. In addition,
if the NIS weakens against the U.S. dollar, the U.S. dollar value of our financial assets held in NIS will decline.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Provisions of our 2010 Option Plan, Israeli law and our articles
of association may delay, prevent or otherwise impede a merger with, or an acquisition of, our company, or an acquisition of a
significant portion of our shares, which could prevent a change of control, even when the terms of such a transaction are favorable
to us and our shareholders.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our 2010 Option Plan provides that all options granted by us
will be fully accelerated upon a &ldquo;hostile takeover&rdquo; of the Company. A &ldquo;hostile takeover&rdquo; is defined in
our 2010 Option Plan as an event in which any person, entity or group that was not an &ldquo;interested party&rdquo;, as defined
in the Israeli Securities Law &ndash; 1968, on the date of the&nbsp;initial public offering of our ordinary shares on the TASE,
shall become a &ldquo;controlling&nbsp;shareholder&rdquo; as defined in the Israel Securities Law, 1968, or a &ldquo;holder,&rdquo;
as defined in the Israel Securities Law 1968, of 25% or more of the voting rights in the Company or any merger or consolidation
involving the Company, in each case without a resolution by the Board of Directors of the Company supporting the transaction. In
addition, if a &ldquo;Significant Event&rdquo; shall occur and following which the employment of a grantee with the Company or
a related company is terminated by the Company or a related company other than for &ldquo;Cause&rdquo;, and unless the applicable
agreement provides otherwise or the Board of Directors determines otherwise, all the outstanding options held by or for the benefit
of any such grantee will be accelerated and immediately vested and exercisable. A &ldquo;Significant Event&rdquo; is defined in
our 2010 Option Plan as a consolidation or merger of the Company with or into another corporation approved by the Board of Directors
of the Company in which the Company is the continuing or surviving corporation or in which the continuing or surviving corporation
assumes the option or substitutes it with an appropriate option in the surviving corporation.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Israeli Companies Law, 1999, or the Israeli Companies Law, regulates
mergers, requires tender offers for acquisitions of shares or voting rights above specified thresholds, requires special approvals
for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to
these types of transactions. For example, a merger may not be consummated unless at least 50 days have passed from the date that
a merger proposal was filed by each merging company with the Israel Registrar of Companies and at least 30 days from the date that
the shareholders of both merging companies approved the merger. In addition, a majority of each class of securities of the target
company must approve a merger. Moreover, the Israeli Companies Law provides that certain purchases of securities of a public company
are subject to tender offer rules. As a general rule, the Israeli Companies Law prohibits any acquisition of shares or voting power
in a public company that would result in the purchaser holding 25% or more, or more than 45% of the voting power in the company,
if there is no other person holding 25% or more, or more than 45% of the voting power in a company, respectively, without conducting
a special tender offer. The Israeli Companies Law further provides that a purchase of shares or voting power of a public company
or a class of shares of a public company, which will result in the purchaser&rsquo;s holding 90% or more of the company&rsquo;s
shares, class of shares or voting rights, is prohibited unless the purchaser conducts a full tender offer for all of the company&rsquo;s
shares or class of shares. The purchaser will be allowed to purchase all of the company&rsquo;s shares or class of shares (including
those shares held by shareholders who did not respond to the offer), if either (i) the shareholders who do not accept the offer
hold less than 5% of the issued and outstanding share capital of the company or of the applicable class, and more than half of
the shareholders who do not have a personal interest in the offer accept the offer, or (ii) the shareholders who do not accept
the offer hold less than 2% of the issued and outstanding share capital of the company or of the applicable class. The shareholders,
including those who indicated their acceptance of the tender offer (except if otherwise detailed in the tender offer document),
may, at any time within six months following the completion of the tender offer, petition the court to alter the consideration
for the acquisition. At the request of an offeree of a full tender offer which was accepted, the court may determine that the consideration
for the shares purchased under the tender offer was lower than their fair value and compel the offeror to pay to the offerees the
fair value of the shares. Such application to the court may be filed as a class action.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In addition, the Israeli Companies Law provides for certain limitations
on a shareholder that holds more than 90% of the company&rsquo;s shares, or class of shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to our articles of association, the size of our board
of directors shall be no less than five persons and no more than seven, excluding the external directors whose appointment is required
by law. The directors who are not external directors are divided into three classes, as nearly equal in number as possible. At
each annual general meeting, the term of one class of directors expires, and the directors of such class are re-nominated to serve
an additional three-year term that expires at the annual general meeting held in the third year following such election. This process
continues indefinitely. Such provisions of our articles of association make it more difficult for a third party to effect a change
in control or takeover attempt that our management and board of directors oppose.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Furthermore, Israeli tax considerations may, in certain circumstances,
make potential transactions unappealing to us or to some of our shareholders. For example, Israeli tax law does not recognize tax-free
share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain
circumstances but makes the deferral contingent on the fulfillment of numerous conditions, including a holding period of two years
from the date of the transaction during which sales and dispositions of shares of the participating companies are restricted. Moreover,
with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes
payable even if no actual disposition of the shares has occurred.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">These and other similar provisions could delay, prevent or impede
an acquisition of us or our merger with another company, or an acquisition of a significant portion of our shares, even if such
an acquisition or merger would be beneficial to us or to our shareholders.</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 35; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>It may be difficult to enforce a U.S. judgment against us
and our officers and directors in Israel or the U.S., or to serve process on our officers and directors.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are incorporated in Israel. Most of our executive officers
and directors reside outside of the U.S., and most of our assets and most of the assets of our executive officers and directors
are located outside of the U.S. Therefore, a judgment obtained against us or most of our executive officers and our directors in
the U.S., including one based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in
the U.S. and may not be enforced by an Israeli court. It may also be difficult for you to affect service of process on these persons
in the U.S. or to assert U.S. securities law claims in original actions instituted in Israel.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>The obligations and responsibilities of our shareholders are
governed by Israeli law which may differ in some respects from the obligations and responsibilities of shareholders of U.S. companies.
Israeli law may impose obligations and responsibilities on a shareholder of an Israeli company that are not imposed upon shareholders
of corporations in the U.S.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We are incorporated under Israeli law. The obligations and responsibilities
of the holders of our Ordinary Shares are governed by our articles of association and Israeli law. These obligations and responsibilities
differ in some respects from the obligations and responsibilities of shareholders in typical U.S.-based corporations.&nbsp;&nbsp;In
particular, a shareholder of an Israeli company has a duty to act in good faith toward the company and other shareholders and to
refrain from abusing its power in the company, including, among other things, in voting at the general meeting of shareholders
on matters such as amendments to a company&rsquo;s articles of association, increases in a company&rsquo;s authorized share capital,
mergers and acquisitions and interested party transactions requiring shareholder approval. In addition, a shareholder who knows
that it possesses the power to determine the outcome of a shareholder vote or to appoint or prevent the appointment of a director
or executive officer in the company has a duty of fairness toward the company. There is limited case law available to assist us
in understanding the implications of these provisions that govern shareholders&rsquo; actions. These provisions may be interpreted
to impose additional obligations and responsibilities on holders of our Ordinary Shares that are not typically imposed on shareholders
of U.S. corporations.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Claims for indemnification by our directors and officers may
reduce our available funds to satisfy successful shareholder claims against us and may reduce the amount of money available to
us.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Israeli Companies Law and our articles of association permit
us to indemnify our directors and officers for acts performed by them in their capacity as directors and officers. The Israeli
Companies Law provide that a company may not exempt or indemnify a director or an office holder nor enter into an insurance contract,
which would provide coverage for any monetary liability incurred as a result of (a) a breach by the director or officer of his
duty of loyalty, except for insurance and indemnification where the director or officer acted in good faith and had a reasonable
basis to believe that the act would not prejudice the company; (b) a breach by the director or officer of his duty of care if the
breach was done intentionally or recklessly, except if the breach was solely as a result of negligence; (c) any act or omission
done with the intent to derive an illegal personal benefit; or (d) any fine, civil fine, monetary sanctions, or forfeit imposed
on the officer or director. Our articles of association provide that the Company may exempt or indemnify a director or an office
holder to the maximum extent permissible under law.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We have issued letters of indemnification to our directors and officers,
pursuant to which we have agreed to indemnify them in advance for any liability or expense imposed on or incurred by them in connection
with acts they perform in their capacity as a director or officer, subject to applicable law. The amount of the advance indemnity
is limited to the higher of 25% of our then shareholders&rsquo; equity, per our most recent annual financial statements, or $5
million.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our indemnification obligations limit the personal liability of
our directors and officers for monetary damages for breach of their duties as directors by shifting the burden of such losses and
expenses to us. Although we have obtained directors' and officers' liability insurance, certain liabilities or expenses covered
by our indemnification obligations may not be covered by such insurance or the coverage limitation amounts may be exceeded. As
a result, we may need to use a significant amount of our funds to satisfy our indemnification obligations, which could severely
harm our business and financial condition and limit the funds available to who may choose to bring a claim against our company.
These provisions and resultant costs may also discourage us from bringing a lawsuit against directors and officers for breaches
of their duties, and may similarly discourage the filing of derivative litigation by our shareholders against the directors and
officers even though such actions, if successful, might otherwise benefit our security holders.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 36; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Risks Related to this Offering</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We will have broad discretion in how to use the net proceeds
of this offering, and we may not use these proceeds in a manner desired by our investors.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We will have broad discretion as to the use of the net proceeds
from this offering and could use them for purposes other than those contemplated at the time of this offering.&nbsp;Accordingly,
you will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity
as part of your investment decision to assess whether the proceeds are being used appropriately. Our needs may change as the business
and the industry that we address evolves.&nbsp;As a result, the proceeds to be received in this offering may be used in a manner
significantly different from our current expectations. It is possible that the proceeds will be invested in a way that does not
yield a favorable, or any, return. The failure of our management to use such funds effectively could have a material adverse effect
on our business, financial condition, operating results and cash flow.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>You will experience immediate dilution in book value of any
ADSs you purchase.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Because the price per ADS being offered is substantially higher
than our net tangible book value per ADS, you will suffer substantial dilution in the net tangible book value of any ADSs you purchase
in this offering. After giving effect to the sale by us of&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADSs
in this offering, based on a public offering price of $ &nbsp;&nbsp;&nbsp; per a fixed combination of one ADS and a warrant to
purchase 0.5 of an ADS, and after deducting the underwriting discount and estimated offering expenses payable by us, the as adjusted
net tangible book value of our ADSs would be $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , or approximately $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per ADS, as of September 30, 2016.&nbsp;If you purchase ADSs in this offering, you will suffer immediate and substantial dilution
of as adjusted net tangible book value of approximately $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS. This calculation assumes
that none of the warrants issued in this offering is exercised and excludes the proceeds, if any, from the exercise of warrants
issued in this offering. If the underwriters exercise their option to purchase additional ADSs , you will experience additional
dilution. See &ldquo;Dilution&rdquo; on page S-39 for a more detailed discussion of the dilution you will incur in connection with
this offering.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>ADSs representing a substantial percentage of our outstanding
shares may be sold in this offering, which could cause the price of our ADSs and Ordinary Shares</I> to <I>decline</I>.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to this offering, we will sell&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
ADSs representing&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ordinary Shares, or approximately&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; % of our outstanding Ordinary Shares as of December 19, 2016. In addition, pursuant to this offering,
we will sell&nbsp;warrants to purchase up to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADSs,
representing approximately&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; % of our outstanding Ordinary Shares as of December 19, 2016. These
sales and any future sales of a substantial number of ADSs and/or warrants in the public market, or the perception that such sales
may occur, could materially adversely affect the price of our ADSs and Ordinary Shares. We cannot predict the effect, if any, that
market sales of those ADSs and warrants or the availability of those ADSs and warrants for sale will have on the market price of
our ADSs and Ordinary Shares.&nbsp;</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will grant to any investor purchasing, together with
its affiliates, at least $15 million in this offering the right to nominate a member to our board of directors and, consequently,
the ability to exert influence over us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will grant to any investor purchasing, together with its
affiliates, at least $15 million of ADSs and warrants in this offering the right to nominate a person for election at our next
annual meeting of shareholders to our board of directors, subject to meeting applicable legal and stock exchange requirements and
subject to the consent of our current board of directors, which consent shall not be unreasonably withheld and subject to shareholder
approval of an amendment to our articles of association increasing the maximum number of directors that may serve on our board
of directors. Upon the selection of this director nominee, and the approval of this director nominee by our board of directors,
our board shall recommend the election of the director nominee to our board of directors by our shareholders. As a result, this
investor may be able to exert influence over our policies and management, potentially in a manner which may not be in our best
interests or the best interests of the other shareholders.<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>[1]</SUP></FONT>
See comments above on S-8.</P>
<!-- Field: Page; Sequence: 37; Options: NewSection; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>There is no public market for the warrants to purchase
ADSs&nbsp;being offered in this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There is no established public trading market for the warrants
being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list the warrants
on The NASDAQ, the TASE or any other national securities exchange, or any other recognized&nbsp;trading system. In addition, the
warrants provide that no warrant holder shall list any warrants on any such exchange or trading system or on any other trading
platform. Without an active market, the liquidity of the warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The warrants are speculative in nature and and holders
of the warrants may not be able to recover their investment in the warrants, and the warrants may expire worthless.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The warrants offered by us in this offering do not confer any
rights of ownership of ADSs on its holders but only represent the right to acquire ADSs at a fixed price for a limited period of
time. Specifically, commencing on the date of issuance, holders of the warrants may exercise their right to acquire the ADSs and
pay an exercise price of $ per ADS, subject to adjustment upon certain events, prior to three years from the date of issuance,
after which date any unexercised warrants will expire and have no further value. If the price of our ADSs does not increase to
an amount sufficiently above the applicable exercise price of the warrants during the period the warrants are exercisable, the
holders of the warrants will be unable to recover any of their investment in the warrants. There can be no assurance that the market
price of our ordinary shares will ever equal or exceed the exercise price of the warrants and, consequently, whether it will ever
be profitable for holders of the warrants to exercise the warrants. Furthermore, at the time of exercise the holder must pay a
fee of $0.05 per ADS and any other applicable taxes or charges for issuance of ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Holders of warrants will have no rights as shareholders
until such holders exercise their warrants and acquire our ADSs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Until holders of warrants acquire ADSs upon exercise of the
warrants, holders of warrants will have no rights with respect to our ADSs. Upon exercise of the warrants, the holders will be
entitled to exercise the rights of a holder of ADSs only as to matters for which the record date occurs after the exercise date.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><A NAME="a_006"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We estimate that the net proceeds from the sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
of our ADSs representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ordinary Shares and warrants to purchase ADSs in this
offering will be approximately $&nbsp;&nbsp; &nbsp;million after deducting underwriting discounts and commissions and estimated
offering expenses payable by us, assuming that none of the warrants issued in this offering is exercised. If the underwriters&rsquo;
option to purchase additional shares is exercised in full, we estimate that we will receive net proceeds of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million,
after deducting underwriter discounts and commissions and estimated offering expenses payable by us, assuming that none of the
warrants issued in this offering is exercised. We cannot predict when or if the warrants will be exercised. It is possible that
the warrants may expire and may never be exercised.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We currently intend to use the net proceeds from the sale of
our ADSs and warrants and any proceeds from the exercise of the warrants to fund clinical development programs, for potential acquisitions,
to support commercial operations and for general corporate purposes.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The amounts and timing of our actual expenditures will depend upon
numerous factors, including the progress of our development and commercialization efforts, the status of and results from our clinical
trials, whether or not we enter into strategic collaborations or partnerships, and our operating costs and expenditures. Accordingly,
our management will have significant flexibility in applying the net proceeds of this offering. In addition, while we have not
entered into any binding agreements or commitments relating to any significant transaction as of the date of this prospectus supplement,
we may use a portion of the net proceeds to pursue acquisitions, joint ventures and other strategic transactions.</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 39; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><A NAME="a_007"></A><B>DILUTION</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you invest in our ADSs and warrants, your interest will be
diluted immediately to the extent of the difference between the public offering price per a fixed combination of one ADS and one
warrant to purchase 0.5 of an ADS and the as-adjusted net tangible book value per ADS after this offering.&nbsp;</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The net tangible book value of our ADSs as of September 30,
2016 was approximately $ million, or approximately $ per ADS.&nbsp;Net tangible book value per ADS represents the amount of our
total tangible assets less total liabilities divided by the total number of our Ordinary Shares outstanding as of September 30,
2016 and multiplying such amount by 10 (one ADS represents 10 Ordinary Shares).&nbsp;</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">After giving effect to the sale of our ADSs and warrants offered
by this prospectus supplement at the public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp; per a fixed combination of one ADS and
a warrant to purchase 0.5 of an ADS in connection with this offering, and after deducting the underwriting discount and estimated
offering expenses payable by us, our as adjusted net tangible book value as of September 30, 2016 would have been approximately
$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per ADS. This calculation assumes that none of the warrants issued in this offering is exercised and excludes the proceeds, if
any, from the exercise of warrants issued in this offering. This represents an immediate increase in net tangible book value of
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS to our existing security holders and an immediate dilution in as-adjusted
net tangible book value of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS to purchasers of our ADSs in this offering, as
illustrated by the following table:</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 86%; border-top: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%; border-top: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 1%; border-top: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 11%; border-top: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%; border-top: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Public offering price per ADS and warrant to purchase 0.5 of an ADS&#9;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Net tangible book value per ADS as of September 30, 2016&#9;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Increase in net tangible book value per ADS attributable to this offering&#9;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">As-adjusted net tangible book value per ADS as of September 30, 2016 after giving effect to this offering&#9;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Dilution per ADS to new investors purchasing our ADSs and warrants in this offering&#9;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the underwriters exercise in full their option to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
additional ADSs at the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per a fixed combination of one ADS and one
warrant to purchase 0.5 of an ADS, the as-adjusted net tangible book value after this offering would be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per ADS, representing an increase in net tangible book value of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS to
existing security holders and immediate dilution in net tangible book value of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per ADS to new investors purchasing our ADSs and warrants in this offering at the public offering price. This calculation assumes
that none of the warrants issued in this offering is exercised and excludes the proceeds, if any, from the exercise of warrants
issued in this offering.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The number of Ordinary Shares to be outstanding after this offering
is based on 127,474,294 Ordinary Shares outstanding as of September 30, 2016, and excludes as of such date (i) 22,431,338 Ordinary
Shares issuable upon the exercise of outstanding options to purchase 22,431,338 Ordinary Shares at a weighted average exercise
price of $0.94 per share (equivalent to 2,243,133 ADSs at a weighted average exercise price of $9.40 per ADS), (ii) 4,183,496 Ordinary
Shares issuable upon the exercise of outstanding warrants to purchase 4,183,496 Ordinary Shares at an exercise price of $1.40 per
share (equivalent to 418,349 ADSs at an exercise price of $14.00 per ADS) and (iii) 3,578,960 Ordinary Shares issuable upon the
exercise of outstanding warrants to purchase 3,578,960 Ordinary Shares at an exercise price of $1.10 per share (equivalent to 357,896
ADSs at an exercise price of $11.00 per ADS).</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The as-adjusted information discussed above is illustrative only.
Our net tangible book value following the completion of the offering is subject to further adjustment based on the actual offering
price of our ADSs and other terms of this offering determined at pricing.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 40; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><A NAME="a_008"></A><B>CAPITALIZATION AND INDEBTEDNESS</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth our total capitalization as of
September 30, 2016:</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">on an actual basis; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">on an as-adjusted basis to reflect the sale of&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ADSs representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Ordinary Shares and warrants to purchase ADSs at the public offering price of $&nbsp;&nbsp; &nbsp;per <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
fixed combination of one ADS and one warrant to purchase 0.5 of an ADS and the receipt by us of net proceeds of approximately $&nbsp;&nbsp;&nbsp;
, after deducting the underwriting discounts and commissions and the estimated offering expenses payable by us (assuming no exercise
of the warrants offered in this offering and no proceeds, if any, from the exercise of warrants issued in this offering).</FONT></P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The information set forth in the following table should be read
in conjunction with and is qualified in its entirety by reference to the audited and unaudited financial statements and notes thereto
incorporated by reference in this prospectus supplement and the accompanying prospectus.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center">As of September 30, 2016</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: italic">(In thousands, except share data)</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; text-align: center">Actual</TD><TD STYLE="font-style: italic">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-style: italic; text-align: center">As Adjusted</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center">(unaudited)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Derivative financial instruments&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,107</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Ordinary shares, par value NIS 0.01 per share:&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">344</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Additional paid-in capital&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,730</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Warrants&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,057</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated deficit&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(81,646</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total shareholders&rsquo; equity&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">40,485</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.25pt">Total capitalization&#9;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">41,592</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The number of shares in the above table is based on 127,474,294
Ordinary Shares outstanding as of September 30, 2016. This number does not include, as of September 30, 2016 (i) 22,431,338 Ordinary
Shares issuable upon the exercise of outstanding options to purchase 22,431,338 Ordinary Shares at a weighted average exercise
price of $0.94 per share, (ii) 4,183,496 Ordinary Shares issuable upon the exercise of outstanding non-tradable warrants to purchase
4,183,496 Ordinary Shares at an exercise price of $1.40 per share and (iii) 3,578,960 Ordinary Shares issuable upon the exercise
of outstanding non-tradable warrants to purchase 3,578,960 Ordinary Shares at an exercise price of $1.10 per share.</P>




<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 41; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><A NAME="a_009"></A><B>PRICE RANGE OF OUR ORDINARY
SHARES </B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our Ordinary Shares have been trading on the TASE under the symbol
&ldquo;RDHL&rdquo; since February 3, 2011. Prior to that date, there was no public market for our Ordinary Shares. U.S. dollar
per Ordinary Share amounts are calculated using the U.S. dollar representative rate of exchange on the date to which the high or
low market price is applicable, as reported by the Bank of Israel. The following table lists the high and low closing prices for
our Ordinary Shares for the periods indicated as reported by the TASE.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid">NIS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid">$U.S.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid">Price per Ordinary <BR> Share</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid">Price per Ordinary <BR> Share</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Annual</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Low</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: justify">2015</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">7.80</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">4.34</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2.03</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1.12</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.96</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.78</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.92</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.19</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.71</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.08</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.45</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">2011 (beginning on February 3, 2011)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.82</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.49</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Third quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.58</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.09</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Second quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.41</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.01</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">First quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.14</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.86</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2015</B></P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Fourth quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.34</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.39</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.12</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Third quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.62</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.88</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.19</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Second quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.52</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.03</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.41</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">First quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.89</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.57</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.26</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2014</B></P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Fourth quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.78</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Third quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.89</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.72</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.20</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Second quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.96</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.39</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">First quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.04</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.96</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.14</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">Most Recent Six Months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">December 2016 (through December 19, 2016)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.08</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">November 2016 &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.74</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.33</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.12</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">October 2016 &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.51</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.45</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.22</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">September 2016&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.84</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.55</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.46</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">August 2016&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.58</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.36</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">July 2016&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.09</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">June 2016&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.01</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">On&nbsp;December 19, 2016,
the last reported sales price of our Ordinary Shares on the TASE was NIS 4.37 per share, or $1.13 per share (based on the exchange
rate reported by the Bank of Israel for such date).&nbsp;On&nbsp;December 19, 2016, the exchange rate of the NIS to the U.S. dollar
was $1.00 = NIS 3.867, as reported by the Bank of Israel.&nbsp;</FONT></P>



<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><A NAME="a_010"></A><FONT STYLE="font-variant: small-caps"><B>PRICE RANGE OF OUR ADSs
</B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Our ADSs have been trading on The NASDAQ under the symbol &ldquo;RDHL&rdquo; since December
26, 2012.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The following table sets forth, for the periods indicated, the reported high and low
closing sale prices of our ADSs on The NASDAQ in U.S. dollars.&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$U.S.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price per ADS</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">Annual</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: justify">2015</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">19.79</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">11.05</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.31</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Third quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.80</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Second quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.79</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">First quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.61</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.21</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2015</B></P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Fourth quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.72</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.05</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Third quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.16</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Second quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19.79</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">First quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.52</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2014</B></P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Fourth quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Third quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.14</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Second quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14.01</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">First quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.38</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;Most Recent Six Months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">December 2016 (through December 19, 2016)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.43</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.71</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">November 2016&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.19</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.91</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">October 2016&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14.47</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.92</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">September 2016&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.89</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">August 2016&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14.55</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">July 2016&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.80</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">June 2016&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On&nbsp;December 19, 2016, the last reported sales price of
our ADSs on The NASDAQ was $<FONT STYLE="background-color: white">10.71</FONT>, per ADS.</P>




<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><A NAME="a_011"></A><B>DIVIDEND POLICY</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We have never declared or paid any cash dividends to our shareholders.
We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do
not anticipate declaring or paying any cash dividends for the foreseeable future.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_011a"></A><B>DESCRIPTION OF WARRANTS WE ARE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>The following summary of certain terms
and provisions of the warrants offered hereby is not complete and is subject to, and qualified in its entirety by the provisions
of the warrant, the form of which will be filed with the SEC by us as an exhibit to a Current Report on Form 6-K in connection
with this offering. Prospective investors should carefully review the terms and provisions of the form of warrant for a complete
description of the terms and conditions of the warrants. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 43; Options: NewSection; Value: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Exercisability.
</I>The warrants are exercisable immediately upon issuance and at any time during the following 36 months. The warrants will be
exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice accompanied
by payment in full for the number of ADSs purchased upon such exercise, together with the ADS issuance fee of $0.05 per ADS and
other applicable charges and taxes. Unless otherwise specified in the form of warrant, the holder (together with its affiliates)
will not have the right to exercise any portion of the warrant, to the extent that after giving effect to the issuance after exercise,
the holder would beneficially own in excess of 9.99% of the number of our ordinary shares outstanding immediately after giving
effect to the exercise, as such percentage is determined in accordance with the terms of the warrants.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Exercise Price. </I>The initial exercise
price per ADS purchasable upon exercise of the warrants is equal to $ per full ADS (which may be adjusted as set forth below).
In addition to the exercise price per ADS, the $0.05 issuance fee per ADS and other applicable charges and taxes are due and payable
upon exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Adjustment Provisions.</I> The exercise
price and the number of ADSs issuable upon exercise are subject to appropriate adjustment in the event of certain stock dividends
and distributions, stock splits, stock subdivisions and combinations, reclassifications or similar events affecting our ADSs or
ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Transferability. </I>Subject to applicable
laws, the warrants may be transferred at the option of the holders upon surrender of the warrants to the warrant agent, together
with the appropriate instruments of transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Exchange Listing.&nbsp;</I>There
is no established public trading market for the warrants, and we do not intend to apply to list the warrants on any securities
exchange or automated quotation system</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Fundamental Transaction</I>. If, at any
time while the warrants are outstanding, (1) we consolidate or merge with or into another person, (2) we sell, lease, license,
assign, transfer, convey or otherwise dispose of all or substantially all of our assets, (3) any purchase offer, tender offer or
exchange offer (whether by us or another person) is completed pursuant to which holders of our ordinary shares are permitted to
sell, tender or exchange their ordinary shares for other securities, cash or property and has been accepted by the holders of 50%
or more of our outstanding shares of ordinary shares, (4) we effect any reclassification or recapitalization of our ADSs or ordinary
shares or any compulsory share exchange pursuant to which our ordinary shares are converted into or exchanged for other securities,
cash or property, or (5) we consummate a stock or share purchase agreement or other business combination with another person whereby
such other person acquires more than 50% of our outstanding ordinary shares, each, a &ldquo;Fundamental Transaction&rdquo;, then
upon any subsequent exercise of the warrants, the holders thereof will have the right to receive the same amount and kind of securities,
cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been,
immediately prior to such Fundamental Transaction, the holder of the number of ADSs then issuable upon exercise of the warrant,
and any additional consideration payable as part of the Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Rights as a Shareholder. </I>Except as
otherwise provided in the Warrants or by virtue of such holder&rsquo;s ownership of ADSs or ordinary shares, the holder of warrants
does not have rights or privileges of a holder of ADSs or ordinary shares, including any voting rights, until the holder exercises
the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><A NAME="a_012"></A>MATERIAL TAX CONSIDERATIONS</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Taxation</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Israeli Tax Considerations</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>General</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a summary of the material tax consequences
under Israeli law concerning the purchase, ownership and disposition of Ordinary Shares, ADSs and warrants to purchase ADSs of
our company.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This discussion does not purport to constitute a complete analysis
of all potential tax consequences applicable to investors upon purchasing, owning or disposing of Ordinary Shares, ADSs and warrants
to purchase ADSs of our company. In particular, this discussion does not take into account the specific circumstances of any particular
investor (such as tax-exempt entities, financial institutions, certain financial companies, broker-dealers, investors that own,
directly or indirectly, 10% or more of our outstanding voting rights, all of whom are subject to special tax regimes not covered
under this discussion). To the extent that issues discussed herein are based on legislation which has yet to be subject to judicial
or administrative interpretation, there can be no assurance that the views expressed herein will accord with any such interpretation
in the future.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Potential investors are urged to consult their own tax advisors
as to the Israeli or other tax consequences of the purchase, ownership and disposition of the Ordinary Shares or ADSs or warrants
to purchase ADSs being offered hereby, including, in particular, the effect of any foreign, state or local taxes.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>General Corporate Tax Structure in Israel</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">As of January 1, 2016 and thereafter, the Israeli corporate tax
rate applicable to Israeli resident companies is 25%.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Taxation of Shareholders</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Capital Gains</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Capital gains tax is imposed on the disposal of capital assets by
an Israeli resident and on the disposal of such assets by a non-Israeli resident if those assets are either (i) located in Israel;
(ii) are shares or a right to a share in an Israeli resident corporation, or (iii) represent, directly or indirectly, rights to
assets located in Israel, unless an exemption is available or unless an applicable double tax treaty between Israel and the seller&rsquo;s
country of residence provides otherwise. The Israeli Income Tax Ordinance distinguishes between &ldquo;Real Gain&rdquo; and the
&ldquo;Inflationary Surplus.&rdquo; Real Gain is the excess of the total capital gain over Inflationary Surplus computed generally
on the basis of the increase in the Israeli Consumer Price Index between the date of purchase and the date of disposal. Inflationary
Surplus is not subject to tax.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Real Gain accrued by individuals on the sale of the Ordinary
Shares, ADSs or warrants to purchase ADSs will be taxed at the rate of 25%. However, if the individual shareholder is a &ldquo;Controlling
Shareholder&rdquo; (<I>i.e</I>., a person who holds, directly or indirectly, alone or together with another, 10% or more of one
of the Israeli resident company&rsquo;s means of control) at the time of sale or at any time during the preceding 12 month period,
such gain will be taxed at the rate of 30%.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Corporate and individual shareholders dealing in securities in Israel
are taxed at the tax rates applicable to business income which is 25% in 2016 for corporations, and a marginal tax rate of up to
50% in 2016 for individuals, including a 2% excess tax (as discussed below).</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Notwithstanding the foregoing, capital gains generated from the
sale of our Ordinary Shares or ADSs by a non-Israeli shareholder may be exempt from Israeli tax under the Israeli Income Tax Ordinance
provided that the following cumulative conditions are met: (i) the Ordinary Shares or ADSs were purchased upon or after the registration
of the Ordinary Shares or ADSs on the stock exchange and (ii) the seller does not have a permanent establishment in Israel to which
the generated capital gain is attributed. However, non-Israeli resident corporations will not be entitled to the foregoing exemption
if Israeli residents: (i)&nbsp;have a 25% or more interest in such non-Israeli corporation or (ii)&nbsp;are the beneficiaries of,
or are entitled to, 25% or more of the income or profits of such non-Israeli corporation, whether directly or indirectly. In addition,
such exemption would not be available to a person whose gains from selling or otherwise disposing of the Ordinary Shares or ADSs
are deemed to be business income.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>



<!-- Field: Page; Sequence: 45; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In addition, the sale of the Ordinary Shares or ADSs may be exempt
from Israeli capital gains tax under the provisions of an applicable double tax treaty. For example, the Convention between the
Government of the U.S. and the Government of the State of Israel with respect to Taxes on Income (the &ldquo;U.S.- Israel Double
Tax Treaty&rdquo;) exempts a U.S. resident (for purposes of the treaty) from Israeli capital gains tax in connection with the sale
of the Ordinary Shares or ADSs, provided that: (i) the U.S. resident owned, directly or indirectly, less than 10% of the voting
power of the company at any time within the 12 month period preceding such sale; (ii) the U.S. resident, being an individual, is
present in Israel for a period or periods of less than 183 days during the taxable year; and (iii) the capital gain from the sale
was not derived through a permanent establishment of the U.S. resident in Israel; however, under the U.S-Israel Double Tax Treaty,
the taxpayer would be permitted to claim a credit for such taxes against the U.S. federal income tax imposed with respect to such
sale, exchange or disposition, subject to the limitations under U.S. law applicable to foreign tax credits. The U.S-Israel Double
Tax Treaty does not relate to U.S. state or local taxes.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In general, the exercise of warrants to purchase ADSs would
not be subject to tax in Israel. Capital gains generated from the sale or other disposition of the warrants to purchase ADSs would
generally be subject to Israeli tax, however, a non-Israeli resident may be exempt from Israeli tax.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payers of consideration for the Ordinary Shares, ADSs or warrants
to purchase ADSs, including the purchaser, the Israeli stockbroker or the financial institution through which the Ordinary Shares
or ADSs are held, are obligated, subject to certain exemptions, to withhold tax upon the sale of Ordinary Shares, ADSs or warrants
to purchase ADSs .</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Upon the sale of traded securities, a detailed return, including
a computation of the tax due, must be filed and an advanced payment must be paid to the Israeli Tax Authority on January 31 and
July 31 of every tax year in respect of sales of traded securities made within the previous six months. However, if all tax due
was withheld at source according to applicable provisions of the Israeli Income Tax Ordinance and regulations promulgated thereunder,
such return need not be filed and no advance payment must be paid. Capital gains are also reportable on annual income tax returns.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Dividends</I></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Dividends distributed by a company to a shareholder who is an Israeli
resident individual will be generally subject to income tax at a rate of 25%. However, a 30% tax rate will generally apply if the
dividend recipient is a Controlling Shareholder, as defined above, at the time of distribution or at any time during the preceding
12 month period. If the recipient of the dividend is an Israeli resident corporation, such dividend will generally not be subject
to tax provided that the income from which such dividend is distributed, derived or accrued within Israel.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Dividends distributed by an Israeli resident company to a non-Israeli
resident (either an individual or a corporation) are generally subject to Israeli withholding tax on the receipt of such dividends
at the rate of 25% (30% if the dividend recipient is a Controlling Shareholder at the time of distribution or at any time during
the preceding 12 month period). These rates may be reduced under the provisions of an applicable double tax treaty. For example,
under the U.S.-Israel Double Tax Treaty, the following tax rates will apply in respect of dividends distributed by an Israeli resident
company to a U.S. resident: (i) if the U.S. resident is a corporation which holds during that portion of the taxable year which
precedes the date of payment of the dividend and during the whole of its prior taxable year (if any), at least 10% of the outstanding
shares of the voting stock of the Israeli resident paying corporation and not more than 25% of the gross income of the Israeli
resident paying corporation for such prior taxable year (if any) consists of certain types of interest or dividends the tax rate
is 12.5%; (ii) if both the conditions mentioned in clause (i) above are met and the dividend is paid from an Israeli resident company&rsquo;s
income which was entitled to a reduced tax rate under The Law for the Encouragement of Capital Investments, 1959, the tax rate
is 15%; and (iii) in all other cases, the tax rate is 25%. The aforementioned rates under the U.S.-Israel Double Tax Treaty will
not apply if the dividend income is attributed to a permanent establishment of the U.S. resident in Israel.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Excess Tax</I></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Individual holders who are subject to tax in Israel (whether
any such individual is an Israeli resident or non-Israeli resident) and who have taxable income that exceeds a certain threshold
in a tax year (NIS 810,720 for 2016, which is approximately $209,651, based on the representative U.S. dollar &ndash; NIS rate
of exchange of 3.867 on December 19, 2016)), will be subject to an additional tax at the rate of 2% on his or her taxable income
for such tax year that is in excess of such amount. For this purpose, taxable income includes taxable capital gains from the sale
of securities and taxable income from interest and dividends, subject to the provisions of an applicable double tax treaty.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 46; Options: NewSection; Value: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Proposed Amendments to Israeli Tax Law</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2016, a bill was presented to the Israeli parliament
(the Knesset), which, if passed, would, commencing in 2017, reduce the marginal tax rate for individuals from 48% to 47% and increase
the excess tax applicable to individuals described above to 3% on income that exceeds a certain threshold in a tax year (NIS 640,000
for 2017, which is approximately $165,503, based on the representative U.S. dollar &ndash; NIS rate of exchange of 3.867 on December
19, 2016). In addition, the bill, if passed, would, reduce the corporate tax to 24% in 2017 and 23% in 2018 and thereafter. The
aforesaid proposed amendments were approved by the Finance Committee of the Knesset in December 2016 and are expected to be brought
to the Knesset for approval in the near future. There can be no assurance whether the Knesset will approve the proposed amendments
as described above, in another form or at all.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>U.S. Federal Income Tax Considerations</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a summary of the material U.S. federal income
tax consequences relating to the ownership and disposition of our Ordinary Shares, ADSs and warrants to purchase ADSs (&ldquo;Warrants&rdquo;)
by U.S. Holders, as defined below. This summary addresses solely U.S. Holders who acquire ADSs and Warrants pursuant to this offering
and who hold Ordinary Shares, ADSs or Warrants as applicable, as capital assets for tax purposes. This summary is based on current
provisions of the Internal Revenue Code of 1986, as amended (&ldquo;Code&rdquo;), current and proposed Treasury regulations promulgated
thereunder, and administrative and judicial decisions as of the date hereof, all of which are subject to change, possibly on a
retroactive basis. In addition, this section is based in part upon representations of the Depositary and the assumption that each
obligation in the deposit agreement and any related agreement will be performed in accordance with its terms. This summary does
not address all U.S. federal income tax matters that may be relevant to a particular holder or all tax considerations that may
be relevant with respect to an investment in our Ordinary Shares,ADSs or Warrants.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This summary does not address tax considerations applicable
to a holder of our Ordinary Shares, ADSs or Warrants that may be subject to special tax rules including, without limitation, the
following:</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">dealers or traders in securities, currencies or notional principal contracts;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">financial institutions;</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">insurance companies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">real estate investment trusts;</FONT></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">banks;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">persons subject to the alternative minimum tax;</FONT></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">tax-exempt organizations;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">traders that have elected mark-to-market accounting;</FONT></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">investors that hold Ordinary Shares, ADSs or Warrants as part of a &ldquo;straddle&rdquo;, &ldquo;hedge&rdquo;,
or &ldquo;conversion transaction&rdquo; with other investments;</P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">regulated investment companies;</FONT></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">persons that actually or constructively own 10 percent or more of our voting shares;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">persons that are treated as partnerships or other pass through entities for U.S. federal income tax purposes
and persons who hold Ordinary Shares, ADSs or Warrants through partnerships or other pass through entities; and</P>


</TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">persons whose functional currency is not the U.S. dollar.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This summary does not address the effect of any U.S. federal
taxation other than U.S. federal income taxation. In addition, this summary does not address any state, local, or foreign tax consequences
to a holder of our Ordinary Shares, ADSs or Warrants.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>You are urged to consult your own tax advisor regarding the
foreign and U.S. federal, state, and local and other tax consequences of an investment in our Ordinary Shares, ADSs or Warrants.</B></P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of this summary, a &ldquo;U.S. Holder&rdquo; means
a beneficial owner of an Ordinary Share,ADS or Warrants that is for U.S. federal income tax purposes:</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an individual who is a citizen or resident of the U.S.;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or organized in the U.S. or under the laws of the U.S. or any political subdivision thereof;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a trust (1) if (a) a court within the U.S. is able to exercise primary supervision over the administration of the trust and (b) one or more U.S. persons have the authority to control all substantial decisions of the trust or (2) that has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 47; Options: NewSection; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an entity that is classified as a partnership for U.S. federal
tax purposes holds Ordinary Shares, ADSs or Warrants the U.S. federal tax treatment of its partners will generally depend upon
the status of the partners and the activities of the partnership. Entities that are classified as partnerships for U.S. federal
tax purposes and persons holding Ordinary Shares, ADSs or Warrants through such entities should consult their own tax advisors.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Allocation of Purchase Price to ADSs and Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For U.S. federal income tax purposes, a U.S. Holder&rsquo;s
acquisition of ADSs and Warrants will be treated as the acquisition of an &ldquo;investment unit&rdquo; consisting of one ADS and
a warrant to purchase 0.5 of an ADS. The purchase price for each unit will be allocated between these two components in proportion
to their relative fair market values at the time the unit is purchased by a U.S. Holder. This allocation of the purchase price
for each unit will establish a U.S. Holder&rsquo;s initial tax basis for U.S. federal income tax purposes in the ADS and the Warrant
included in each unit. Each U.S. Holder should consult its own tax advisor regarding the allocation of the purchase price for a
unit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Taxation of Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Exercise of Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A U.S. Holder will not be required to recognize taxable gain
or loss upon the exercise of a Warrant for ADSs, except with respect to cash received in lieu of a fractional ADS. The U.S. Holder&rsquo;s
adjusted tax basis in the ADSs received upon exercise generally will be an amount equal to the sum of the holder&rsquo;s tax basis
in the Warrant plus the exercise price of the Warrant, less any portion of the tax basis attributable to the receipt of cash in
lieu of a fractional ADS. Except as provided under the heading &ldquo;Passive Foreign Investment Companies&rdquo; below, the holding
period for the ADSs received upon exercise of the Warrant will begin on the date of exercise of the Warrant. A U.S. Holder&rsquo;s
receipt of cash in lieu of a fractional ADS will generally be treated as if such U.S. Holder had received the fractional ADS upon
exercise of the Warrant and then received such cash in redemption of such ADS. For more information regarding the tax considerations
related to the ownership and disposition of our ADSs acquired upon exercise of the Warrant, see the discussion below regarding
&ldquo;Taxation of ADSs.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Lapse of Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except as provided under the heading &ldquo;Passive Foreign
Investment Companies&rdquo; below, if a Warrant is allowed to lapse unexercised, a U.S. Holder will recognize a capital loss in
an amount equal to its tax basis in the Warrant. Such loss will be long-term capital loss if the Warrant has been held for more
than one year as of the date the Warrant lapsed. The deductibility of capital losses is subject to limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Disposition of Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except as provided under the heading &ldquo;Passive Foreign
Investment Companies&rdquo; below, upon the sale, exchange or other disposition of our Warrants, a U.S. Holder will recognize capital
gain or loss in an amount equal to the difference between such U.S. Holder&rsquo;s tax basis in the sold Warrants and the amount
realized on the disposition of such Warrants (or its U.S. dollar equivalent determined by reference to the spot rate of exchange
on the date of disposition, if the amount realized is denominated in a foreign currency). The gain or loss realized on the sale
or exchange or other disposition of Warrants will be long-term capital gain or loss if the U.S. Holder has a holding period in
the warrants of more than one year at the time of the disposition. The deductibility of capital losses is subject to limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Certain Adjustments to Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under Section 305 of the Code, an adjustment to the number of
ADSs that will be issued on the exercise of the Warrants, or an adjustment to the exercise price of the Warrants, may be treated
as a constructive distribution to a U.S. Holder of the Warrants if, and to the extent that, such adjustment has the effect of increasing
such U.S. Holder&rsquo;s proportionate interest in our &quot;earnings and profits&quot; or assets, depending on the circumstances
of such adjustment (for example, if such adjustment is to compensate for a distribution of cash or other property to our shareholders).
For more information regarding the tax considerations related to distributions, see the discussion below regarding &ldquo;Taxation
of ADSs.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 48; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Taxation of ADSs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Exchange of ADSs for Ordinary Shares</I></P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In general, if you hold ADSs, you will be treated as the holder
of the underlying Ordinary Shares represented by those ADSs for U.S. federal income tax purposes. Accordingly, gain or loss generally
will not be recognized if you exchange ADSs for the underlying Ordinary Shares represented by those ADSs.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Distributions</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the discussion under &ldquo;Passive
Foreign Investment Companies&rdquo; below, the gross amount of any distribution, including the amount of any Israeli taxes withheld
from such distribution (see &ldquo;Israeli Tax Considerations&rdquo;), actually or constructively received by a U.S. Holder with
respect to our Ordinary Shares (or, in the case of ADSs, received by the Depositary) will be taxable to the U.S. Holder as foreign
source dividend income to the extent of our current and accumulated earnings and profits as determined under U.S. federal income
tax principles. The U.S. Holder will not be eligible for any dividends received deduction in respect of the dividends paid by us.
Distributions in excess of earnings and profits will be non-taxable to the U.S. Holder to the extent of the U.S. Holder&rsquo;s
adjusted tax basis in its Ordinary Shares or ADSs. Distributions in excess of such adjusted tax basis will generally be taxable
to the U.S. Holder as capital gain from the sale or exchange of property as described below under &ldquo;Sale or Other Disposition
of Ordinary Shares or ADSs.&rdquo; If we do not report to a U.S. Holder the portion of a distribution that exceeds earnings and
profits, the distribution will generally be taxable as a dividend. The amount of any distribution of property other than cash will
be the fair market value of that property on the date of distribution.</P>




<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Under the Code, certain dividends received by non-corporate U.S.
Holders will be subject to a maximum federal income tax rate of 20%. This reduced income tax rate is only applicable to dividends
paid by a &ldquo;qualified foreign corporation&rdquo; that is not a PFIC for the year in which the dividend is paid or for the
preceding taxable year, and only with respect to Ordinary Shares or ADSs held by a qualified U.S. Holder (i.e., a non-corporate
holder) for a minimum holding period (generally 61 days during the 121-day period beginning 60 days before the ex-dividend date).
As discussed below, however, we believe we may be a &ldquo;passive foreign investment company&rdquo; (see &ldquo;Passive Foreign
Investment Companies&rdquo; below) for our current taxable year and future taxable years. Accordingly, dividends paid by us to
individual U.S. Holders may not be eligible for the reduced income tax rate applicable to qualified dividends. You should consult
your own tax advisor regarding the availability of this preferential tax rate under your particular circumstances.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The amount of any distribution paid in a currency other than U.S.
dollars (a &ldquo;foreign currency&rdquo;), including the amount of any withholding tax thereon, will be included in the gross
income of a U.S. Holder in an amount equal to the U.S. dollar value of the foreign currency calculated by reference to the exchange
rate in effect on the date of the U.S. Holder&rsquo;s (or, in the case of ADSs, the Depositary&rsquo;s) receipt of the dividend,
regardless of whether the foreign currency is converted into U.S. dollars. If the foreign currency is converted into U.S. dollars
on the date of receipt, a U.S. Holder generally should not be required to recognize a foreign currency gain or loss in respect
of the dividend. If the foreign currency received in the distribution is not converted into U.S. dollars on the date of receipt,
a U.S. Holder will have a basis in the foreign currency equal to its U.S. dollar value on the date of receipt. Any gain or loss
on a subsequent conversion or other disposition of the foreign currency will be treated as U.S. source ordinary income or loss.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Subject to certain conditions and limitations, any Israeli taxes
withheld on dividends may be creditable against a U.S. Holder&rsquo;s U.S. federal income tax liability, subject to generally applicable
limitations. The rules relating to foreign tax credits and the timing thereof are complex. U.S. Holders should consult their own
tax advisors regarding the availability of a foreign tax credit in their particular situation.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 49; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>Sale or Other Disposition of Ordinary Shares or ADSs</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Subject to the discussion under &ldquo;Passive Foreign Investment
Companies&rdquo; below, if a U.S. Holder sells or otherwise disposes of its Ordinary Shares or ADSs, gain or loss will be recognized
for U.S. federal income tax purposes in an amount equal to the difference between the amount realized on the sale or other disposition
and such holder&rsquo;s adjusted basis in the Ordinary Shares or ADSs. Such gain or loss generally will be a capital gain or loss,
and will be a long-term capital gain or loss if the holder had held the Ordinary Shares or ADSs for more than one year at the time
of the sale or other disposition. Long-term capital gains realized by non-corporate U.S. Holders are generally subject to a preferential
U.S. federal income tax rate. In general, gain or loss recognized by a U.S. Holder on the sale or other disposition or our Ordinary
Shares or ADSs will be U.S. source gain or loss for purposes of the foreign tax credit limitation. As discussed below in &ldquo;Passive
Foreign Investment Companies,&rdquo; however, we may be a PFIC for our current taxable year and future taxable years. If we are
a PFIC, any such gain will be subject to the PFIC rules, as discussed below, rather than being taxed as a capital gain.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">If a U.S. Holder receives foreign currency upon a sale or exchange
of Ordinary Shares or ADSs, gain or loss will be recognized in the manner described above under &ldquo;Distributions.&rdquo; However,
if such foreign currency is converted into U.S. dollars on the date received by the U.S. Holder, the U.S. Holder generally should
not be required to recognize any foreign currency gain or loss on such conversion.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">As discussed above under the heading &ldquo;Israeli Tax Considerations-Taxation
of Shareholders,&rdquo; a U.S. Holder who holds Ordinary Shares or ADSs through an Israeli broker or other Israeli intermediary
may be subject to Israeli withholding tax on any capital gains recognized on a sale or other disposition of the Ordinary Shares
or ADSs if the U.S. Holder does not obtain approval of an exemption from the Israeli Tax Authorities or claim any allowable refunds
or reductions. U.S. Holders are advised that any Israeli tax paid under circumstances in which an exemption from (or a refund of
or a reduction in) such tax was available will not be creditable for U.S. federal income tax purposes. U.S. Holders are advised
to consult their Israeli broker or intermediary regarding the procedures for obtaining an exemption or reduction.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>Medicare Tax on Unearned Income</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Certain U.S. Holders that are individuals, estates or trusts are
required to pay an additional 3.8% tax on their net investment income, which would include dividends paid on the Ordinary Shares
or ADSs and capital gains from the sale or other disposition of the Ordinary Shares or ADSs.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Passive Foreign Investment Companies</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Based on the value and composition of our assets, we may be a PFIC
for U.S. federal income tax purposes for our current taxable year and future taxable years. A non-U.S. corporation is considered
a PFIC for any taxable year if either:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">at least 75% of its gross income for such taxable year is passive income, or</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">at least 50% of the value of its assets (based on an average of the quarterly values of the assets during a taxable year) is attributable to assets that produce or are held for the production of passive income.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">For purposes of the above calculations, if a non-U.S. corporation
owns, directly or indirectly, 25% or more of the total value of the outstanding shares of another corporation, it will be treated
as if it (a)&nbsp;held a proportionate share of the assets of such other corporation and (b)&nbsp;received directly a proportionate
share of the income of such other corporation. Passive income generally includes dividends, interest, rents, royalties and capital
gains, but generally excludes rents and royalties which are derived in the active conduct of a trade or business and which are
received from a person other than a related person.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A separate determination must be made each taxable year as to
whether we are a PFIC (after the close of each such taxable year). Because the value of our assets for purposes of the asset test
will generally be determined by reference to the market price of our Ordinary Shares, our PFIC status will depend in large part
on the market price of the Ordinary Shares, which may fluctuate significantly. Based on our retention of a significant amount of
cash and cash equivalents, and depending on the market price of the ADSs, we may be a PFIC for the current taxable year and future
taxable years.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">If we are a PFIC for any year during which you hold the ADSs, we
generally will continue to be treated as a PFIC with respect to you for all succeeding years during which you hold the ADSs, unless
we cease to be a PFIC and you make a &ldquo;deemed sale&rdquo; election with respect to the ADSs you hold. If such election is
made, you will be deemed to have sold the ADSs you hold at their fair market value on the last day of the last taxable year in
which we qualified as a PFIC, and any gain from such deemed sale would be subject to the consequences described below. After the
deemed sale election, the ADSs with respect to which the deemed sale election was made will not be treated as shares in a PFIC
unless we subsequently become a PFIC.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">For each taxable year we are treated as a PFIC with respect to you,
you will be subject to special tax rules with respect to any &ldquo;excess distribution&rdquo; you receive and any gain you realize
from a sale or other disposition (including a pledge) of the ADSs, unless you make a &ldquo;mark-to-market&rdquo; election as discussed
below. Distributions you receive in a taxable year that are greater than 125% of the average annual distributions you received
during the shorter of the three preceding taxable years or your holding period for the ADSs will be treated as an excess distribution.
Under these special tax rules, if you receive any excess distribution or realize any gain from a sale or other disposition of the
ADSs:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the excess distribution or gain will be allocated ratably over your holding period for the ADSs</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the amount of excess distribution or gain allocated to the current taxable year, and any taxable year before the first taxable year in which we were a PFIC, shall be included in gross income (as ordinary income) for the current tax year, and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the amount allocated to each other year will be subject to the highest tax rate in effect for that year and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The tax liability for amounts allocated to years before the year
of disposition or &ldquo;excess distribution&rdquo; cannot be offset by any net operating losses for such years, and gains (but
not losses) realized on the sale of the ADSs cannot be treated as capital, even if you hold the ADSs as capital assets.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">If we are treated as a PFIC with respect to you for any taxable
year, to the extent any of our subsidiaries, if any, are also PFICs, you will be deemed to own your proportionate share of any
such lower-tier PFIC, and you may be subject to the rules described in the preceding two paragraphs with respect to the shares
of such lower-tier PFICs you would be deemed to own. As a result, you may incur liability for any &ldquo;excess distribution&rdquo;
described above if we receive a distribution from such lower-tier PFICs or if any shares in such lower-tier PFICs are disposed
of (or deemed disposed of). You should consult your own tax advisor regarding the application of the PFIC rules to any of our subsidiaries.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Alternatively, a U.S. Holder of &ldquo;marketable stock&rdquo; (as
defined below) in a PFIC may make a mark-to-market election for such stock to elect out of the general tax treatment for PFICs
discussed above. If you make a mark-to-market election for the ADSs, you will include in income for each year we are a PFIC an
amount equal to the excess, if any, of the fair market value of the ADSs as of the close of your taxable year over your adjusted
basis in such ADSs.You are allowed a deduction for the excess, if any, of the adjusted basis of the ADSs over their fair market
value as of the close of the taxable year. However, deductions are allowable only to the extent of any net mark-to-market gains
on the ADSs included in your income for prior taxable years. Amounts included in your income under a mark-to-market election, as
well as gain on the actual sale or other disposition of the ADSs, are treated as ordinary income. Ordinary loss treatment also
applies to the deductible portion of any mark-to-market loss on the ADSs, as well as to any loss realized on the actual sale or
disposition of the ADSs to the extent the amount of such loss does not exceed the net mark-to-market gains previously included
for the ADSs. Your basis in the ADSs will be adjusted to reflect any such income or loss amounts. If you make a valid mark-to-market
election, the tax rules that apply to distributions by corporations which are not PFICs would apply to distributions by us, except
the lower applicable tax rate for qualified dividend income would not apply. If we cease to be a PFIC when you have a mark-to-market
election in effect, gain or loss realized by you on the sale of the ADSs will be a capital gain or loss and taxed in the manner
described above under &ldquo;Sale or Other Disposition of Ordinary Shares or ADSs.&rdquo;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The mark-to-market election is available only for &ldquo;marketable
stock,&rdquo; which is stock that is traded in other than de minimis quantities on at least 15 days during each calendar quarter,
or regularly traded, on a qualified exchange or other market, as defined in applicable U.S. Treasury regulations. Any trades that
have as their principal purpose meeting this requirement will be disregarded. The ADSs are listed on The NASDAQ and, accordingly,
provided the ADSs are regularly traded, if you are a holder of ADSs, the mark-to-market election would be available to you if we
are a PFIC. Once made, the election cannot be revoked without the consent of the IRS unless the ADSs cease to be marketable stock.
If we are a PFIC for any year in which the U.S. Holder owns ADSs but before a mark-to-market election is made, the interest charge
rules described above will apply to any mark-to-market gain recognized in the year the election is made. If any of our subsidiaries,
if any, are or become PFICs, the mark-to-market election will not be available with respect to the shares of such subsidiaries
that are treated as owned by you. Consequently, you could be subject to the PFIC rules with respect to income of the lower-tier
PFICs the value of which already had been taken into account indirectly via mark-to-market adjustments. A U.S. Holder should consult
its own tax advisors as to the availability and desirability of a mark-to-market election, as well as the impact of such election
on interests in any lower-tier PFICs.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In certain circumstances, a U.S. Holder of stock in a PFIC can make
a &ldquo;qualified electing fund election&rdquo; to mitigate some of the adverse tax consequences of holding stock in a PFIC by
including in income its share of the corporation&rsquo;s income on a current basis. However, we do not currently intend to prepare
or provide the information that would enable you to make a qualified electing fund election.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Unless otherwise provided by the U.S. Treasury, each U.S. shareholder
of a PFIC is required to file an annual report containing such information as the U.S. Treasury may require. A U.S. Holder&rsquo;s
failure to file the annual report will cause the statute of limitations for such U.S. Holder&rsquo;s U.S. federal income tax return
to remain open with regard to the items required to be included in such report until three years after the U.S. Holder files the
annual report, and, unless such failure is due to reasonable cause and not willful neglect, the statute of limitations for the
U.S. Holder&rsquo;s entire U.S. federal income tax return will remain open during such period. U.S. Holders should consult their
own tax advisors regarding the requirements of filing such information returns under these rules, taking into account the uncertainty
as to whether we are currently treated as or may become a PFIC.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">YOU ARE STRONGLY URGED TO CONSULT YOUR OWN TAX ADVISOR REGARDING
THE IMPACT OF OUR POTENTIAL PFIC STATUS ON YOUR INVESTMENT IN THE ADSs AS WELL AS THE APPLICATION OF THE PFIC RULES TO YOUR INVESTMENT
IN THE ADSs.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Backup Withholding and Information Reporting</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Payments of dividends with respect to Ordinary Shares or ADSs and
the proceeds from the sale, retirement, or other disposition of Ordinary Shares or ADSs made by a U.S. paying agent or other U.S.
intermediary will be reported to the IRS and to the U.S. Holder as may be required under applicable U.S. Treasury regulations.
We, or an agent, a broker, or any paying agent, as the case may be, may be required to withhold tax (backup withholding), currently
at the rate of 28%, if a non-corporate U.S. Holder that is not otherwise exempt fails to provide an accurate taxpayer identification
number and comply with other IRS requirements concerning information reporting. Certain U.S. Holders (including, among others,
corporations and tax-exempt organizations) are not subject to backup withholding. Any amount of backup withholding withheld may
be used as a credit against your U.S. federal income tax liability provided that the required information is furnished to the IRS.
U.S. Holders should consult their own tax advisors as to their qualification for exemption from backup withholding and the procedure
for obtaining an exemption.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">U.S. Holders may be required to file certain U.S. information reporting
returns with the IRS with respect to an investment in our Ordinary Shares or ADSs, including, among others, IRS Form 8938 (Statement
of Specified Foreign Financial Assets). As described above under &lsquo;&lsquo;Passive Foreign Investment Companies,&rdquo; each
U.S. Holder who is a shareholder of a PFIC must file an annual report containing certain information. U.S. Holders paying more
than $100,000 for our Ordinary Shares or ADSs may be required to file IRS Form 926 (Return by a U.S. Transferor of Property to
a Foreign Corporation) reporting this payment. Substantial penalties may be imposed upon a U.S. Holder that fails to comply with
the required information reporting.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">U.S. Holders should consult their own tax advisors regarding the
backup withholding tax and information reporting rules.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR
REGARDING THE TAX CONSEQUENCES OF AN INVESTMENT IN OUR ORDINARY SHARES OR ADSs IN LIGHT OF SUCH INVESTOR&rsquo;S PARTICULAR CIRCUMSTANCES.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><A NAME="a_013"></A>UNDERWRITING</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to the terms and conditions set forth in the underwriting
agreement, dated December , 2016, between us and Roth Capital Partners, LLC, 888 San Clemente Drive, Newport Beach, CA 92660, as
the representative of the underwriters named below and the sole book-running manager of this offering, we have agreed to sell to
the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the respective number
of ADSs and warrants shown opposite its name below:</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; font-weight: bold; text-decoration: underline; padding-bottom: 1pt">Underwriter</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Number of ADSs </U></B></FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Number of warrants </U></B></FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Roth Capital Partners, LLC&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Echelon Wealth Partners Inc.&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.25pt; padding-left: 20pt">Total&#9;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Echelon Wealth Partners Inc. is a manager only for Canadian offers
and sales to &ldquo;permitted clients&rdquo; as such term is defined in section 1.1 of National Instrument 31-103 Registration
Requirements, Exemptions and Ongoing Registrant Obligations.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The underwriting agreement provides that the obligations of
the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters of officers&rsquo;
certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that
the underwriters will purchase all of the ADSs and warrants if any of them are purchased. If an underwriter defaults, the underwriting
agreement provides that the purchase commitments of the non-defaulting underwriters may be increased or the underwriting agreement
may be terminated. We have agreed to indemnify the underwriters and certain of their controlling persons against certain liabilities,
including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in
respect of those liabilities.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The underwriters have advised us that, following the completion
of this offering, they currently intend to make a market in the ADSs as permitted by applicable laws and regulations. However,
the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without
notice in their sole discretion. Accordingly, no assurance can be given as to the liquidity of the trading market for the ADSs,
that you will be able to sell any of the ADSs held by you at a particular time or that the prices that you receive when you sell
will be favorable.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The underwriters are offering the ADSs and warrants subject
to their acceptance of the ADSs and warrants from us and subject to prior sale. The underwriters reserve the right to withdraw,
cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that
they do not intend to confirm sales to any account over which they exercise discretionary authority.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain of our directors have indicated an interest in purchasing
(or having their affiliates purchase) approximately $1,600,000 of our ADSs and warrants in this offering. Because indications of
interest are not binding agreements or commitments to purchase, these persons may decide to buy, or the underwriters may decide
to sell to them, a greater or lesser amount of ADSs and warrants or no ADSs or warrants at all. The underwriters will receive the
same underwriting discount on any ADSs and warrants purchased by these persons as they will on the other ADSs and warrants sold
to the public in this offering.</P>






<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 53; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Commission and Expenses</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The underwriters have advised us that they propose to offer
the ADSs and warrants to the public at the public offering price set forth on the cover page of this prospectus supplement and
to certain dealers, which may include the underwriters, at that price less a concession not in excess of $ &nbsp;&nbsp;&nbsp;&nbsp;per
a fixed combination of one ADS and a warrant to purchase 0.5 of an ADS. The underwriters may allow, and certain dealers may reallow,
a discount from the concession not in excess of $ &nbsp;&nbsp;&nbsp;&nbsp;per a fixed combination of one ADS and a warrant to purchase
0.5 of an ADS to certain brokers and dealers. After the offering, the public offering price, concession and reallowance to dealers
may be reduced by the representatives. No such reduction will change the amount of proceeds to be received by us as set forth on
the cover page of this prospectus supplement.</P>




<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>


<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The following table shows the public offering price, the underwriting discounts and commissions
that we are to pay the underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are
shown assuming both no exercise and full exercise of the underwriters&rsquo; option to purchase additional ADSs.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt 0">Per ADS and accompanying warrant</P>


</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Without<BR> Option to <BR>
Purchase <BR>
Additional <BR>
ADSs</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">With<BR> Option to <BR>
Purchase <BR>
Additional <BR>
ADSs</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Without<BR> Option to <BR>
Purchase <BR>
Additional <BR>
ADSs</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">With<BR> Option to <BR>
Purchase <BR>
Additional <BR>
ADSs</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-size: 10pt">Public offering price&#9;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Underwriting
discounts and commissions for securities sold to certain agreed upon investors originally identified by us</P>


</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Underwriting
discounts and commissions for securities sold to all other investors</P>


</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Proceeds to us, before expenses&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We estimate that the expenses of this offering payable by us,
not including underwriting discounts and commissions, will be approximately&nbsp;$ .</P>




<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company may elect to pay certain of the underwriters an
additional fee based on their efforts and results of the offering. In addition to the amounts payable to the underwriters, the
Company may pay to banks and brokers in non-U.S. jurisdictions who raise capital in connection with this offering in such non-U.S.
jurisdictions, an amount equal to 2% to 3% of the amounts raised by such non-U.S. banks and brokers. In addition, we have agreed
to reimburse the underwriters up to $ for certain legal and out-of-pocket expenses, including their FINRA counsel fees, related
to this offering. In accordance with FINRA Rule 5110 these reimbursed fees and expenses are deemed underwriting compensation for
this offering. In no event shall such discretionary and additional fees and reimbursements together with the underwriting discounts
and commissions exceed 8% of the offering proceeds, which excludes any proceeds from the sales made under the option to purchase
additional shares.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Listing</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our ADSs are listed on The NASDAQ Capital Market under the trading
symbol &ldquo;RDHL.&rdquo; There is no established trading market for the warrants, and we do not expect a market to develop. In
addition, we do not intend to list the warrants on The NASDAQ, the TASE or any other national securities exchange or any other
recognized trading system. Wwarrant holders are prohibited from listing any warrants on any such exchange or trading system or
on any other trading platform.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Stamp Taxes</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you purchase ADSs and warrants offered in this prospectus
supplement, you may be required to pay stamp taxes and other charges under the laws and practices of the country of purchase, in
addition to the offering price listed on the cover page of this prospectus supplement.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Option to Purchase Additional ADSs</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have granted to the underwriters an option, exercisable for
30 days from the date of the underwriting agreement, to purchase, from time to time, in whole or in part, up to an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs from us at the public offering price set forth on the cover page of this prospectus supplement, less underwriting discounts
and commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to specified conditions,
to purchase a number of additional ADSs proportionate to that underwriter&rsquo;s initial purchase commitment as indicated in the
table above. This option may be exercised only if the underwriters sell more ADSs than the total number set forth on the cover
page of this prospectus supplement.</P>





<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 54; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>No Sales of Similar Securities</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We, our officers and our directors have agreed, subject to specified
exceptions, not to directly or indirectly:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer,
establish an open &ldquo;put equivalent position&rdquo; within the meaning of Rule 16a-l(h) under the Securities Exchange Act of
1934, as amended, or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">otherwise dispose of any ADSs, ordinary shares, options or warrants to acquire ordinary shares
or ADSs, or securities exchangeable or exercisable for or convertible into ordinary shares or ADSs currently or hereafter owned
either of record or beneficially, or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">publicly announce an intention to do any of the foregoing for a period of 90 days after the date of this
prospectus supplement without the prior written consent of Roth Capital Partners, LLC.</P>


</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This restriction terminates after the close of trading of the ADSs
and the ordinary shares on and including the 90<SUP>th</SUP> day after the date of this prospectus supplement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Roth Capital Partners, LLC may, in its sole discretion and at
any time or from time to time before the termination of the 90-day period release all or any portion of the securities subject
to lock-up agreements. There are no existing agreements between the underwriters and any of our shareholders who will execute a
lock-up agreement, providing consent to the sale of ADSs, Ordinary Shares or warrants prior to the expiration of the lock-up period.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Stabilization</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The underwriters have advised us that they, pursuant to Regulation
M under the Securities Exchange Act of 1934, as amended, and certain persons participating in the offering may engage in short
sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with
this offering. These activities may have the effect of stabilizing or maintaining the market price of the ADSs at a level above
that which might otherwise prevail in the open market. Establishing short sales positions may involve either &ldquo;covered&rdquo;
short sales or &ldquo;naked&rdquo; short sales.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&ldquo;Covered&rdquo; short sales are sales made in an amount not
greater than the underwriters&rsquo; option to purchase additional shares of our ADSs in this offering. The underwriters may close
out any covered short position by either exercising their option to purchase additional ADSs or purchasing our ADSs in the open
market. In determining the source of ADSs to close out the covered short position, the underwriters will consider, among other
things, the price of ADSs available for purchase in the open market as compared to the price at which they may purchase ADSs through
the option to purchase additional ADSs.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&ldquo;Naked&rdquo; short sales are sales in excess of the option
to purchase additional ADSs. The underwriters must close out any naked short position by purchasing ADSs in the open market. A
naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the
price of our ADSs in the open market after pricing that could adversely affect investors who purchase in this offering.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">A stabilizing bid is a bid for the purchase of ADSs on behalf of
the underwriters for the purpose of fixing or maintaining the price of the ADSs. A syndicate covering transaction is the bid for
or the purchase of ADSs on behalf of the underwriters to reduce a short position incurred by the underwriters in connection with
the offering. Similar to other purchase transactions, the underwriter&rsquo;s purchases to cover the syndicate short sales may
have the effect of raising or maintaining the market price of our ADSs or preventing or retarding a decline in the market price
of our ADSs. As a result, the price of our ADSs may be higher than the price that might otherwise exist in the open market. A penalty
bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in
connection with the offering if the ADSs originally sold by such syndicate member are purchased in a syndicate covering transaction
and therefore have not been effectively placed by such syndicate member.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Neither we, nor any of the underwriters make any representation
or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our
ADSs. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued
at any time.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The underwriters may also engage in passive market making transactions
in our ADSs on The NASDAQ Capital Market in accordance with Rule&nbsp;103 of Regulation&nbsp;M during a period before the commencement
of offers or sales of our ADSs in this offering and extending through the completion of distribution. A passive market maker must
display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are
lowered below the passive market maker&rsquo;s bid, that bid must then be lowered when specified purchase limits are exceeded.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 55; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Electronic Distribution</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A prospectus in electronic format may be made available by e-mail
or on the web sites or through online services maintained by one or more of the underwriters or their affiliates. In those cases,
prospective investors may view offering terms online and may be allowed to place orders online. The underwriters may agree with
us to allocate a specific number of ADSs and warrants for sale to online brokerage account holders. Any such allocation for online
distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic
format, the information on the underwriters&rsquo; web sites and any information contained in any other web site maintained by
any of the underwriters is not part of this prospectus supplement, has not been approved and/or endorsed by us or the underwriters
and should not be relied upon by investors.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Other Activities and Relationships </B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The underwriters and certain of their affiliates are full service
financial institutions engaged in various activities, which may include securities trading, commercial and investment banking,
financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities.
The underwriters and certain of their affiliates have, from time to time, performed, and may in the future perform, various commercial
and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary
fees and expenses.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In the ordinary course of their various business activities, the
underwriters and certain of their affiliates may make or hold a broad array of investments and actively trade debt and equity securities
(or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts
of their customers, and such investment and securities activities may involve securities and/or instruments issued by us and our
affiliates. If the underwriters or their respective affiliates have a lending relationship with us, they routinely hedge their
credit exposure to us consistent with their customary risk management policies. The underwriters and their respective affiliates
may hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation
of short positions in our securities or the securities of our affiliates, including potentially the ADSs offered hereby. Any such
short positions could adversely affect future trading prices of the ADSs offered hereby. The underwriters and certain of their
respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish
or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients
that they acquire, long and/or short positions in such securities and instruments.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 56; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><A NAME="a_014"></A><B>NOTICE TO INVESTORS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Canada</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus supplement constitutes an &ldquo;exempt offering
document&rdquo; as defined in and for the purposes of applicable Canadian securities laws. No prospectus has been filed with any
securities commission or similar regulatory authority in Canada in connection with the offer and sale of the ADSs and warrants.
No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon this prospectus supplement
or on the merits of the ADSs and warrants and any representation to the contrary is an offence.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Canadian investors are advised that this prospectus supplement
has been prepared in reliance on section 3A.3 of National Instrument 33-105 <I>Underwriting Conflicts</I> (&ldquo;NI 33-105&rdquo;).
Pursuant to section 3A.3 of NI 33-105, the company and the underwriters in the offering are exempt from the requirement to provide
Canadian investors with certain conflicts of interest disclosure pertaining to &ldquo;connected issuer&rdquo; and/or &ldquo;related
issuer&rdquo; relationships as would otherwise be required pursuant to subsection 2.1(1) of NI 33-105.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Resale Restrictions</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The offer and sale of the ADSs and warrants in Canada is being
made on a private placement basis only and is exempt from the requirement that the company prepares and files a prospectus under
applicable Canadian securities laws. Any resale of ADSs and warrants acquired by a Canadian investor in this offering must be made
in accordance with applicable Canadian securities laws, which may vary depending on the relevant jurisdiction, and which may require
resales to be made in accordance with Canadian prospectus requirements, a statutory exemption from the prospectus requirements,
in a transaction exempt from the prospectus requirements or otherwise under a discretionary exemption from the prospectus requirements
granted by the applicable local Canadian securities regulatory authority. These resale restrictions may under certain circumstances
apply to resales of the ADSs and warrants outside of Canada.</P>



<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Representations of Purchasers</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each Canadian investor who purchases the ADSs and warrants will
be deemed to have represented to the company, the underwriters and to each dealer from whom a purchase confirmation is received,
as applicable, that the investor is (i) purchasing as principal, or is deemed to be purchasing as principal in accordance with
applicable Canadian securities laws; (ii) an &ldquo;accredited investor&rdquo; as such term is defined in section 1.1 of National
Instrument 45-106 <I>Prospectus Exemptions </I>(&ldquo;NI 45-106&rdquo;) or, in Ontario, as such term is defined in section 73.3(1)
of the <I>Securities Act </I>(Ontario); and (iii) a &ldquo;permitted client&rdquo; as such term is defined in section 1.1 of National
Instrument 31-103 <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>.</P>




<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Taxation and Eligibility for Investment</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any discussion of taxation and related matters contained in
this prospectus supplement does not purport to be a comprehensive description of all of the tax considerations that may be relevant
to a Canadian investor when deciding to purchase the ADSs and warrants and, in particular, does not address any Canadian tax considerations.
No representation or warranty is hereby made as to the tax consequences to a resident, or deemed resident, of Canada of an investment
in the ADSs and warrants or with respect to the eligibility of the ADSs and warrants for investment by such investor under relevant
Canadian federal and provincial legislation and regulations.</P>




<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Rights of Action for Damages or Rescission</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Securities legislation in certain of the Canadian jurisdictions
provides certain purchasers of securities pursuant to an offering memorandum (such as this prospectus supplement), including where
the distribution involves an &ldquo;eligible foreign security&rdquo; as such term is defined in Ontario Securities Commission Rule
45-501 Ontario Prospectus and Registration Exemptions and in Multilateral Instrument 45-107 Listing Representation and Statutory
Rights of Action Disclosure Exemptions, as applicable, with a remedy for damages or rescission, or both, in addition to any other
rights they may have at law, where the offering memorandum, or other offering document that constitutes an offering memorandum,
and any amendment thereto, contains a &ldquo;misrepresentation&rdquo; as defined under applicable Canadian securities laws. These
remedies, or notice with respect to these remedies, must be exercised or delivered, as the case may be, by the purchaser within
the time limits prescribed under, and are subject to limitations and defences under, applicable Canadian securities legislation.
In addition, these remedies are in addition to and without derogation from any other right or remedy available at law to the investor.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 57; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Language of Documents</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Upon receipt of this document, each Canadian investor hereby confirms
that it has expressly requested that all documents evidencing or relating in any way to the sale of the securities described herein
(including for greater certainty any purchase confirmation or any notice) be drawn up in the English language only. <I>Par la r&eacute;ception
de ce document, chaque investisseur canadien confirme par les pr&eacute;sentes qu&rsquo;il a express&eacute;ment exig&eacute; que
tous les documents faisant foi ou se rapportant de quelque mani&egrave;re que ce soit &agrave; la vente des valeurs mobili&egrave;res
d&eacute;crites aux pr&eacute;sentes (incluant, pour plus de certitude, toute confirmation d'achat ou tout avis) soient r&eacute;dig&eacute;s
en anglais seulement.</I></P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Australia</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This prospectus is not a disclosure document for the purposes
of Australia&rsquo;s Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not been lodged with the Australian
Securities &amp; Investments Commission and is only directed to the categories of exempt persons set out below. Accordingly,
if you receive this prospectus in Australia:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>You confirm and warrant that you are either:</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a &ldquo;sophisticated investor&rdquo; under section 708(8)(a) or (b) of the Corporations Act;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a &ldquo;sophisticated investor&rdquo; under section 708(8)(c) or (d) of the Corporations Act and
that you have provided an accountant&rsquo;s certificate to the company which complies with the requirements of section 708(8)(c)(i)
or (ii) of the Corporations Act and related regulations before the offer has been made; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a &ldquo;professional investor&rdquo; within the meaning of section 708(11) (a) or (b) of the Corporations
Act.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">To the extent that you are unable to confirm or warrant that you
are an exempt sophisticated investor or professional investor under the Corporations Act any offer made to you under this prospectus
is void and incapable of acceptance.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You warrant and agree that you will not offer any of the ADSs
and warrants issued to you pursuant to this prospectus for resale in Australia within 12 months of those securities being issued
unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708 of the Corporations
Act.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>European Economic Area</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In relation to each member state of the European Economic Area which
has implemented the Prospectus Directive, each referred to herein as a Relevant Member State, with effect from and including the
date on which the Prospectus Directive is implemented in that Relevant Member State, referred to herein as the Relevant Implementation
Date, no offer of any securities which are the subject of the offering contemplated by this prospectus has been or will be made
to the public in that Relevant Member State other than any offer where a prospectus has been or will be published in relation to
such securities that has been approved by the competent authority in that Relevant Member State or, where appropriate, approved
in another Relevant Member State and notified to the relevant competent authority in that Relevant Member State in accordance with
the Prospectus Directive, except that with effect from and including the Relevant Implementation Date, an offer of such securities
may be made to the public in that Relevant Member State:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">to any legal entity which is a &ldquo;qualified investor&rdquo; as defined in the Prospectus Directive;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the
2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive),
as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives of the underwriters
for any such offer; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">in any other circumstances falling within Article 3(2) of the Prospectus Directive,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">provided that no such offer of securities shall require the Company
or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus
pursuant to Article 16 of the Prospectus Directive.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">For the purposes of this provision, the expression an &ldquo;offer
to the public&rdquo; in relation to any securities in any Relevant Member State means the communication in any form and by any
means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide
to purchase or subscribe the securities, as the same may be varied in that Relevant Member State by any measure implementing the
Prospectus Directive in that Relevant Member State and the expression &ldquo;Prospectus Directive&rdquo; means Directive 2003/71/EC
(and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and
includes any relevant implementing measure in the Relevant Member State and the expression &ldquo;2010 PD Amending Directive&rdquo;
means Directive 2010/73/EU.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 58; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Hong Kong</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">No securities have been offered or sold, and no securities may be
offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy or sell shares
or debentures, whether as principal or agent; or to &ldquo;professional investors&rdquo; as defined in the Securities and Futures
Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or in other circumstances which do not result in the
document being a &ldquo;prospectus&rdquo; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute
an offer to the public within the meaning of the Companies Ordinance (Cap.32) of Hong Kong. No document, invitation or advertisement
relating to the securities has been issued or may be issued or may be in the possession of any person for the purpose of issue
(in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read
by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities
which are or are intended to be disposed of only to persons outside Hong Kong or only to &ldquo;professional investors&rdquo; as
defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This prospectus has not been registered with the Registrar of Companies
in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong Kong, and the securities may not
be offered for subscription to members of the public in Hong Kong. Each person acquiring the securities will be required, and is
deemed by the acquisition of the securities, to confirm that he is aware of the restriction on offers of the securities described
in this prospectus and the relevant offering documents and that he is not acquiring, and has not been offered any securities in
circumstances that contravene any such restrictions.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Japan</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The offering has not been and will not be registered under the Financial
Instruments and Exchange Law of Japan (Law No. 25 of 1948 of Japan, as amended), or FIEL, and the Initial Purchaser will not offer
or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used
herein means, unless otherwise provided herein, any person resident in Japan, including any corporation or other entity organized
under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to a resident of Japan, except
pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable
laws, regulations and ministerial guidelines of Japan.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Singapore</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This prospectus has not been and will not be lodged or
registered with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in
connection with the offer or sale, or the invitation for subscription or purchase of the securities may not be issued,
circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to the public or any member of the public in Singapore other than
(i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA,
(ii) to a relevant person as defined under Section 275(2), or any person pursuant to Section 275(1A) of the SFA, and in
accordance with the conditions, specified in Section 275 of the SFA, or (iii) otherwise pursuant to, and in accordance with
the conditions of any other applicable provision of the SFA.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Where the securities are subscribed or purchased under Section 275
of the SFA by a relevant person which is:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a corporation (which is not an accredited investor as defined under Section 4A of the SFA) the
sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of
whom is an accredited investor; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments
and each beneficiary is an accredited investor,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">shares, debentures and units of shares and debentures of that corporation
or the beneficiaries&rsquo; rights and interest in that trust shall not be transferable for six months after that corporation or
that trust has acquired the Offer Shares under Section 275 of the SFA except:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">to an institutional investor under Section 274 of the SFA or to a relevant person defined in Section
275(2) of the SFA, or to any person pursuant to an offer that is made on terms that such shares, debentures and units of shares
and debentures of that corporation or such rights and interest in that trust are acquired at a consideration of not less than $200,000
(or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of
securities or other assets, and further for corporations, in accordance with the conditions, specified in Section 275 of the SFA;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">where no consideration is given for the transfer; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">where the transfer is by operation of law.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 59; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Switzerland</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The securities may not be publicly offered in Switzerland and will
not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This
prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156
of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules
or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus nor any
other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly
available in Switzerland.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Neither this prospectus nor any other offering or marketing material
relating to the offering, the Company or the securities have been or will be filed with or approved by any Swiss regulatory authority.
In particular, this prospectus will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial
Market Supervisory Authority FINMA, or FINMA, and the offer of securities has not been and will not be authorized under the Swiss
Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective
investment schemes under the CISA does not extend to acquirers of securities.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Israel</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This document does not constitute a prospectus under the Israeli
Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority. In
the State of Israel, this document is being distributed only to, and is directed only at, and any offer of the securities offered
hereby is directed only at, investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting
primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors,
members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50 million and
&ldquo;qualified individuals&rdquo;, each as defined in the Addendum (as it may be amended from time to time), collectively referred
to as qualified investors (in each case purchasing for their own account or, where permitted under the Addendum, for the accounts
of their clients who are investors listed in the Addendum). Qualified investors will be required to submit written confirmation
that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it.</P>




<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>United Kingdom</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This prospectus is only being distributed to, and is only directed
at, persons in the United Kingdom that are</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">qualified investors within the meaning of Article 2(1)(e) of the
Prospectus Directive that are also (i) investment professionals falling within Article 19(5) of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005, as amended, referred to herein as the Order, and/or (ii) high net worth entities falling
within Article 49(2)(a) to (d) of the Order and other persons to whom it may lawfully be communicated. Each such person is referred
to herein as a Relevant Person.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This prospectus and its contents are confidential and should not
be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom.
Any person in the United Kingdom that is not a Relevant Person should not act or rely on this document or any of its contents.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><A NAME="a_015"></A>LEGAL MATTERS</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Certain matters concerning this offering will be passed upon for
us by Haynes and Boone, LLP, New York, New York.&nbsp;The validity of the securities being offered by this prospectus will be passed
upon for us by Gross, Kleinhendler, Hodak, Halevy, Greenberg &amp; Co., Tel Aviv, Israel. Certain legal matters related to the
offering will be passed upon for the underwriters by Covington &amp; Burling LLP, New York, New York. Certain legal matters related
to the offering concerning Israeli law will be passed upon for the underwriters by <FONT STYLE="background-color: white">Gornitzky
&amp; Co.</FONT>, Tel Aviv, Israel.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 60; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><A NAME="a_016"></A><B>EXPERTS</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial statements of RedHill Biopharma Ltd. incorporated
in this prospectus supplement by reference to the Annual Report on Form 20-F for the year ended December 31, 2015 have been so
incorporated in reliance on the report of Kesselman &amp; Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers
International Limited, an independent registered public accounting firm, given on the authority of said firm as experts in auditing
and accounting.</P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>


<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>


<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><A NAME="a_017"></A><B>WHERE</B>&nbsp;<B>YOU</B>&nbsp;<B>CAN</B>&nbsp;<B>FIND</B>&nbsp;<B>MORE</B>&nbsp;<B>INFORMATION</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">We are subject to the informational requirements of the U.S. Securities Exchange Act
of 1934, as amended, and in accordance therewith file annual and special reports with, and furnish other information to, the SEC.
You may read and copy the registration statement and any other documents we have filed at the SEC, including any exhibits and schedules,
at the SEC&rsquo;s public reference room at 100 F Street N.E., Washington, D.C. 20549. You may call the SEC at 1-800-SEC-0330 for
further information on this public reference room. In addition, the SEC maintains a web site that contains reports and other information
regarding issuers that file electronically with the SEC. You may access the SEC's website at <U>http://www.sec.gov</U>. These SEC
filings are also available to the public on the Israel Securities Authority&rsquo;s Magna website at www.magna.isa.gov.il and from
commercial document retrieval services.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">This prospectus supplement is part of the registration statement on Form F-3 filed with
the SEC in connection with this offering and does not contain all of the information included in the registration statement. Whenever
a reference is made in this prospectus supplement to any of our contracts or other documents, the reference may not be complete
and, for a copy of the contract or document, you should refer to the exhibits that are a part of the registration statement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><A NAME="a_018"></A><B>INCORPORATION OF INFORMATION BY REFERENCE</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The SEC allows us to &ldquo;incorporate by reference&rdquo; information into this prospectus
supplement, which means that we can disclose important information to you by referring you to other documents which we have filed
or will file with the SEC. We are incorporating by reference in this prospectus supplement the documents listed below and all amendments
or supplements we may file to such documents, as well as any future filings we may make with the SEC on Form 20-F under the U.S.
Securities Exchange Act of 1934, as amended before the time that all of the securities offered by this prospectus have been sold
or de-registered:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the description of our Ordinary Shares contained in our Registration Statement on Form 20-F filed with the SEC on December 26, 2012;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our Annual Report on Form 20-F for the fiscal year ended December 31, 2015, filed with the SEC on February 25, 2016; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: center"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0">Current Reports on Form 6-K filed on March 1, 2016, March 8, 2016, March 9, 2016, March 10, 2016, March
28, 2016, March 29, 2016, March 31, 2016, April 11, 2016, April 13, 2016, April 18, 2016, April 19, 2016, April 20, 2016, April
25, 2016, May 4, 2016,&nbsp;&nbsp;May 31, 2016, June 8, 2016, June 15, 2016, June 20, 2016, June 21, 2016, June 22, 2016, July
5, 2016, July 13, 2016, July 19, 2016, July 21, 2016, July 26, 2016, August 1, 2016, August 11, 2016, August 29, 2016, September
8, 2016, September 12, 2016, September 21, 2016, October 5, 2016, October 6, 2016 (2), October 18, 2016, November 1, 2016, November
2, 2016, November 3, 2016, November 10, 2016, November 14, 2016, November 21, 2016, December 12, 2016, December 13, 2016 and December
14, 2016.</P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In addition, any reports on Form 6-K submitted to the SEC prior
to the termination of the offering that we specifically identify in such forms as being incorporated by reference into the registration
statement of which this prospectus supplement forms a part.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Certain statements in and portions of this prospectus supplement
update and replace information in the above listed documents incorporated by reference. Likewise, statements in or portions of
a future document incorporated by reference in this prospectus supplement may update and replace statements in and portions of
this prospectus supplement or the above listed documents.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We will provide you without charge, upon your written or oral request,
a copy of any of the documents incorporated by reference in this prospectus supplement, other than exhibits to such documents which
are not specifically incorporated by reference into such documents. Please direct your written or telephone requests to RedHill
Biopharma Ltd., 21 Ha'arba'a Street, Tel Aviv 6473921, Israel, Attn: Micha Ben Chorin, telephone number<BR>
+972 (3) 541-3131. You may also obtain information about us by visiting our website at <I>www.redhillbio.com</I>. Information contained
in our website is not part of this prospectus supplement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>


<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 61; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$120,000,000 of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">American Depositary Shares representing
Ordinary Shares,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Ordinary Shares,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">Warrants to Purchase
American Depositary Shares,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Subscription Rights and/or Units</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Offered by the Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><img src="logo.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REDHILL BIOPHARMA LTD. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may offer to the
public from time to time in one or more series or issuances American Depositary Shares (&quot;ADSs&quot;), ordinary shares, warrants,
subscription rights and/or units consisting of two or more of these classes or series of securities. Each ADS represents 10 ordinary
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We refer to the ADSs,
ordinary shares, warrants, subscription rights and units collectively as &ldquo;securities&rdquo; in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each time we sell securities
pursuant to this prospectus, we will provide a supplement to this prospectus that contains specific information about the offeror,
the offering and the specific terms of the securities offered. This prospectus may not be used to consummate a sale of securities
by us unless accompanied by the applicable prospectus supplement. You should read this prospectus and the applicable prospectus
supplement carefully before you invest in our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We
may, from time to time, offer to sell the securities, through public or private transactions, directly or through underwriters,
agents or dealers, on or off the Nasdaq Capital Market or Tel Aviv Stock Exchange (the &quot;TASE&quot;), as applicable, at prevailing
market prices or at privately negotiated prices. If any underwriters, agents or dealers are involved in the sale of any of these
securities, the applicable prospectus supplement will set forth the names of the underwriter, agent or dealer and any applicable
fees, commissions or discounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares
are traded on the TASE, and our ADSs are traded on the Nasdaq Capital Market under the symbol &ldquo;RDHL.&rdquo; The last reported
sale price for our ADSs on February 24, 2016 as quoted on the Nasdaq Capital Market was $9.38 per ADS, and the last reported sale
price for our ordinary shares on February 24, 2016 as quoted on the TASE was NIS 3.68 per share, or $0.94 per share (based on the
exchange rate reported by the Bank of Israel for such date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Investing in these
securities involves a high degree of risk. Please carefully consider the risks discussed in this prospectus under &ldquo;Risk Factors&rdquo;
beginning on page 3 and the &ldquo;Risk Factors&rdquo; in &ldquo;Item 3: Key Information- Risk Factors&rdquo; of our most recent
Annual Report on Form 20-F incorporated by reference in this prospectus and in any applicable prospectus supplement for a discussion
of the factors you should consider carefully before deciding to purchase these securities. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of the securities being offered by this
prospectus, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is March
11, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS </B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>Page</U></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 90%; text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_019">ABOUT THIS PROSPECTUS</A></TD>
    <TD STYLE="width: 10%; text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_019">2</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_020">REDHILL BIOPHARMA LTD.</A></TD>
    <TD STYLE="text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_020">2</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_021">RISK FACTORS</A></TD>
    <TD STYLE="text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_021">3</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_022">FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_022">3</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_023">CAPITALIZATION</A></TD>
    <TD STYLE="text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_023">4</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_024">PRICE RANGE OF OUR ORDINARY SHARES</A></TD>
    <TD STYLE="text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_024">4</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_025">PRICE RANGE OF OUR ADSs</A></TD>
    <TD STYLE="text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_025">5</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_026">USE OF PROCEEDS</A></TD>
    <TD STYLE="text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_026">6</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_027">DESCRIPTION OF ORDINARY SHARES</A></TD>
    <TD STYLE="text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_027">6</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_028">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</A></TD>
    <TD STYLE="text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_028">6</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_029">DESCRIPTION OF WARRANTS</A></TD>
    <TD STYLE="text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_029">7</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_030">DESCRIPTION OF SUBSCRIPTION RIGHTS</A></TD>
    <TD STYLE="text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_030">7</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_031">DESCRIPTION OF UNITS</A></TD>
    <TD STYLE="text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_031">8</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_032">PLAN OF DISTRIBUTION</A></TD>
    <TD STYLE="text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_032">8</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_033">LEGAL MATTERS</A></TD>
    <TD STYLE="text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_033">11</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_034">EXPERTS</A></TD>
    <TD STYLE="text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_034">11</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_035">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
    <TD STYLE="text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_035">11</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_036">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></TD>
    <TD STYLE="text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_036">12</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_037">ENFORCEABILITY OF CIVIL LIABILITIES</A></TD>
    <TD STYLE="text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_037">12</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0in"><A HREF="#a_038">OFFERING EXPENSES</A></TD>
    <TD STYLE="text-align: right; padding-top: 6pt; padding-bottom: 6pt"><A HREF="#a_038">13</A></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_019"></A>ABOUT THIS PROSPECTUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus is
part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a &ldquo;shelf&rdquo;
registration process. Under this process, we may offer and sell our securities under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under this shelf process,
we may sell the securities described in this prospectus in one or more offerings up to a total price to the public of $120,000,000.
The offer and sale of securities under this prospectus may be made from time to time, in one or more offerings, in any manner described
under the section in this prospectus entitled &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus provides
you with a general description of the securities we may offer. Each time we sell securities we will provide a prospectus supplement
that will contain specific information about the terms of that offering. The prospectus supplement may also add, update or change
information contained in this prospectus, and may also contain information about any material federal income tax considerations
relating to the securities covered by the prospectus supplement. You should read both this prospectus and any prospectus supplement
together with additional information under the headings &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation
of Certain Documents by Reference.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary may not
contain all of the information that may be important to you. You should read this entire prospectus, including the financial statements
and related notes and other financial data incorporated by reference in this prospectus, before making an investment decision.
This summary contains forward-looking statements that involve risks and uncertainties. Our actual results may differ significantly
from the results discussed in the forward-looking statements. Factors that might cause or contribute to such differences include
those discussed in &ldquo;Risk Factors&rdquo; and &ldquo;Forward-Looking Statements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_020"></A>REDHILL BIOPHARMA LTD.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our legal and commercial
name is RedHill Biopharma Ltd. We were incorporated on August 3, 2009 and were registered as a private company limited by shares
under the laws of the State of Israel. Our ordinary shares are traded on TASE under the symbol &ldquo;RDHL&rdquo; and our ADSs
are traded on the Nasdaq Capital Market under the symbol &quot;RDHL&quot;. Each ADS represents 10 ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an emerging
biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary, orally administered,
small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer. In particular, we acquire
or in-license and develop patent-protected new formulations and combinations of existing drugs in advanced stages of development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depending on the specific
development program, our therapeutic candidates are designed to provide improvements over existing drugs by improving their safety
profile, reducing side effects, lowering the number of administrations, using a more convenient administration form, providing
a cost advantage and/or exhibiting greater efficacy. Where applicable, we intend to seek U.S. Food and Drug Administration approval
for the commercialization of certain of our therapeutic candidates through the alternative Section 505(b)(2) regulatory path under
the Federal Food, Drug, and Cosmetic Act of 1938, as amended, and in corresponding regulatory paths in other foreign jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our current pipeline consists of nine late
clinical development therapeutic candidates, including one therapeutic candidate (RP101) for which we have an option to acquire.
Our current product pipeline includes: (i) <B>RHB-105</B> - an oral combination therapy for the treatment of Helicobacter pylori
infection with successful top-line results from a first Phase III study; (ii) <B>RHB-104</B> - an oral combination therapy for
the treatment of Crohn's disease with an ongoing first Phase III study; (iii) <B>BEKINDA&reg; (RHB-102)</B> - a once-daily oral
pill formulation of ondansetron with an ongoing Phase III study in the U.S. for acute gastroenteritis and gastritis; (iv) <B>RHB-106</B>
- an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) <B>YELIVA&reg; (ABC294640)</B> - an orally-administered
first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications with a Phase
I/II study initiated for refractory/relapsed diffuse large B-cell lymphoma (DLBCL); (vi) <B>MESUPRON</B> - a Phase II-stage first-in-class
uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumors; (vii) <B>RP101</B> - currently
subject to an option-to-acquire by RedHill, RP101 is a Phase II-stage first-in-class Hsp27 inhibitor, administered by oral tablet,
targeting pancreatic and other gastrointestinal cancers; (viii) <B>RIZAPORT&reg; (RHB-103)</B> - an oral thin film formulation
of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received
in Germany in October 2015; and (ix) <B>RHB-101</B> - a once-daily oral pill formulation of the cardio drug carvedilol.</P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 64; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We generate our pipeline of therapeutic candidates
by identifying, rigorously validating and in-licensing or acquiring products that are consistent with our products strategy and
that we believe exhibit a relatively high probability of therapeutic and commercial success. With the exception of Rizaport<SUP>&reg;</SUP>
which was approved for marketing in Germany, our therapeutic candidates have not yet been approved for marketing and, to date,
there have been no meaningful sales. We intend to commercialize our therapeutic candidates through licensing and other commercialization
arrangements with pharmaceutical companies on a global and territorial basis. We may also evaluate, on a case by case basis, co-development
and similar arrangements and the independent commercialization of our therapeutic candidates in the U.S.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive
offices are located at 21 Ha&rsquo;arba&rsquo;a Street, Tel Aviv, Israel and our telephone number is +972 (3) 541-3131. Our web
site address is http://www.redhillbio.com. The information on our web site does not constitute part of this prospectus. Our registered
agent in the United States is Puglisi &amp; Associates. The address of Puglisi &amp; Associates is 850 Library Avenue, Suite 204,
Newark Delaware 19715.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_021"></A>RISK FACTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An investment in our
securities involves a high degree of risk. Our business, financial condition or results of operations could be adversely affected
by any of these risks. You should carefully consider the risk factors discussed under the caption &quot;Item 3: Key Information<B>-
</B>Risk Factors&quot; in our Annual Report on Form 20-F for the year ended December 31, 2015, and in any other filing we make
with the SEC subsequent to the date of this prospectus, each of which are incorporated herein by reference, and in any supplement
to this prospectus, before making your investment decision. The risks and uncertainties we have described are not the only ones
we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our
operations. Past financial performance may not be a reliable indicator of future performance, and historical trends should not
be used to anticipate results or trends in future periods. If any of these risks actually occurs, our business, business prospects,
financial condition or results of operations could be seriously harmed. This could cause the trading price of our ordinary shares
(directly or in the form of ADSs) to decline, resulting in a loss of all or part of your investment. Please also read carefully
the section below entitled &ldquo;Forward-Looking Statements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_022"></A>FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus,
including the information incorporated by reference into this prospectus, contains, and any prospectus supplement may contain,
statements that are forward-looking statements within the meaning of Private Securities Litigation Reform Act of 1995. We caution
you that any forward-looking statements presented in this prospectus or any prospectus supplement, or which management may make
orally or in writing from time to time, are based on management&rsquo;s beliefs and assumptions made by, and information currently
available to, management. Such statements may be preceded by the words &quot;intends,&quot; &quot;may,&quot; &quot;will,&quot;
&quot;plans,&quot; &quot;expects,&quot; &quot;anticipates,&quot; &quot;projects,&quot; &quot;predicts,&quot; &quot;estimates,&quot;
&quot;aims,&quot; &quot;believes,&quot; &quot;hopes,&quot; &quot;potential&quot; or similar words. These statements are not guarantees
of future performance, are based on certain assumptions and our current and best understanding of the regulatory status and are
subject to various known and unknown risks and uncertainties, many of which are beyond our control, and cannot be predicted or
quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and uncertainties associated with: &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the initiation, timing, progress and results of our research, manufacturing, preclinical studies,
clinical trials and other therapeutic candidate development efforts, as well as the extent and number of additional studies that
we may be required to conduct;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to advance our therapeutic candidates into clinical trials or to successfully complete
our preclinical studies or clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our receipt of regulatory clarity and approvals for our therapeutic candidates, and the timing
of other regulatory filings and approvals;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the research, manufacturing, clinical development, commercialization and market acceptance of our
therapeutic candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to establish and maintain corporate collaborations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to acquire products approved for marketing in the U.S. that achieve commercial success
and build our own marketing and commercialization capabilities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the interpretation of the properties and characteristics of our therapeutic candidates and of the
results obtained with our therapeutic candidates in research, manufacturing, preclinical studies or clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the implementation of our business model, strategic plans for our business and therapeutic candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the scope of protection we are able to establish and maintain for intellectual property rights
covering our therapeutic candidates and our ability to operate our business without infringing upon the intellectual property rights
of others;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">estimates of our expenses, future revenues, capital requirements and our need for additional financing;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">competitive companies, technologies and our industry; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the impact of the political and security situation in Israel on our business.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We caution you to carefully
consider these risks and not to place undue reliance on our forward-looking statements. Except as required by law, we assume no
responsibility for updating any forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_023"></A>CAPITALIZATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below sets
forth our total capitalization as of December 31, 2015. The financial data in the following table should be read in conjunction
with our financial statements and notes thereto incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of December 31, <BR>
2015</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Actual</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">(in thousands)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 85%; text-align: left">Total debt (1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">6,751</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Ordinary shares,&nbsp;&nbsp;par value NIS 0.01 per share&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">343</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Additional paid-in capital&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,621</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,057</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accumulated deficit&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(61,944</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total shareholders&rsquo; equity&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">60,077</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.25pt">Total capitalization&#9;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">66,828</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents $5,514 thousand under current liabilities, mainly accounts
payable</FONT> <FONT STYLE="font-size: 10pt">and accrued expenses.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_024"></A>PRICE RANGE OF OUR ORDINARY SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares have been trading on
the TASE under the symbol &quot;RDHL&quot; since February 3, 2011. Prior to that date, there was no public market for our ordinary
shares. U.S. dollar per ordinary share amounts are calculated using the U.S. dollar representative rate of exchange on the date
to which the high or low market price is applicable, as reported by the Bank of Israel. The following table lists the high and
low closing prices for our ordinary shares for the periods indicated as reported by the TASE.<FONT STYLE="font-size: 10pt"> </FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid">NIS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid">$U.S.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid">Price per Ordinary Share</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid">Price per Ordinary Share</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: left">Annual</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">High</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">Low</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">High</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">Low</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left">2015</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">7.80</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">4.34</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">2.03</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">1.12</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.96</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.78</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.92</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.19</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.71</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.08</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.45</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2011 (beginning on February 3, 2011)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.82</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.49</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><B>2015</B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fourth quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.34</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.39</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.12</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Third quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.62</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.88</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.19</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Second quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.52</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.03</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.41</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">First quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.89</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.57</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.26</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><B>2014</B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.78</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Third quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.89</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.72</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.20</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.96</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.39</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">First quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.04</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.96</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.14</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Most Recent Six Months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">February 2016 (through February 22, 2016)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.88</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.98</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.86</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">January 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.14</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.86</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.97</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">December 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.01</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.56</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.17</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">November 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.34</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.39</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.12</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">October 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.19</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.57</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.34</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.18</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">September 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.91</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.27</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">August 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.65</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.62</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.19</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">On
February 22, 2016, the last reported sales price of our ordinary shares on the TASE was NIS 3.73 per share, or $0.95 per share
(based on the exchange rate reported by the Bank of Israel for such date).&nbsp;&nbsp;On February 22, 2016 the exchange rate of
the NIS to the U.S. dollar was $1.00 = NIS 3.907, as reported by the Bank of Israel.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_025"></A><B>PRICE RANGE OF OUR ADSs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Our ADSs have
been trading on the Nasdaq Capital Market under the symbol &ldquo;RDHL&rdquo; since December 27,</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT><FONT STYLE="font-size: 10pt">2012.</FONT></P>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
following table sets forth, for the periods indicated, the reported high and low closing sale prices of our ADSs on the Nasdaq
Capital Market in U.S. dollars.&nbsp; </FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>$U.S.</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Price per ADS</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Low</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">Annual</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">2015</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">19.79</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">11.05</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.31</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><B>2015</B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fourth quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.72</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.05</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Third quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.16</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Second quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19.79</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">First quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.52</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><B>2014</B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Third quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.14</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14.01</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">First quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.38</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Most Recent Six Months</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">February 2016 (through February 22, 2016)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.43</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.21</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">January 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.61</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.75</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">December 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.64</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">November 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.05</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">October 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.72</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.31</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">September 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.28</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.78</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">August 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14.63</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.16</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On <FONT STYLE="background-color: white">February
22, 2016</FONT>, the last reported sales price of our ADSs on the Nasdaq Capital Market was $9.37 per ADS.&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_026"></A>USE OF PROCEEDS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated
in an accompanying prospectus supplement, the net proceeds from the sale of securities will be used for general corporate purposes,
including research and development related purposes in connection with our therapeutic candidates, and for potential acquisitions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><A NAME="a_027"></A>DESCRIPTION OF
ORDINARY SHARES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A description of our
ordinary shares, par value NIS 0.01 per share, can be found in Item 10B of the Registration Statement on Form 20-F filed with the
SEC on December 26, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_028"></A>DESCRIPTION OF AMERICAN DEPOSITARY
SHARES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A description of our
ADSs, each of which represents 10 of our ordinary shares, can be found in Item 12 of the Registration Statement on Form 20-F filed
with the SEC on December 26, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_029"></A>DESCRIPTION OF WARRANTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue warrants
to purchase ADS and/or ordinary shares. Warrants may be issued independently or together with any other securities and may be attached
to, or separate from, such securities. Each series of warrants will be issued under a separate warrant agreement to be entered
into between us and a warrant agent. The warrant agent will act solely as our agent and will not assume any obligation or relationship
of agency for or with holders or beneficial owners of warrants. The terms of any warrants to be issued and a description of the
material provisions of the applicable warrant agreement will be set forth in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The applicable
prospectus supplement will describe the following terms of any warrants in respect of which this prospectus is being delivered:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the title of such warrants;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the aggregate number of such warrants;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the price or prices at which such warrants will be issued and exercised;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the currency or currencies in which the price of such warrants will be payable;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the securities purchasable upon exercise of such warrants;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the date on which the right to exercise such warrants shall commence and the date on which such
right shall expire;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if applicable, the minimum or maximum amount of such warrants which may be exercised at any one
time;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if applicable, the designation and terms of the securities with which such warrants are issued
and the number of such warrants issued with each such security;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if applicable, the date on and after which such warrants and the related securities will be separately
transferable;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">information with respect to book-entry procedures, if any;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any material Israeli and United States federal income tax consequences;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the anti dilution provisions of the warrants, if any; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any other terms of such warrants, including terms, procedures and
limitations relating to the exchange and exercise of such warrants. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Amendments and Supplements to Warrant Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and the warrant
agent may amend or supplement the warrant agreement for a series of warrants without the consent of the holders of the warrants
issued thereunder to effect changes that are not inconsistent with the provisions of the warrants and that do not materially and
adversely affect the interests of the holders of the warrants.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_030"></A>DESCRIPTION OF SUBSCRIPTION RIGHTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue subscription
rights to purchase our ordinary shares and/or our ADSs. These subscription rights may be issued independently or together with
any other security offered hereby and may or may not be transferable by the shareholder receiving the subscription rights in such
offering. In connection with any offering of subscription rights, we may enter into a standby arrangement with one or more underwriters
or other purchasers pursuant to which the underwriters or other purchasers may be required to purchase any securities remaining
unsubscribed for after such offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The prospectus
supplement relating to any subscription rights we offer, if any, will, to the extent applicable, include specific terms relating
to the offering, including some or all of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the price, if any, for the subscription rights;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the exercise price payable for each ordinary share and/or ADS upon the exercise of the subscription
rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the number of subscription rights to be issued to each shareholder;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the number and terms of the ordinary shares and/or ADSs which may be purchased per each subscription
right;&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the extent to which the subscription rights are transferable;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any other terms of the subscription rights, including the terms, procedures and limitations relating
to the exchange and exercise of the subscription rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the date on which the right to exercise the subscription rights shall commence, and the date on
which the subscription rights shall expire;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the extent to which the subscription rights may include an over-subscription privilege with respect
to unsubscribed securities;&nbsp;and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if applicable, the material terms of any standby underwriting or purchase arrangement which may
be entered into by us in connection with the offering of subscription rights.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The description in
the applicable prospectus supplement of any subscription rights we offer will not necessarily be complete and will be qualified
in its entirety by reference to the applicable subscription right agreement, which will be filed with the SEC if we offer subscription
rights. For more information on how you can obtain copies of the applicable subscription right agreement if we offer subscription
rights, see &ldquo;Where You Can Find More Information; Incorporation of Information by Reference&rdquo; beginning on page&nbsp;11.
We urge you to read the applicable subscription right agreement and any applicable prospectus supplement in their entirety.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_031"></A>DESCRIPTION OF UNITS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue units
comprised of one or more of the other securities that may be offered under this prospectus, in any combination. Each unit will
be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will
have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide
that the securities included in the unit may not be held or transferred separately at any time, or at any time before a specified
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The prospectus supplement relating to
any units we offer, if any, will, to the extent applicable, include specific terms relating to the offering, including some or
all of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the material terms of the units and of the securities comprising the units, including whether and
under what circumstances those securities may be held or transferred separately;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any material provisions relating to the issuance, payment, settlement, transfer or exchange of
the units or of the securities comprising the units; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any material provisions of the governing unit agreement that differ from those described above.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The description in
the applicable prospectus supplement of any units we offer will not necessarily be complete and will be qualified in its entirety
by reference to the applicable unit agreement, which will be filed with the SEC if we offer units. For more information on how
you can obtain copies of the applicable unit agreement if we offer units, see &ldquo;Where You Can Find More Information; Incorporation
of Information by Reference&rdquo; beginning on page&nbsp;11. We urge you to read the applicable unit agreement and any applicable
prospectus supplement in their entirety.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_032"></A>PLAN OF DISTRIBUTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The securities
being offered by this prospectus may be sold:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">through agents;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">to or through one or more underwriters on a firm commitment or agency basis;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">through put or call option transactions relating to the securities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">through broker-dealers;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">directly to purchasers, through a specific bidding or auction process, on a negotiated basis or
otherwise;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">through any other method permitted pursuant to applicable law; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">through a combination of any such methods of sale.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At any time a
particular offer of the securities covered by this prospectus is made, a revised prospectus or prospectus supplement, if required,
will be distributed which will set forth the aggregate amount of securities covered by this prospectus being offered and the terms
of the offering, including the name or names of any underwriters, dealers, brokers or agents, any discounts, commissions, concessions
and other items constituting compensation from us and any discounts, commissions or concessions allowed or reallowed or paid to
dealers. Such prospectus supplement, and, if necessary, a post-effective amendment to the registration statement of which this
prospectus is a part, will be filed with the SEC to reflect the disclosure of additional information with respect to the distribution
of the securities covered by this prospectus. In order to comply with the securities laws of certain states, if applicable, the
securities sold under this prospectus may only be sold through registered or licensed broker-dealers. In addition, in some states
the securities may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from
registration or qualification requirements is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The distribution
of securities may be effected from time to time in one or more transactions, including block transactions and transactions on the
Nasdaq Capital Market or any other organized market where the securities may be traded. The securities may be sold at a fixed price
or prices, which may be changed, or at market prices prevailing at the time of sale, at prices relating to the prevailing market
prices or at negotiated prices. The consideration may be cash or another form negotiated by the parties. Agents, underwriters or
broker-dealers may be paid compensation for offering and selling the securities. That compensation may be in the form of discounts,
concessions or commissions to be received from us or from the purchasers of the securities. Any dealers and agents participating
in the distribution of the securities may be deemed to be underwriters, and compensation received by them on resale of the securities
may be deemed to be underwriting discounts. If any such dealers or agents were deemed to be underwriters, they may be subject to
statutory liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Agents may from
time to time solicit offers to purchase the securities. If required, we will name in the applicable prospectus supplement any agent
involved in the offer or sale of the securities and set forth any compensation payable to the agent. Unless otherwise indicated
in the prospectus supplement, any agent will be acting on a best efforts basis for the period of its appointment. Any agent selling
the securities covered by this prospectus may be deemed to be an underwriter, as that term is defined in the Securities Act, of
the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If underwriters
are used in a sale, securities will be acquired by the underwriters for their own account and may be resold from time to time in
one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at
the time of sale, or under delayed delivery contracts or other contractual commitments. Securities may be offered to the public
either through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting
as underwriters. If an underwriter or underwriters are used in the sale of securities, an underwriting agreement will be executed
with the underwriter or underwriters, as well as any other underwriter or underwriters, with respect to a particular underwritten
offering of securities, and will set forth the terms of the transactions, including compensation of the underwriters and dealers
and the public offering price, if applicable. The prospectus and prospectus supplement will be used by the underwriters to resell
the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a dealer is
used in the sale of the securities, we or an underwriter will sell the securities to the dealer, as principal. The dealer may then
resell the securities to the public at varying prices to be determined by the dealer at the time of resale. To the extent required,
we will set forth in the prospectus supplement the name of the dealer and the terms of the transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may directly
solicit offers to purchase the securities and may make sales of securities directly to institutional investors or others. These
persons may be deemed to be underwriters within the meaning of the Securities Act with respect to any resale of the securities.
To the extent required, the prospectus supplement will describe the terms of any such sales, including the terms of any bidding
or auction process, if used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Agents, underwriters
and dealers may be entitled under agreements which may be entered into with us to indemnification by us against specified liabilities,
including liabilities incurred under the Securities Act, or to contribution by us to payments they may be required to make in respect
of such liabilities. If required, the prospectus supplement will describe the terms and conditions of the indemnification or contribution.
Some of the agents, underwriters or dealers, or their affiliates may be customers of, engage in transactions with or perform services
for us or our subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any person participating
in the distribution of securities registered under the registration statement that includes this prospectus will be subject to
applicable provisions of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the applicable SEC rules and
regulations, including, among others, Regulation M, which may limit the timing of purchases and sales of any of our securities
by that person. Furthermore, Regulation M may restrict the ability of any person engaged in the distribution of our securities
to engage in market-making activities with respect to our securities. These restrictions may affect the marketability of our securities
and the ability of any person or entity to engage in market-making activities with respect to our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain persons
participating in an offering may engage in over-allotment, stabilizing transactions, short-covering transactions, penalty bids
and other transactions that stabilize, maintain or otherwise affect the price of the offered securities. These activities may maintain
the price of the offered securities at levels above those that might otherwise prevail in the open market, including by entering
stabilizing bids, effecting syndicate covering transactions or imposing penalty bids, each of which is described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A stabilizing bid means the placing of any bid, or the effecting of any purchase, for the purpose
of pegging, fixing or maintaining the price of a security.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A syndicate covering transaction means the placing of any bid on behalf of the underwriting syndicate
or the effecting of any purchase to reduce a short position created in connection with the offering.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">A penalty bid means an arrangement that permits the managing underwriter
to reclaim a selling concession from a syndicate member in connection with the offering when offered securities originally sold
by the syndicate member are purchased in syndicate covering transactions. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These transactions
may be effected on an exchange or automated quotation system, if the securities are listed on that exchange or admitted for trading
on that automated quotation system, or in the over-the-counter market or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If so indicated
in the applicable prospectus supplement, we will authorize agents, underwriters or dealers to solicit offers from certain types
of institutions to purchase offered securities from us at the public offering price set forth in such prospectus supplement pursuant
to delayed delivery contracts providing for payment and delivery on a specified date in the future. Such contracts will be subject
only to those conditions set forth in the prospectus supplement and the prospectus supplement will set forth the commission payable
for solicitation of such contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, ordinary
shares or ADSs may be issued upon conversion of or in exchange for debt securities or other securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any underwriters
to whom offered securities are sold for public offering and sale may make a market in such offered securities, but such underwriters
will not be obligated to do so and may discontinue any market making at any time without notice. The offered securities may or
may not be listed on a national securities exchange. No assurance can be given that there will be a market for the offered securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any securities
that qualify for sale pursuant to Rule 144 or Regulation S under the Securities Act, may be sold under Rule 144 or Regulation S
rather than pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent
that we make sales to or through one or more underwriters or agents in at-the-market offerings, we will do so pursuant to the terms
of a distribution agreement between us and the underwriters or agents. If we engage in at-the-market sales pursuant to a distribution
agreement, we will sell our ordinary shares or ADSs to or through one or more underwriters or agents, which may act on an agency
basis or on a principal basis. During the term of any such agreement, we may sell ordinary shares or ADSs on a daily basis in exchange
transactions or otherwise as we agree with the underwriters or agents. The distribution agreement will provide that any ordinary
shares or ADSs sold will be sold at prices related to the then prevailing market prices for our ordinary shares or ADSs. Therefore,
exact figures regarding proceeds that will be raised or commissions to be paid cannot be determined at this time and will be described
in a prospectus supplement. Pursuant to the terms of the distribution agreement, we also may agree to sell, and the relevant underwriters
or agents may agree to solicit offers to purchase, blocks of our ordinary shares, ADSs or warrants. The terms of each such distribution
agreement will be set forth in more detail in a prospectus supplement to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with offerings
made through underwriters or agents, we may enter into agreements with such underwriters or agents pursuant to which we receive
our outstanding securities in consideration for the securities being offered to the public for cash. In connection with these arrangements,
the underwriters or agents may also sell securities covered by this prospectus to hedge their positions in these outstanding securities,
including in short sale transactions. If so, the underwriters or agents may use the securities received from us under these arrangements
to close out any related open borrowings of securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt">&nbsp;</P>

<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may enter into derivative
transactions with third parties or sell securities not covered by this prospectus to third parties in privately negotiated transactions.
If the applicable prospectus supplement indicates, in connection with those derivatives, such third parties (or affiliates of such
third parties) may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale
transactions. If so, such third parties (or affiliates of such third parties) may use securities pledged by us or borrowed from
us or others to settle those sales or to close out any related open borrowings of shares, and may use securities received from
us in settlement of those derivatives to close out any related open borrowings of shares. The third parties (or affiliates of such
third parties) in such sale transactions will be underwriters and, if not identified in this prospectus, will be identified in
the applicable prospectus supplement (or a post-effective amendment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may loan or pledge
securities to a financial institution or other third party that in turn may sell the securities using this prospectus. Such financial
institution or third party may transfer its short position to investors in our securities or in connection with a simultaneous
offering of other securities offered by this prospectus or in connection with a simultaneous offering of other securities offered
by this prospectus.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_033"></A>LEGAL MATTERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain legal matters
with respect to Israeli law and with respect to the validity of the offered securities under Israeli law will be passed upon for
us by Gross, Kleinhendler, Hodak, Halevy, Greenberg &amp; Co.<B> </B>Certain legal matters with respect to U.S. federal securities
law will be passed upon for us by Haynes and Boone, LLP.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_034"></A>EXPERTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements
of RedHill Biopharma Ltd. incorporated in this prospectus by reference to the Annual Report on Form 20-F for the year ended December
31, 2015 have been so incorporated in reliance on the report of Kesselman &amp; Kesselman, Certified Public Accountants (Isr.),
a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm, given on the authority
of such firm as experts in auditing and accounting.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_035"></A>WHERE YOU CAN FIND MORE INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with
the SEC a registration statement on Form F-3 under the Securities Act, with respect to the securities offered by this prospectus.
However, as is permitted by the rules and regulations of the SEC, this prospectus, which is part of our registration statement
on Form F-3, omits certain non-material information, exhibits, schedules and undertakings set forth in the registration statement.
For further information about us, and the securities offered by this prospectus, please refer to the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We
are subject to the reporting requirements of the Exchange Act that are applicable to a foreign private issuer. In accordance with
the Exchange Act, we file reports, including annual reports on Form 20-F by April 30 of each year. We also furnish to the SEC under
cover of Form 6-K material information required to be made public in Israel, filed with and made public by any stock exchange or
distributed by us to our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
registration statement on Form F-3 of which this prospectus forms a part, including the exhibits and schedules thereto, and reports
and other information filed by us with the SEC may be inspected without charge and copied at prescribed rates at the SEC&rsquo;s
Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Copies of this material are also available by mail from the
Public Reference Section of the SEC, at 100 F. Street, N.E., Washington D.C. 20549, at prescribed rates. The public may obtain
information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site
that contains reports, proxy and information statements, and other information regarding issuers, such as us, that file electronically
with the SEC (<I>http://www.sec.gov</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As
a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements
to shareholders and our officers, directors and principal shareholders are exempt from the &ldquo;short-swing profits&rdquo; reporting
and liability provisions contained in Section 16 of the Exchange Act and related Exchange Act rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_036"></A>INCORPORATION OF CERTAIN DOCUMENTS
BY REFERENCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We file annual and
special reports and other information with the SEC (File Number 001-35464). These filings contain important information which does
not appear in this prospectus. The SEC allows us to &ldquo;incorporate by reference&rdquo; information into this prospectus, which
means that we can disclose important information to you by referring you to other documents which we have filed or will file with
the SEC. We are incorporating by reference in this prospectus the documents listed below and all amendments or supplements we may
file to such documents, as well as any future filings we may make with the SEC on Form 20-F under the Exchange Act before the time
that all of the securities offered by this prospectus have been sold or de-registered:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our Registration Statement on Form 20-F filed with the SEC on December 26, 2012; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our Annual Report on Form 20-F for the fiscal year ended on December 31, 2015, filed with the SEC
on February 25, 2016</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any reports
on Form 6-K submitted to the SEC by the registrant pursuant to the Exchange Act after the date of the initial registration statement
and prior to effectiveness of the registration statement that we specifically identify in such forms as being incorporated by reference
into the registration statement of which this prospectus forms a part and all subsequent annual reports on Form 20-F filed after
the effective date of this registration statement and prior to the termination of this offering and any reports on Form 6-K subsequently
submitted to the SEC or portions thereof that we specifically identify in such forms as being incorporated by reference into the
registration statement of which this prospectus forms a part, shall be considered to be incorporated into this prospectus by reference
and shall be considered a part of this prospectus from the date of filing or submission of such documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain statements
in and portions of this prospectus update and replace information in the above listed documents incorporated by reference. Likewise,
statements in or portions of a future document incorporated by reference in this prospectus may update and replace statements in
and portions of this prospectus or the above listed documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
will provide you without charge, upon your written or oral request, a copy of any of the documents incorporated by reference in
this prospectus, other than exhibits to such documents which are not specifically incorporated by reference into such documents.
Please direct your written or telephone requests to RedHill Biopharma Ltd., 21 Ha'arba'a Street, Tel Aviv 64739, Israel, Attn:
Dror Ben-Asher, telephone number +972 (3) 541-3131. You may also obtain information about us by visiting our website at <I>www.redhillbio.com</I>.
Information contained in our website is not part of this prospectus</FONT>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_037"></A>ENFORCEABILITY OF CIVIL LIABILITIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated
under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named
in this prospectus, substantially all of whom reside outside the United States, may be difficult to obtain within the United States.
Furthermore, because substantially all of our assets and substantially all of our directors and officers are located outside the
United States, any judgment obtained in the United States against us or any of our directors and officers may not be collectible
within the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It may be difficult
to assert U.S.&nbsp;securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based
on a violation of U.S.&nbsp;securities laws because Israel is not the most appropriate forum to bring such a claim. In addition,
even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S.&nbsp;law is applicable to the claim.
If U.S.&nbsp;law is found to be applicable, the content of applicable U.S.&nbsp;law must be proved as a fact which can be a time-consuming
and costly process. Certain matters of procedure will also be governed by Israeli law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to specified
time limitations and legal procedures, Israeli courts may enforce a United States judgment in a civil matter which, subject to
certain exceptions, is non-appealable, including judgments based upon the civil liability provisions of the Securities Act and
the Exchange Act and including a monetary or compensatory judgment in a non-civil matter, provided that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the judgments are obtained after due process before a court of competent jurisdiction, according
to the laws of the state in which the judgment is given and the rules of private international law currently prevailing in Israel;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the prevailing law of the foreign state in which the judgments were rendered allows the enforcement
of judgments of Israeli courts (however, the Israeli courts may waive this requirement following a request by the attorney general);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">adequate service of process has been effected and the defendant has had a reasonable opportunity
to be heard and to present his or her evidence;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the judgments are not contrary to public policy, and the enforcement of the civil liabilities set
forth in the judgment does not impair the security or sovereignty of the State of Israel;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the judgments were not obtained by fraud and do not conflict with any other valid judgment in the
same matter between the same parties;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">an action between the same parties in the same matter is not pending in any Israeli court at the
time the lawsuit is instituted in the foreign court;&nbsp;and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the obligations under the judgment are enforceable according to the laws of the State of Israel
and according to the law of the foreign state in which the relief was granted.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have irrevocably
appointed Puglisi &amp; Associates<B> </B>as our agent to receive service of process in any action against us in any United States
federal or state court arising out of this offering or any purchase or sale of securities in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a foreign judgment
is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli
currency and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli
currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in
force on the date of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount
of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus
interest at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk
of unfavorable exchange rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_038"></A>OFFERING EXPENSES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a
statement of expenses in connection with the distribution of the securities registered. All amounts shown are estimates except
the SEC registration fee. The estimates do not include expenses related to offerings of particular securities. Each prospectus
supplement describing an offering of securities will reflect the estimated expenses related to the offering of securities under
that prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 85%; text-align: left">SEC registration fees</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right"><P STYLE="margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,943.83</FONT></P>


</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accountants fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Miscellaneous</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0">20,943.83</P>


</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->




<P STYLE="margin: 0"><FONT STYLE="font-size: 14pt">&nbsp;</FONT></P>



<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 14pt"><B>American Depositary Shares&#9;Representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ordinary
Shares</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 14pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 14pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Warrants
to Purchase American Depositary Shares</B></FONT><B><FONT STYLE="font-size: 10pt">&nbsp;</FONT></B></P>



<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>



<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 14pt"><B></B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><img src="logo.jpg"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 24pt"><B>RedHill Biopharma Ltd.</B></FONT></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>


<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>


<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">___________________________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 16pt"><B>PROSPECTUS SUPPLEMENT</B></FONT><B>
</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">___________________________________</P>


<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>
<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Sole Book-Running Manager</P>



<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 14pt"><B>Roth Capital Partners</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 14pt"><B>&nbsp;</B></FONT></P>


<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Canadian Manager</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 12pt"><B>Echelon Wealth Partners</B></FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">December , 2016</P>






<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>


<P STYLE="margin: 0"></P>

<HR NOSHADE SIZE="4" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" "  .4# 2(  A$! Q$!_\0
M'    @,! 0$!              8%!P@$ P(!_\0 51   0,# @,$! 8*#0H'
M     0(#!  %$08A!Q(Q$T%180@4(G$R@9&ALM$6-D)256)T=;&S%1<C-#=%
M5X*4H[33\!@D,SA6<I.5HK5#5&5SI<'A_\0 &P$!  (# 0$
M  ,$ @4& 0?_Q  R$0 " @( ! ('!P4          0(#!!$%$B$Q!D$B,E%A
M<8&A$Q0CD;'!T1460U)3_]H # ,!  (1 Q$ /P#5%%%% %%%% %%%% %<%TN
M\"UL*>GRFF4)&?:.Y]P&Y^*D_B'?E%IRUP58SL^L>'WH_P#OY/&JL?BXSM6O
MR,Y5RY8K9O<#@SR8JRR7*G^8V:KXH37EEG3Z/5FDJ_T[B0I:_<D[ ?+\5?</
MB^ZU;.6;; ]<$[<S:^1M0\3U(/EO\5(+S'E7$ZQY5KOOMW-O9U,."X$H*#AV
M\_/YLN32W%>USVRW? +=)!V.ZFUCWXV/D?EJQH[[<EE#S#B7&EI"DK2<A0/0
M@UDEUFOMBZ76"DI@W*='3@##+ZT# [MC5FKB+2U-;*>5X5JM?-C2Y?<^J^7F
M:WHJF>&/$M#4==NU5,4%(W9ENY/,/O5'KGP/^#8,/7.FILMJ-&O$9;[JN5",
MD<Q[AN*V5=\+$FF<KE\+R<6R5<H-Z\TGKXC+1114QKPHHHH HHHH HHHH HH
MHH HHHH HHHH HHHH HHHH HHHH J'U#<3$CEN.?\X6-C]Z/&I*4[V+9/57<
M*6I;*G5J6O=1W)J"Z;2TNY9QJU*6Y=A,E1<DD[FHJ3$Z[4Z2(O7:HR1$Z[5J
M)U'3TY0ER8G7:HQ^,1W4YR8G7:HN3$Z[56E#1M:<D4GF/*N)UGRIFD1.N!4<
M_'([JC:T;.J_8O.L>5<BFU(6%H)2M)R% X(-3SK'E7$ZS7JDT7H6[Z,L72W%
M^<B3;H5XC,*CY2T[*"B%XZ<Q[O?5Z)4E8!200>\5CIUCP%=FG[_=M-RE/VB4
MMDJ&%H^$A7O2=C6SHSVNEG4YKB7ABK(]/$:B_9Y/^#75%98LW$?4MKNRYKD]
MR8'#EUF0>9"AY#[GXL4U7CC;<GT<EIML>+D8*WEET@^0V'RYJY'-K:VS26^%
M,^$U&"4D_/?3ZE^T52.DN- ;BK:U/'<==0,H?C)&7/(IR #Y]*G[+QDL<^Z>
MK2F'X#"]FY#Q!3G\;'P>[?<5)')KEKJ4+N Y]+DG6VEYKJOD6?14+J/4EOL%
MC<NDMY"F.7+02H$NDC8)\<__ +5:7'C?$5:B;=;'Q<5;!+Y'9)\\@Y/NP*RG
M="OUF5\3A>7F+=,&UO6RY:*SYHSB]<HER6G4BS+A/+R5I2 ICW #<>76KXMU
MQB7&&S+A2&WH[PRA:59!_P >%*KH6K<3/B/"LGATE&Y='V:['71114IK0HHH
MH HHHH"AM;\9-4VSBG<]&Z8TM'O#\1+:T8<4'%A3*'%$CIMSXKS_ &S.+O\
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M5C4^FT>L.!5QB8:D#O5]ZOXP/E!IWK'VE-0S=,WAJ?;W"%).'&R?9=1WI/\
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M-CIAQ63C 2"3LFNLZ7OEQ27KOJVZ1I"B5)8M26F6&? #G;4M9'3*R0>O*.E
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M_:VJ?: 2;O ;E<7]-R7">:':ISC8[N8N,(S\BC\M.U*LO^%*U?F:9^OC4U4
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J'RB@%_1:KNW:68=\MS,-V(RVR'&9(>0^4IPI2=@0-@1D9W\J*8** __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>pipeline.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pipeline.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_X1?;17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  #J5^   G
M$  .I7X  "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,38Z,3(Z
M,C @,#DZ,C0Z,3,      Z !  ,    !  $  * "  0    !   #(* #  0
M   !   !\P         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $  !:E
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 9 "@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MN$@GQ"2D ZCT<U^J,JDU!Q87BQI;N&W<W=NV^W>Q%<:GU,NQ]E@>S=4[=[7
M@%I:[\[<U-]BZ; 'V:J XO ],?2,;G_1^D[:U/8(J%>-MJ<UA;5+"6-B-OZ-
MNSV?VDE(VNRI.ZBH 3$7$GC_ (MOYRBVS,]H=C5=@XB\^6Z!Z2<#J(>)MH+)
M!/Z)\P(D#])^=_T$O\HR8LHCL/2?X_\ &?NI*:7UAR>HXE>.[I+'/L=86W>G
M7Z[A7M<Z?3W-_P (VO\ .6+^U_KA(_1W$=R,%VGWV+8Z]1UG(QL5O3WD7ML)
MO-+_ $)9M<WVNLW_ .$-2QOV9]<OWL@G_P .-_\ 2:FQ\/#KP_X6[5S<?&:]
MROZG%PKGJ_UOG2NZ--3@GB/=IZA3CJ_UPF"RT")G["_F/H_33?LSZXZ^[(\O
MUQO_ *32_9OUP\<B/_#K9_\ /6U/]/\ 4_YK%^L_UW_/4WJ_UOD>RW:=21@N
MT,GVG](F'6/KD2)JM C4_8G&#[=/I_UTATWZX_OY'?C,;X_\6H.Z7]>BXEE]
MH;/M!R6D@>;M-R7I_P!7^"KR?Z[_ )R0]8^N,"*[B9UG"<('_;B8]7^N/(KM
M+P#M'V)PGRGU$?I/3_KG5U"I^7>3C _I?5M]0;?S@VIOTK'?19^XNK);ZC?Z
MKORM3)RC$U4)>3+CQSF"3+)#^]?\7B?VU]>O^XK_ /V&*ZCHF3G9/3V6]3J^
MSY!T+2=KB.UCZO\  N=_H_\ J/YIFA+4Q<P<_D3)3$A0B(^3+CQ2@;.24O"3
M!S:9;QSX^1\U+;1Y?>F<YDM^/@? ^2EOK_U!3&5;;1Y?>IB !''91WU_Z@J0
M@B1PDI__T?1>H,M?U#IA:'&MEUCGEK7&/T-S&E[V_HF5>_;^E_PGI>FI9N;D
MXHJ]##LR_4>X.-9:-@!^D_?_ -]4\O#-^9AY 96[[*][BYXES=S'5?H?:?<[
M=^_6HYG3,7J#:QD[R*GN<P,>YGNGZ4UEKO:DIK'K&> #^R<G4$P'5SQ.S^<V
M;M_L][]G^C]177&ZVH![746/#A["'.:)]KMQ]ON:J@^KG36U^FWU@TO=;'JO
M)W.V?G/<Y_\ @F(XP\?'PQB G[.&O:XN>6D-<=Q_2-C;RDI0Q\H?]JL@ZZ^V
MC_TBGKQ\ACVN=D9%FWEKA3!'@[96Q2HIIQS-426@ .L<[VM)=^?N_P!(C[W>
M#?\ ._\ ,4E.']:<&G/HQF7Y%.&VJTO#LH L<=CF>GM]2O\ ?W_V%SQ^K?3C
MQU7IH^ _ORUT'UI9T^^C$=G91Q&-M+J;*V>MN=L>-NST[/\ !^H]<\<3ZLD@
M_M=XCPPP/^IQE8Q$\(HD>4;:7,"/N&XQ.WS3X3_TE_\ FUTZ"/VKTTDSK&HG
M]W];_-_,3GZM]-(C]I]-&A$B9D\._I?YBB,+ZM ;/VJ_6=#AZZG=WQMWTTG8
MGU8>"T]6=!;M,88!_K2W'W-?_+3[E^]+_%_]!8N&'[D/_#(_]^P'U4P8_P"6
M\+_H_P#I=+_FI@_^7>%_T?\ TNHCI/U5(G]K7?+'?_Z1_=2_9/U5_P#+:_\
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M-B?V3TT\F/5KF/\ V&2'UDZ;I_DGINOC;7^/ZNK/_.#ZRM&F+OU,AN#D3/\
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M[%?=A^_D_P ;_P!!<M]GUHW$MZ@T,GVAV5CD@?RB"FW_ %K_ /+%GC_2J/\
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MDOE5))3_ /_9_^T<LE!H;W1O<VAO<" S+C  .$))300E       0
M             #A"24T#[0      $ !?_*P  0 ! %_\K  !  $X0DE-!"8
M      X             /X   #A"24T$#0      !    !XX0DE-!!D
M  0    >.$))30/S       )           ! #A"24T$"@       0  .$))
M32<0       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-!         (  #A"24T$ @       @  .$))300P       ! 0 X
M0DE-!"T       8  0    ,X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #10    8              ?,
M  ,@    " !P &D < !E &P :0!N &4    !
M  $              R    'S                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   'S     %)G:'1L;VYG   #(     9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !\P    !29VAT;&]N9P   R     #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    !/_         X0DE-!!0
M  0    #.$))300,     !;!     0   *    !D   !X   NX   !:E !@
M ?_8_^  $$I&248  0(  $@ 2   _^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" !D * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M1BV&1)_2MT/[NMB2G-^M.?1T^C&?D8U.:VRTL#<DM:UIV.?ZFYU5G[FQ<_\
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M    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P R
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M4D="               !  #VU@ !     -,M2% @(
M                                            $6-P<G0   %0
M,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M    %&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0
M  +$    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE
M87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (
M#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE
M='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V
M+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                                  !865H@
M    \U$  0    $6S%A96B                      6%E:(        &^B
M   X]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0
M +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M   6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                 &1E<V,         +DE%0R V,3DV
M-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M    +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@
M<U)'0@                            !D97-C         "Q2969E<F5N
M8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M   L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0                                  =FEE=P      $Z3^ !1?+@ 0
MSQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M      $                        "CP    )S:6<@     $-25"!C=7)V
M        !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0
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MBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____N "%!9&]B90!D0
M  $# ! # @,&                _]L A  " @(" @(" @(" P(" @,$ P("
M P0%! 0$! 0%!@4%!04%!08&!P<(!P<&"0D*"@D)# P,# P,# P,# P,# P,
M 0,# P4$!0D&!@D-"@D*#0\.#@X.#P\,# P,# \/# P,# P,#PP,# P,# P,
M# P,# P,# P,# P,# P,# P,# S_P@ 1" 'S R # 1$  A$! Q$!_\0!#  !
M  $$ P$!              ,"! 4& 0<("0H! 0 # 0$! 0             !
M @,$!08'$   !@( !@( ! 8" @(" P   0(#! 8%!Q$4%18(&!(3$" P,T!0
M8"$R%S$U<#20-B,)02(E$0 ! P($ @4%"0P( P8$ @L! @,$$04 $A,&(3%!
M42(4!S(C,],587&10E(TE!8W8G*2TE.3)#65-A<($" P@;%#8X- H271LG.S
M5";!@G1U)Z)P\42$U$48"<*CA1(  0($! 0$! 4" P@" @,  0 1(3&1 D&A
M$C)18>$S<8$B Q"QT4)08,%2$T#P(/%R,'!B@I*B(P204\+2LN)#_]H # ,!
M 0(1 Q$   #[SFM@       C("[      + OP       "V*R8       L2\*
M@      6!?@    %^;4 #1CJ        %L61E@#S4=BG90*RDZX.S #7S83@
M       &-)2]       ,"9HD      !@#/@    &TG=X -&.H   =?F7-I
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M73/$AU 71EC4CLLUDU4V([/+ QAL0!:%V 8@RX !U]:GR*^S_*:@ <')P<@
MX.0 0%1*   <'(  !9ET5    %P>[/%^K]@>)]<!IYN          !KQG20^
M;QY&.SC3SWJ>&3:3TL>[BR,>>%CVV>-R<LCN8T<U<QYN1JADCW4:#;/\_OZ'
M^'^H?,^AUS3#8L]\3;//9[873*%6UM7,TUTS;EI.X./T]2VYH46%J8B^62KI
MFJ:\&0K>]K>YB?/WH>-VAR^A;37:LNC5]>?9<][*:X+3''VID*WT;?D[FXO4
MQ-\Z413&$OE2=E<W=HN_)EZZ4'F7TO G.VCZR_%?K7H#S_:&K&T@
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M&/,Z      :5-?$'T'Q*0       L20N@      #$&3)   ;+GM[H\+[&>)
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M0L#"F?.3@Y. <G!R< Y.#3$=;]_D<(Y*2HX!R4E1P#DI*C@&*)3(G .2DJ.
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MT I*@   #2)K\[OI_P ^J0       +4J+@     ]#>=[WL#R/I@-5-D)@
M   :L;2        #@^!Q]\C5B@C*RHH)2 K*B@E,661GR@E("LJ*"4@*RHH)
M34#(7RJ*"4@*RHH)2 K*B@E("LJ,*79=%944$I 5E102D!65%!*:F;$7!02D
M!65%!?1-W72LJ*"4@-=-G*"4@*RHH)2 K*BZ-A  !2?'L^PQKIGB0    %B8
MTX-A   +4Y+D Z]OG\!OT+\/S]-<%?$2IK3S"1-E-)$SQ:TF@$R8D<
M   YEQ    =T4V^L'QGZMWCP>R !J1MH        .#Y"GU[-=,\2     LC'
MG@LVLZU.T36#831#/F/+P]Y&3!H-\_S\_H?X=ZJ\KZ2UFN-MG@M,;&:Y6NEM
M-<;;/:,NC/4VT7;DV[+IW7'JTK;EQ%\J#S_W^*            ,N>N?+^A^N
M_P =^I@ :L;2        #RJ>,#Z\FNF>,2=4F -Y,>;$:D;>:X=N$)C#8@
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MS7(5OB[YWE;65J4&:IK;36UM7*4T&@='&       !V=#Z.?,?H7L_P '[(
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MLK(B8@*RLS66O9GG]@   &O&=)#HXC-A-+.UC3RQ,J=MED8\J,V"V*2V,H
M =?:9? 3]"_$,]GKBKYW$321(D386I<Q.3KI@;X[#GOKVF'*>#)UO!,9:FEC
M:EO,9_/;#WRQELQ4FE%W%ZX6=JY"M[*:#NJ-/HKX7Z'V-R>QG[5DD      -
M;K;9+5BBODW?@]%8]>EWST><_2&/9P=.^%YVY]_1NOH=6:Y]]\\CT@   ->,
MZ2'SH/))V4::>\#PR8X]=GT!+$QQ\Y3M4MC6CO<ZY-9,R69P>ISM0'7FF7P
M_0OP_P!3>5]'A;Y8Z^>>SVPM\MWPZ^F^SR^]^'V-6UY]&WX\I73.9[8RV>Q9
M[ZCMS;QAU]5]7G=F<W?J.W-@;X[3ET9&NDIRGB&.OG C(5O96IYU]#Q!D#V+
MP_1>^O$^\V"U99      #6J6V6]88KXMZO-U6::Y>EL=I9[4^1C9?'<&U]?1
MZ\^T^@S7/OOGD>D   !KIGB0    %@8XV       Z_OG\K_M?R^L   X1RD
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MCS3['R_        ,:2EZ    =@8=GI'S?=  T\VDG      !IYN
M!X^--/:1G20'BTQ)L1&:2>PS?061CCRD9TU G,V9 ]5@  &@6S^ /Z'^']R\
MGI]=]'%N^'7K>N$2-SQZM5UY\?;.[BUW6^+OGG,]<1?.]BV+MG?5O?Q>PFF2
MKI8VI;S7)5TQML[J+8ZU+JMLK738NCA^B?ROZ-Z^\3ZX :J;(3       U4V
MH        PYF#PN5GL0TXU0OC#&')#8RU)C%&@GJLF-2+ N#.FC'8Q9F7,\
M =?WS_/]^A_A_?/![&MZ82IO*VAF+2:S1.1KIC[9V-JXZV>R9[RQ:0Q-L\9?
M/,TUS^>T,QK>F&U9=&'OEP<EG-<M72>+=$]WC_07P/L_J!\Q^A #4S92<
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MF^B^)ME/%LI6^+MGRG)UOC+4OHMK=\_M%\9^J=N^?[>RDX      -3-L
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M"8      &JFU         'G\VHW4SI(    "Q,>9X      T>:^&/HOAN0
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M3#WR@F)HG)5TQUL]]P[>C^WR.W.3T^D^WR=^P[(D8:^6<IM:37H?N\<
M    #83ZA_+_ *)[B\+[    =:GS./KV:F;.:D:8==G;1F#5"<V4N#;BR,<>
M6"V-\,V84MCTL2   T6U/EY]9^:5R       %J5DQR    <(Y2 ,>7I6
M  #'F0   !WGP>S]!_G_ +4   #3SP,?2DTXVPZW/#1*;J:P>R3S 1FH'OHV
M QYU661U,=MFUFCGH@J  !I1\D3?C9B<N"8R!@BZ,67!&6Y=&QD9C#&F5,*7
M!EB@H,<9LQY8DIF"(I+4OC23="@%9<%B8XS18$P)R,N"(P1F#'%\5DII9NQ9
MF2.O#DOSZJ'( !YY/+I]*#4S9SID\V&&-W.OSOXZ(-S.J#WR;J8TV$
MZ_/R9G:QWH;D5EX7)KIVR>5STJ1G01W.6Q:$)KAV$>?CL\WHU,K.NS83<SJ@
MRAV661KIM)='31VR6AIAVH=?F8,@#0#/& .YS5#33.&4,::.=PFLG59JQZ)+
M,W0\7EB=JGZ8RL   &FFVDH    +(QYG0     #1C\[94       "(Y)
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M7)68HWPS
M
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MP1\#ZU('6I ZU('6I ZU('6I ZU('6I ZU('6I ZU('6I ZU('6I ZU('6I
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MX=.'3ATX=.'3ATX=.'3ATX'C@6.'3ATX=.'3ATX=.'3ATX=.'3ATX=.'3@J
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M..MQQUN..MQQUN..MQQUN..MQQUN..MQQUN..MQQ/S!.)_\ F+__V@ ( 0,
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MF\.\WAWF\.\WAWF\.\WAWF\.\WAWF\.\WAWF\.\WAWF\&[FY\F'T/H_H)[_
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MJ.$XEGD7^+6.?<=3"=</D7%#DWO@J"^DX^->=6DS(5^P%)+^A7O\#!9E1'U
MOAU'^ZL@@DNY13C74W.,?)?42LKQ-W)FX]SB4*1,^*TY)"5%DD$3>64A3N0)
MQLYQFA>1^:6<Q]:BRQDF1/)U#F8-1-9(DDQ/0VAG)_6;F2-:F\LI"RRW]R%=
MP!NG_0JT_)/9CP[,>'9CP[,>'9CP[,>'9CP[,>'9CP[,>'9CP[,>'9CP[,>'
M9CP[,>'9CP[,>'9CP[,>'9CP[,>'9CP[,>'9CP[,>'9CP[,>$"HDTZ1$1?\
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M0!W1 '=$ =T0!W1 '=$ =T0!W1 '=$ =T0!W1 '=$ =T0!W1 '=$ =T0!W1
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M_AQW_AQW_AQW_AQW_AQW_AQW_AQW_AQW_AQW_AQW_AQE-GX/%8U&P<,M'?\
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MZWL#$X/$U_:\C"OY;9^2RTW&[GS.,SC.Y'>8:6]#'B[X[9>XN_DO9*.FQO\
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MI9Z8@.9+'Z\DX]%@H;V:S;^O,5(+%ZMCX][$X=O$J_\ /G__V@ ( 0("!C\
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M$.'!,6@8 \XQPFBT?2X \'CB$22"7$O$+'>:,KXQ&#8?NYKTD$!XM-@\O&"
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MTY^:T, "?[?]$!> 0S>2ML]KWC;9;<+A:1JTD28N#I& +K^6^\W^YB9!N#2
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M?5!R6;$AIIM4& EP1-Q@Y('C"?Z9H70,IC@&@7A0J[C<\?%&+.V$(!N(0&J
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M-082AP+AX_)%R'+X0]32H@;6QF)0 _1,#)N/VAHL1DF! $.,[?-VSYI@0!#
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MB"2X)B&,Y-^JTD<<:#JA>;?4[D.(P:'AS5GI=B28B#O#-&XD$$'",_'!?QL
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M9N!?@M6G$F>!MTM$&/./@M3$D7."2'9M)&T"4F ;@4#=:;M-PNM>X/ ,Q:T
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MD01X)R7G_P!VZO\ DM5MHM,7@+G!P(8 CQ!\5JU1=\)MI^4&DC;=:+Q !V@
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M@(N&H8D'TPA+%U<]A+R#AK8 .(:GAQ;DM5MA<LY)#W1QT@!^!;Q=?QV BU@
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M(F5<0<#$*QKF@//X^BTW#BX \GG\D6@1,&8^HYB'P'X+=X'Y? :@2"-5T/\
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MJE=3JI74ZJ5U.JE=3JI74ZK^.TD7&3AGY>/Y'N\#\OA;[,'N#NYTMXMQA*:
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M%GD1PQ1.G]^/_P!GTS5UXMW%Y_\ ";6!;G/) W6FX@DVDW1#C3&'JY2^ _\
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MW +@:=@TD-_Q.6XB#JV^XL=#$M*^+7-BT%=[=A=]+EFU$ ZKN3ED7=QH%I;
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MZ+[:]%]M>B^VO1?;7HOMKT7VUZ+[:]%]M>B^VO1?;7HOMKT7VUZ+^3_V6+2
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ME3BA&<ID2GRP3B\;?V+8;8O?/B1XVWW:&W9-[FW.3;(RF 77)LL/RGWB A%
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M6-P!O<&X)CR;<\&UEY*G2H,-M@@18;CA55LK[#:CF6JB:94I81]8K\VK("7
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M[N7G@NN; 2W(" H1?:T<U5I,K*<X13@M;B*_<9N2AC,C886YF4-+VK'' &2
M:Y.D-,G_ '?N%582-C@MK6D/.>TV!II*XZ2JF3C1+CJJ#\G3XXQPV$%>9*_U
MK''G-!Q8;\CI<2ANOW6;DDX<:5LD(C)>*&Y7M)@YF]<MZF3)4>: <I[N7GC<
MRI&R6;>Z;4^HZUWC::5=W:60I>>.  M;B*EQ [&;, H4CJ;V*EUS(!IBZQP*
M#O !KE4.(:9/,^E^X-6$C8X+:UI#SGM-@::2N.DJIDXT2XZJ@_)T^.,<-A!7
MF2O]:QQYS0<6&_(Z7$H;K]UFY).'&E;)"(R7BAN5[28.9O7+>IDR5'F@'*>[
MEYX+KFP$MR @*$7VM'-5:3*RG.$4X+6XBOW&;DH8S(V&%N9E#2]JQQP!D@&N
M3I#3)_W?N%582-C@MK6D/.>TV!II*XZ2JF3C1+CJJ#\G3XXQPV$%>9*_UK''
MG-!Q8;\CI<2ANOW6;DDX<:5LD(C)>*&Y7M)@YF]<MZF3)4>: <I[N7G@NN;
M2W(" H1?:T<U5I,K*<X13@M;B*_<9N2AC,C886YF4-+VK'' &2 :Y.D-,G_=
M^X55A(V."VM:0\Y[38&FDKCI*J9.-$N.JH/R=/CC'#805YDK_6L<><T'%AOR
M.EQ*&Z_=9N23AQI6R0B,EXH;E>TF#F;URWJ9,E1YH!RGNY>>"ZYL!+<@("A%
M]K1S56DRLISA%."UN(K]QFY*&-GN?4YEIYNYR5-17+K'"GR(5Q2$-G.WVBE#
M:_)70+/9&0J#"1L<%M:TAYSVFP--)7'254R<:)<=50?DZ?'&.&P@KS)7^M8X
M\YH.+#?D=+B4-U^ZS<DG#C2MDA$9+Q0W*]I,',WKEO4R9*CS0#E/=R\\%US8
M"6Y 0%"+[6CFJM)E93G"*<%K<17[C-R4,9D;#"W,RAI>U8XX R0#7)TAID_[
MOW"JL)&QP6UK2'G/:; TTE<=)53)QHEQU5!^3I\<8X;""O,E?ZUCCSF@XL-^
M1TN)0W7[K-R2<.-*V2$1DO%#<KVDP<S>N6]3)DJ/- .4]W+SP77-@);D! 4(
MOM:.:JTF5E.<(IP6MQ%?N,W)0QF1L,+<S*&E[5CC@#) -<G2&F3_ +OW"JL)
M&QP6UK2'G/:; TTE<=)53)QHEQU5!^3I\<899N.TQ;(BT)+TWO[+^11;4I2=
M-*03102FO36O1_97NM*=T76N6G+[OL_#AK[Q/^']G/"<V8QG0,N:M<AY90I5
M?>!/N8V^EPK*TVV*%ET.!=0TFN8.H;<KUYDI5U@'A_;;@DMI=6N+'2^$,:NH
MH-.)60G0;>7Q Z$'W:"IPL)\+IB@E1347%KH-/R6/LLF_M%KU6/LLF_M%KU6
M/LLF_M%KU6/LLF_M%KU6/LLF_M%KU6/LLF_M%KU6/LLF_M%KU6/LLF_M%KU6
M/LLF_M%KU6/LLF_M%KU6/LLF_M%KU6/LLF_M%KU6/LLF_M%KU6/LLF_M%KU6
M/LLF_M%KU6/LLF_M%KU6+A!3X83FE38SS"71<VT%)<04@A09)%*\P#B'$5X7
MSG%16&VE+-S;45%"0DG,6036G.F/LLF_M%KU6/LLF_M%KU6/LLF_M%KU6/LL
MF_M%KU6/LLF_M%KU6/LLF_M%KU6/LLF_M%KU6/LLF_M%KU6/LLF_M%KU6/LL
MF_M%KU6/LLF_M%KU6/LLF_M%KU6/LLF_M%KU6/LLF_M%KU6/LLF_M%KU6+I:
MF_#*?'<N$9QA#Z;HVV4%8I4+2PHIIU@'#:/X6S24)"23<FC6@ISTL?99-_:+
M7JL?99-_:+7JL?99-_:+7JL?99-_:+7JL?99-_:+7JL?99-_:+7JL18]]V'/
MV[8%.H:N>XN](DHAARH0XXVAM*BG,.T1R'&F(\R'(;EQ)3:7HTIE06VXVL9D
MK0I-000:@C^OLLH+H2BZ/ET(#Q24]PE#MZ;:T@5(](I":THHJRI/_"WLYLM(
MCG:KEIPZZ*I\&&OO$_X?V=RU,N3NKV?-EI3(:US]FGO\.O&V>[Y-#V5#T=/3
MR9-%&7+H@-TIRR=GJX8W5N"U;Y&S+#M7=4[;MGVLQ;8DUJ:W9I'=Y;US<D([
MQF?<2YD3'=9R(R$E:LV&'+3X<;CF/7J_7#;>S(BW+<RY>9MH>F-W%;.I+"6F
M6$0EN:CQ0%"@3579Q:=PV39^YKS9H^T-Q/;JV(R8+,BV3[!=6HD]4E3\AME3
MC!;<;1INJU*U1F''!,/9]_N>U(KNWD7C?#28B(,1&YVF'+<X6G9"9+E>\(#@
M;:*FZ@D4(Q9MA;H5,WINWQ ND^[P'W)MOMT")%ESBW&ML!ZY/1#*5';*1I-!
M;M.V4@+2,;7LT#;=PWAN?>$I^/8]O6UR*RXIN(R7Y4AQZ8\PRAMI %:KJ2I(
M2"3BW;@WC<;[?&(FQKYN>YV#V:P[,4J+N.1#0I<A+H<2XTUE:4V6]-*4E:G.
MR<;2W'<+0TW+WS,F1MLVQ.X+ 8TAJ @+D/B[FX"W!*:Y0G7SE7 )X&FT-\I@
MNSML;KAF<+@;C:8A:;;?[O(0PW*F-+FN,+2K.F('>&4IS9T9MS[+]DR([.SH
M;LZ_WF5+@L.(CLQ42S(9MBWQ<'F"EQ*4O(8+975(55)P_8K,TF%/5:4WZU->
MTK9<%2;:IQ#1=6BVRY2HRTEUNK3X0OM<NRO+_1O#O6EH=P5GUM')Y2:5[P"W
MSI2O]W&F)"TDU"UDCKH3B#"7?+D@R5KCI7<X+=J9ENJM#]R;>M\AQ]]+[#2V
MTH>6I*,H4#T\'K#:O9EPN"(46XQ3&F:[,R-,"M!V,ZTA:5)44E-590#P.-KZ
M;<-4_>3^AMRQ]Z'?Y%'EL+<#(21D;6VH+4%'+TCCA_:VXR+3,;LDJ^1WT)4Z
MV^PQ'6^C)GTE47D*:D @]!Q<[I[6+GLZQ6.]:&C3/[95ETLV<TTOE4[74,>&
MJH^X NW;XA)EWVX*CT%GRL(EO)6D.G4 CN)4@DHSJJGA2N/$*<F_)=E;.N=P
M@V6V%@I=NK%H>2W<)*>V=,,H<2O+VJT6*]FI5<$76XOEBXMVXM76VBVIF%R,
M)!DVU0D/]X817*M9":$CG7&Z+7)W0S;HVV7[&T]=)+.5DHO+L=M3CE'#D#.O
M7IS4XY:U%OV/8FKA)N-V+2+<B[QD6]QQ;I510TWI33C:@,R'&G5I4#P[51B=
M(@[FL$VZQMP0-O1K2Q.0H2)$]"BG3=4$]I"DY2DIZ%U(R<6+BTNWP+8_&>EF
MZW":W%C--L2A".JXO@A2WU!" >*JUY<<;@CP,DBPVE5T<8N;\EHG0M4A$9\.
MJ0 D.9W4!*0*JS)(X'"=P1^XEEZ&_<8MI5,;3<GX,99;?E,Q#VU-(4#4]0)I
M083$F/V1(0Y-9N4UNZL.1K>Y;F1)E(FNH)#)0T0JAK4'KX8F1'UV=4Z,I],.
MWMW-E3]P5%81)D)@-\WRTVL%5*<> J<%JU2(++:(]G6MV[S8T#/)O32W(C#/
MG7 M3A0H)X@\LR4XE[IEN6V-"@-M.R[:Y-;%P0V_)<B-+,4551;K*PGC\4G$
M&5 EPH<9VRQ[U<)]XEQX$9EF3*[FWE<+B\P+A2!4)5Q\FG'&Z/;-WAV29L^]
MV^SW6S//H$EU<M]QET,&I!4DMD(H"%GJIQF6*Q)A7F*A^YB/<8LU$IIIJV/I
M9=1*7'2K(ZC4;S)">:A3AC=6W;PI5HNNT[?=)EPCJ3J'5MC*G5,^4F@7EH%=
M -:''AW;9>X6;=%WU;X\]^YR4!#4%+\J1&*22X JFA4$E JJAR@9L2+0$W)M
M+3;3@1=H@@RAJ)"NTTAV0VH?)6VZM"AQ2HXC[Q@1X\RQR'V(RG&W5:C3DA\1
M6]0*0E(JZ0DT42*BHP84B19 VTW/7/NZ+HPY;X9MCB&IB)4E!*6UM+=0".G,
MFE:XW'MVV7&"S;]L1($F[7ZZSF8\)GO<>.OC) "%!3S^5O*#44]TXMC5\O<"
MWW.XN;@BNV/O;+;[#]G@JE,N+6K,@LK5E*U< ELI4#VA2Z)MENC7-FUL1Y(G
MPY(?C2FY4=4IGNKS:5)<SM(*A7+U&A(&+3[5D03(O,)BX1[?%E(D26F)+:76
M3(;14ME:5@A)XX<M3]PL<>;"AKG7UMVYM)3:66P@GVBJE&%5<2 GB2>&(=L=
MB1N\W"<[ MZTRFU-/N-Q6YNHVX#0M+8>0M"^2JTYXVPB9<[1;8&XY%J;>D">
MR\_!9O+>K">DQDJ"D:R00@$BJNR:5!Q80]=;6_!W'<I%NM"[?.8D297=5K;=
M>886MH*;2I%,REI'4<6*\0K*%P=QR&&+8IQPH524MQ##CE4Y0APM*I11/+AQ
M%9-M=GPK@[%(2[)M[_>&,U.TD.94]I)X*!%001CGCGCGCGCGB79[PVVN!=55
MD*<(IRRCB>5!B+LO<.X(]U\,;LY2PW!+R'G;*\ZKR%A*BKNZE'B*=@\1V:X!
M'$'B#_6V'K:6K[8D=USZ.;/[-F5R:H*ZY:^C[5*U[.;_ (:]$$@]U70@J!Y=
M: 5?!AK[Q/\ A_9W IK41G2,M:UR'EE4DU]X@^Z,;>4O/G5;8I7J%974M)KF
M+KCJZ]>9:CUJ)XXN&X+1N?<NUF;[+;G[FVY9IZ8]NN,M "5/NH4TMUE;B4I2
MX8SK170%555)LEBMMQO-AD[9OMPW%MO<UOE(3<H,ZZ2)+\PMN.M.M+;=$MUM
M3;C:TE"J4J H%B)[04MZPW6P3YCTHN/RF[U)[Y<)4AQ2:KD//U67.LF@ H!<
MMMI-R]FW7ZO&565YS_VPW&;@959>'"(WJ<.UQY5Q&C[@W%?&=O)0A%RVE#<B
MMP)R4.AVD@KBN2$DE(!+3S9IR(/'%@F2+M=MNWO:\EV38MQ620B/,C]Y:+$A
ML%UMYM2'FU95!2#T%)2H XBQ=KW:_6&1 L,O;MMNS,U,B6Q$F7!5S<4')C3X
M6[K*("W HY>!J>.(J(]\O\;<D6\R[ZG?;3T075<N>PW%DYP8AB%#C#+;90(^
M7L)53/51K?-R[F>>F6!G;6Y9+,J*PY=[?&><?91++45.12''EG-'#1-:*J.&
M(FY-Q7N];CCVP2/8VUYSD3V;#,J(N"Z6DLQ6GU58<<3E<>4GMDTKE*51[5NF
M_76SM1&X-JL%T<ANQH,=HC20PMJ(U(5D2 @%UU9R\ZGC_3NU3>IG%O732+H7
MS%:%EUA?P+'NU' OI'!)6L$_WGEA[=LAZ.N[/17H926SW=+3\,P5A#16<ITE
M'D?*XX@-Q8UHG-6MNW)MS4Z*MQ++EKUNZO -O-YEI$A8.?,@U\BO'#,&RQ[5
M:PFY,W:7*:9?6[*E,*<4E3R7I#C5%:JDJTVT$I.6M,2;Y;[?;+0_*@/VYR%$
M;?,8,R6BRZ4ID/O+"BE1XYZ ]&)MN>5&[M/MEMM$C*U17=K4<T;*<W!5?*/3
M[F)=D9E1$6^=$M<)]ONXSZ5G%(V5955)4GLN$>6.!P%-7E,2 XJXKG6".'&K
M;,5=7779:I44.9'2LO$55Q "1T8F7N\O(<FSE NI:!0TFB0BC:"I6442.G"(
MLB#9'%NF![:GJ@YG[JW;!EBM7 K<4AQ"0!4(0@J(!420#BQSYEGL_<]N11"L
M^VVF9"+<TP%K=R9!(UC5;A43K5K[@IA^XO,VHRE2K5-@N&,XLPY%E1IPW&%.
M/K4HI02E6LIS,#[U.YFP[:39#"<@JVTB X("FW)8GA:D=XU"XA\9TJ+GW)!3
MPQNJQ3FVS-WCN%%]NTUI"&VD)2@YV&&P*H2XYE4H5IV$\.&&[$S%M2C'@OVN
M%?G(I5<H\"4LN/16G]0("%E2N);*@"0% 8GWJ]PN_-7*;<[JZ+:HPWV;A<V0
MPX\TXE8(0E((" H'B>UBYOV*QVZ%$=D3'[#)N"')URMJKBTEJ8MB2M[RGZ%1
MU YE).2G/$515#)AR++*9\Q_F6!MQJ%7M<1E=5G'QO<Q;]H/V&6FZP]-8G&:
MYW)N1KNOOR&HR7,F9W5(H4<*GM''L-Q44P/9D2T4#7G.[0I8FM=K-Y6J.)IQ
M'#&Y[HY'MLR3NV<S<[DB1'66VYD=]<AEZ.E#J"@H6XJ@)4*&A!Q+;#=NF0KB
M_<Y%RMDEAPQY*KNXP[(2YI.M+RA<9M3>5:2D@\37#NX;:Q";>?$AJ1:W&E.P
MG(\M"FWHRVW'%+4TI"BFA7FI\:O'$6X2[)87V[=%C0;5:5Q%JA1(D8K(CM,J
M>)*'"XHN%:E+))4%)5QPR)UNMD5N%&BPK2U#:=;3"B1 L(CQ\[SA"%%94K.5
M*)I10Y8BV)N-:2W$C0H:+FJ,LS%1K?+$Z,RI>MIA*'14E+84H<%$\\3&5Q[7
M<8%R>NKUTM4R,I<:3[96P[*0XE#K:\H7&;4WE4"DCF:XO]XGVZRW5&YV(T:]
M6*7#)MSK<-+28X2RTZTM&GHIRY%CIKP)&)1FMVR5)DOW-],]<4AYD7>)W*6R
MSD<2VEM35 D%!*2D$'F"JQ3(=KNMJ$6)%CPY;+U&#!87&9?:4P^RH.Z:R%%1
M*54%4\!AF?.6V),>)#A-+93D ;@L(CLFE3V@AM-3TGCB7>)-BVZ_,N\1R'N8
M*AO:=W;<TR534"2 5A3:5!3.F<W'$B285BE.JDF5;>\0,R;:HQ$P,L$)=2&T
M]W0E "\],H5Y7:PB7%<AI?;-C*5*8J/_ &ZA+<'AF^2D:GRO<QMZZ18MMMZ]
MK/27K'"C,+$=HRGEON)*7'5J4G.XJ@*N Z<62)=;+9;TJPH;8AS9C4K77'9*
MRU'>+,MI"D(U#0A(7P2,U!A5\O'=T2S'CQ$-QDK2VAF*VEII(+JW7%42D#,M
M:E'KQS&.8QS&.8QS&!FXA7+_ +,6[Q/\2K:#=5!,G:>U9".$0<T2Y2%#BZ>;
M:#Y'E'MTR_UMEA.IE7='PYD+H33V?*/;TW6TD5 \M*Q6E$A5%)_X.)X7V7QE
MM%UWS/O/U?@V2*Q-=#UQUBP&6Y"8Y855P4"PYD/,*IQ_HO0 ))BKX *)Y=22
M#\!PU]XG_#^CP=VG"\;F/ G9&[;7>Y6Z-WO6&)?@A^$&S%3HR&G%#.I62J2
M*U./ [Q)WUN6-9[=?/%ENP7S?:[.B,C<&RD%U3=U5 6TZJ,9+:,WFDI-!F0
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M0M*H2G-C<^Z+?MFXP)&^(RV]T);N45UQ+Y?:D)<@+D6UU+*0ML@H=0]5)H%
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MF6EM9_F_E57G^^2D\J@K?^M-[4%NZF@7F--(UB[D T*Y:')S\D4Y\<%@[PW
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MHO*JO/\ ?)2>505O_P 29*@MW4T#<(>FD:Q=R :=<M#DY^2*<^."P?%"<LE
M1KJN,'4X-M-YJAH"M6BKEY2U]! &3^)LQ'$G.FXPLW$OFGHNC7 '_AM]1S-+
M_B7* :4%% N,+*NBV%45YKD=$@TZ%KZQE^TZ:/-%OA<87,M+:S^B\JJ\_P!\
ME)Y5!6__ !)DJ"W=30-PAZ:1K%W(!IURT.3GY(ISXX+!\4)RR4!&NJXP=3@V
MTWFJ&@*U:*N7E+7T$ 9/XFS$<2<Z;C"S<2^:>BZ-< ?^&WU',TO^)<H!I044
M"XPLJZ+8517FN1T2#3H6OK&7[3IH\T6^%QA<RTMK/Z+RJKS_ 'R4GE4%;_\
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MJ..#=1:Y9M*7=!5U##G=0[^3U\NGF^YS5QY/_/#>LPXSJH#C6HDISH5Y*TU
MJD]!'##K,"&Y+=8CO2GFVA4I8C-J=></W*$)*B>H8\G_ )X\G_GCR?\ GAJ-
M$BNRY+ZLK$9A"G'%JZDH0"HGW ,$%-".!&/)_P">/)_YX\G_ )X\G_GCR?\
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MZD*0M)',*!!&+EJ4T^ZO9\V6E,AK7/5-/?X=>-L]WR:'LJ'HZ>GDR:*,N71
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M=C]H1?Q\?N.Q^T(OX^/W'8_:$7\?'[CL?M"+^/C]QV/VA%_'Q+NESVC$A6^
MTI^;+<N,;(VV@54I5%DT ZAA*T;(CJ0L!2%"XQJ$'B#Y>/W'8_:$7\?'[CL?
MM"+^/C]QV/VA%_'Q^X['[0B_CX_<=C]H1?Q\?N.Q^T(OX^/W'8_:$7\?%LA;
MOM;.U-ME17=[NB4S(=#2*$MM-MJ4<Z^22> YGJ-MVOM>VM6JRVIH-18K0_O4
MM:CQ4M1XJ4>)/$_UMAZVGJ^V)'=<^CFS^S9E<FJ"NN6OHR%4K7LYA_P9ISIP
MZ<>']PWWLO\ G4A;ZF;B9D;BFW>=)3L-$U<HK6Y)CIELM(MU>):#&5+?8RJ
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MCQ/\.]K^(<OQENNY-OQMJ^'NW'[/8=NP[$P_6&\^CN+<1"VVV7=125$FC=$
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MOA/5Y9<;:"?3\\[R$TZU)'2,"0JR;83'4WJI>-P.0MZ1?S9M>E-,%=?D\>6
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MRX4?O"D44RA5'*AM%0"5U33A@[5D6SZNWEN(_.E,7Q#T'0CQHZI3CCJ5-J<
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MJJ9BZ\3_ .%CTNW_ *6OU6/2[?\ I:_58]+M_P"EK]5CTNW_ *6OU6/2[?\
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M[WVSO^3*N%U\.XGA_M7Q2W5M25L-N5KW-,FX-Q[:>\S4:+"%ME]202XOL42
M<?S?^'"=H[1L35Q\([=MRU,;81=VH#TEFV/LVJ/:)$]M*7:I*TRBM68+*:<U
M'&W=G?RT7GQ)V.)VP'[+_,)_%5^_1[)#F.:#285K$QIS3>.F^E*K>C(EOXPQ
M_.[X<#8VU(";EL&PVJVV?:[5U:ARI,"'_P!-B65ZX(;0ZC10XB1G45:A12M5
M8M?BA"VGN/:NP? KP$W9:/$2X;FLTRQLBX72&RA-LCB>RVI_33&65*;"D>31
M1K3'@];[\%MW1C8T,R0\1F"7(Y<;S9E('D*3S4/?&-MD*2L>RXE%H*"D^93Q
M!;=>21]ZXL=2E<\6_<MQ?M,R# \0]P;R984%N.H9NMK$&-IA;65+[:ZE1!H$
MGLJ)X8N^VK2[LV[+W7L2Y['NJ[PN9W>V-R+K<9\>1%9;BK[RE3<Y*'&5%@)4
MVA06L )P_N.URK%<;I;-S;7W'9+-<'Y+,28;)8A9I#,N0B,\IDU6MYEQ++M%
M)02CG1^!;KGMC;<.][<-MN5LM,Z7;(T.>N6_)<6YHVUUVZ,J2ZD!#BXP2O4<
M":NE(\5K=%D6(V7?UUVQ?;;<7I4I,IB19E6Y,F,]&3$6@H6B$5(<2]4J5E4V
M!VL0;=*?V^-H67Q&N'B-;]U-/2?;S[TTR'4P'8JHVBC(J2II4A,E16RA*=%-
M>&S+.[:MN7R)M[PQG[*O-@,N1:X\V=+EVZ4EU$J/"?6TA*XKKFII%8<4%!-2
MHB5;]^WQ-ZG*N#SMH;[ZY='8<%24!N.[<GHL%R6H+"UZBV$$!0;[63.K^KN6
M*'6V52HP92Z\IM*$EQQ" 5%U^.D"IZ7!_>>!64>(-F2%J*B.Z2#S-?E8^T*S
M?1)'XV/M"LWT21^-C[0K-]$D?C8^T*S?1)'XV/M"LWT21^-C[0K-]$D?C8^T
M*S?1)'XV/M"LWT21^-C[0K-]$D?C8^T*S?1)'XV/M"LWT21^-C[0K-]$D?C8
M^T*S?1)'XV/M"LWT21^-C[0K-]$D?C8^T*S?1)'XV)]Q=\0+,MN!'=DN([LX
MW5+2"LC.ZXA":TYJ4 .D@8B3$>(-F2B6RV\A/=G5T#B0H#,A:DGGS22#T''V
MA6;Z)(_&Q]H5F^B2/QL?:%9OHDC\;'VA6;Z)(_&Q]H5F^B2/QL?:%9OHDC\;
M'VA6;Z)(_&Q]H5F^B2/QL?:%9OHDC\;$.]^(.XX>Z;3;J.L6*(PXTA]Y)JCO
M"EJ-4#GE'/IX8;99;2TRTD(::0 E*4I% E('  #D/ZNZ"I:&TBVR*N.%M*!V
M#Q477XR /OG4#[H8C]/FD<13Y(ZB1_S/]OL6JT))NS^5*BV"K_ITO@D+?:43
MT]A#AI\4"JT_\#9=@?RY7N-M;?NX]K7)C>]^NTF.S;5[66^VR]"RKCRWP\\^
MXG*XRU5*0H%:,R:_77>>_MQ;DW-:HERVE-VE=%V]R#:+I[02]N!Z%(@(3KMS
M9<5MUK/0M-@-A*>*1MEF%.\0HT6^[QMMMO<'PH<=:WE-B+9E.J9M*V&G%A27
M&D/.@%&9I#B<XS95;^[HW_,8V.]6_/\ _P!0BY:I)[#]/8W>E*.G^6R].2N-
MQ.0X[<N4B"Z8\5UQ+*'%@<$J<6E:4@]9!Q>MC[TV+;+WL[<+'<KK!<NKJ.\1
MB]2ITF&UH4$)2X,BP0K@%<,V(5NB[1M[#=MB-1H40WEUZB&6&4I0IYR*5JHH
MK3F54D)"CQ71-4;7MRG<RAD-T4!0&10U[H>80ST?'5\CML@;9MY;4I(?7[35
M5"2M@$@=UXD)6Z:5'%"1\>J>&UK<1I%7ZU5Z316H)^:<M0(17J)53AE+B%[;
M@)C!TI;?%R45%O6*0HH[KP.E1=*\^S7XV"MS:EM1)R A@7913FTVE$9^Z#AG
M4XFM.20KXU$U1M>W*=S*&0W10% 9%#7NAYA#/1\=7R.VR!MFWEM2DA]?M-54
M)*V 2!W7B0E;II4<4)'QZIX;6MQ&D5?K57I-%:@GYIRU A%>HE5.&4WO8^]M
MCP+QL^^E+%S@^V)#)D1VY06G.8[+2Q5#:5E(70\6S5-29$5C9]LA"+;U-1(,
M>Z+"&PB,UE;040Z@)65H&5/)"2!VJ)L%-L0W'DP(Z5)?NCR5D!MT K+L,.9B
M$,DA:0H%:J\4=ID#;-O+:E)#Z_::JH25L D#NO$A*W32HXH2/CU3PVM;B-(J
M_6JO2:*U!/S3EJ!"*]1*J<,I<0O;<!,8.E+;XN2BHMZQ2%%'=>!TJ+I7GV:_
M&P5N;4MJ).0$,"[**<VFTHC/W0<,ZG$UIR2%?&HFJ-KVY3N90R&Z* H#(H:]
MT/,(9Z/CJ^1VV0-LV\MJ4D/K]IJJA)6P"0.Z\2$K=-*CBA(^/5/#:UN(TBK]
M:J])HK4$_-.6H$(KU$JIPREQ"]MP$Q@Z4MOBY**BWK%(44=UX'2HNE>?9K\;
M!6YM2VHDY 0P+LHIS:;2B,_=!PSJ<36G)(5\:B:HVO;E.YE#(;HH"@,BAKW0
M\PAGH^.KY';9 VS;RVI20^OVFJJ$E; ) [KQ(2MTTJ.*$CX]4\-K6XC2*OUJ
MKTFBM03\TY:@0BO42JG#*7$+VW 3&#I2V^+DHJ+>L4A11W7@=*BZ5Y]FOQL7
M35VQ%8D%MDI;B720M>?-&5E2IB$IRF=3B24I\E(4>"B$U1M>W*=J1D-T4!0%
M^AKW0\PAGH^.KY';9 VS;RVI20^OVFJJ$E; ) [KQ(2MTTJ.*$CX]4\-K6XC
M2*OUJKTFBM03\TY:@0BO42JG#*7$+VW 3&#I2V^+DHJ+>L4A11W7@=*BZ5Y]
MFOQL%;FU+:B3D!# NRBG-IM*(S]T'#.IQ-:<DA7QJ)JC:]N4[F4,ANB@* R*
M&O=#S"&>CXZOD=MD#;-O+:E)#Z_::JH25L D#NO$A*W32HXH2/CU3PVM;B-(
MJ_6JO2:*U!/S3EJ!"*]1*J<,I<0O;<!,8.E+;XN2BHMZQ2%%'=>!TJ+I7GV:
M_&P5N;4MJ).0$,"[**<VFTHC/W0<,ZG$UIR2%?&HFJ-KVY3N90R&Z* H#(H:
M]T/,(9Z/CJ^1VV0-LV\MJ4D/K]IJJA)6P"0.Z\2$K=-*CBA(^/5/#:UN(TBK
M]:J])HK4$_-.6H$(KU$JIPREQ"]MP$Q@Z4MOBY**BWK%(44=UX'2HNE>?9K\
M;!6YM2VHDY 0P+LHIS:;2B,_=!PSJ<36G)(5\:B:HVO;E.YE#(;HH"@,BAKW
M0\PAGH^.KY';9 VS;RVI20^OVFJJ$E; ) [KQ(2MTTJ.*$CX]4WM(VO"&:UR
MB%-71[4#G='E!* U#4OTH0@%(*J$J )&4VYM>W(?=T,,I1(7<G-5385ESK0Y
M$2H*+0"R%<<W9/7@K<VI;42<@(8%V44YM-I1&?N@X9U.)K3DD*^-1-4;7MRG
M<RAD-T4!0&10U[H>80ST?'5\CML@;9MY;4I(?7[355"2M@$@=UXD)6Z:5'%"
M1\>J>&UK<1I%7ZU5Z316H)^:<M0(17J)53AE+B%[;@)C!TI;?%R45%O6*0HH
M[KP.E1=*\^S7XV"MS:EM1)R A@7913FTVE$9^Z#AG4XFM.20KXU$U1M>W*=S
M*&0W10% 9%#7NAYA#/1\=7R.VR!MFWEM2DA]?M-54)*V 2!W7B0E;II4<4)'
MQZIX;6MQ&D5?K57I-%:@GYIRU A%>HE5.&4N(7MN F,'2EM\7)146]8I"BCN
MO Z5%TKS[-?C8*W-J6U$G("&!=E%.;3:41G[H.&=3B:TY)"OC435&U[<IW,H
M9#=% 4!D4->Z'F$,]'QU?([;(&V;>6U*2'U^TU50DK8!('=>)"5NFE1Q0D?'
MJGAM:W$:15^M5>DT5J"?FG+4"$5ZB54X92XA>VX"8P=*6WQ<E%1;UBD**.Z\
M#I472O/LU^-C<>?:\1F4JV/9&XMUD+7G+#2J(4Q"4[744XD%""JB4J JJB6"
MC:]O6[D *%718X#7H23$K4A#/,?'5\CM,@;9MY;4I(?7[355"2M@$@=UXD)6
MZ:5'%"1\>J>&UK<1I%7ZU5Z316H)^:<M0(17J)53AE+B%[;@)C!TI;?%R45%
MO6*0HH[KP.E1=*\^S7XV"MS:EM1)R A@7913FTVE$9^Z#AG4XFM.20KXU$U1
MM>W*=S*&0W10% 9%#7NAYA#/1\=7R.VR!MFWEM2DA]?M-54)*V 2!W7B0E;I
MI4<4)'QZIX;6MQ&D5?K57I-%:@GYIRU A%>HE5.&4N(7MN F,'2EM\7)146]
M8I"BCNO Z5%TKS[-?C8*W-J6U$G("&!=E%.;3:41G[H.&=3B:TY)"OC435&U
M[<IW,H9#=% 4!D4->Z'F$,]'QU?([;(&V;>6U*2'U^TU50DK8!('=>)"5NFE
M1Q0D?'JGAM:W$:15^M5>DT5J"?FG+4"$5ZB54X92XA>VX"8P=*6WQ<E%1;UB
MD**.Z\#I472O/LU^-@K<VI;42<@(8%V44YM-I1&?N@X9U.)K3DD*^-1.T5HV
MU%U$7.0=)NYR--0[G<$IU5-PU)"2$M'SE$YET!*D)SL@;9MY;4I(?7[355"2
MM@$@=UXD)6Z:5'%"1\>J>&UK<1I%7ZU5Z316H)^:<M0(17J)53AE+B%[;@)C
M!TI;?%R45%O6*0HH[KP.E1=*\^S7XV"MS:EM1)R A@7913FTVE$9^Z#AG4XF
MM.20KXU$U1M>W*=S*&0W10% 9%#7NAYA#/1\=7R.VR!MFWEM2DA]?M-54)*V
M 2!W7B0E;II4<4)'QZIX;6MQ&D5?K57I-%:@GYIRU A%>HE5.&4N(7MN F,'
M2EM\7)146]8I"BCNO Z5%TKS[-?C8*W-J6U$G("&!=E%.;3:41G[H.&=3B:T
MY)"OC435&U[<IW,H9#=% 4!D4->Z'F$,]'QU?([;(&V;>6U*2'U^TU50DK8!
M('=>)"5NFE1Q0D?'JEINXV&'"AJ2DNR6IZGUI44**@&S';K102*YN(->BA_J
MVZ7X^^ .R=MV&U727$V!O<^+\K;=WE,N$A26S:K7WL-O(0A;K55(!"<W$).-
MDRX6S['LFUR6'7;/:=O7X;FA.Q5.*+4OVMHL*D.2!YQQ2TY\Y.<E5<;$M&TI
M&X8V_9._;6=@N[<W'"VH_P"U$Q9I"7KI.AST(;+&J A+*E..9$#@HXWXWXZ2
M-T2)$^1;U;:.YMZ0=XK"&T2!(T%PK/:1&%5(S!0<S\*9<IS7LURTBKXDA/1U
MD$#X,-?>)_P_L[EJ4R=U>SYLM*9#6N<%-/?%.O&V>[Y Q[*AZ(;T\F311ERZ
M*4-TIRR)">H4_MMSR7@RI$:*'@E\,J;*FW$*1F$A*VR,P',>]QH<.!#.W:(6
MI-#"<K0&GY?'H-N?0G/7X]!MSZ$YZ_'H-N?0G/7X]!MSZ$YZ_'H-N?0G/7X]
M!MSZ$YZ_'H-N?0G/7X]!MSZ$YZ_'H-N?0G/7X]!MSZ$YZ_'H-N?0G/7X]!MS
MZ$YZ_'H-N?0G/7X]!MSZ$YZ_'H-N?0G/7X]!MSZ$YZ_$VWR8VVUQY[#D=]"H
M"E@H=24*!2MY23P/(@@].(T-B-MM+,1I#+24P5) 2VD) "4O #@.0%,>@VY]
M"<]?CT&W/H3GK\>@VY]"<]?CT&W/H3GK\>@VY]"<]?CT&W/H3GK\>@VY]"<]
M?CT&W/H3GK\>@VY]"<]?CT&W/H3GK\>@VY]"<]?CT&W/H3GK\>@VY]"<]?B+
M>]_6:VS-B]Y[E=I%JC+;E1\P![P@%Q86ENO:32I%:<<0KQ9YS-RM=R93(@3X
MZ@MMUM8JE25#G7&ZN]ALQO9DC7#P9+>7(:YA(0MJGWZ2.L8C9:9=)%*4I3*.
MJ@^#^WV'K!O5]L2.ZYPSFS^S9E<FHE2ZY:^C*54K4Y<P/_ [&NG@J_L6Z>*8
MVQ=8RMJ[[8N#<4V4RHJWYL:Y6Z/(<CN)>TVRVH4="NMO%57.TW*[3;_>Y6Z6
M[%#<@6V'>'9[QN$.*P\VTYIL/YT!:T)4Y34(JK&WY>X=HV;?NR[=O:TR-\;0
MO^Z(^T8$ZW!J4A*'+E)?83F3)4RM#>8YE '*0DT\4_X2^#6V?!YEB9:?;D7;
M>^H>]TSU*;E:*WUQ'GNZEL!82%4SU)'DG%Z()!$5?$%0/+K2"?@&&OO$_P"&
M-_;_ +QOR]2/":V^(EH\.-U;7G7!]=EMD7<-I0[!GHC+66F2W,:2E2DI'!?$
MTKBU>(Z=[WYKPZ\3+5O]C86S43GT6GV/M9A,.'<40\X:+DE]+CP64YO=I3 W
M/:9WCH[XO2MG7Y=BWYO&\S)OAW+NCP=CQ51V9$U]"U(44%.9BB2E1Z./\PFU
MMU;G\8=E?S%6SPKN5TW!MK>=]D7&#*D0U*0Y?ML34N*#2 ZHC*P6P$J% L("
MQ_\ V_7XFZ;O'D;LW?M1C=+S,Z0A=T9?MH6\W-4EP&0A:NTH.9@3Q.-PM>''
MB'XKWOQ\A>.LVWV_:29=ZF[.;VBS/I+$QN0E=L;;;CY^ 7J)[-$CGCQW]G[T
M\7;1OR/XQ(VWX3;MC[A>B^'=J>=E-*1!NS<J5W8 H#E&BPI*A1(I7'BGX8[O
M\3MU;-VCX(V';J8MAV->)&WGKE=KQ%,B5<),F(4/K;14H0V59 ,JJ9L;Q\&E
M>+6Y1)V'_,/:?#;;_BE#N#T>^/6>8PMUEN7-8*%/+86L)6H\5Y>W4X_E>VSN
M2[S+7O#;3^]]I^,NVXTIQN+*N]D@-!J2\PA>FZV^@IE,E0( <[)X'%P(K41G
M2,M:^0>652#\"A[XQMY:\V=5MBE6<K*JEE-:EQUY1/WSBSUJ5SQXA1/%7=;.
MSK?8$W>=9-DS+.XTB;M^VI#C5UM=T"E=]<+8S/M(S*;*LFFF@4JX6VV67<7A
MKO2V7':<Q5NOC,'7D6>\WEB&7V519$YDI6 ZTM"E)=0?*0FJ2;I:)%ON^_MR
M3=Y[BLFW;#8X$.'(;AV;*X\I:IEP;86W&0M*5.J=0IQ2DA+533$+Q??MLK>N
MZH]K=FN0Y(8B.NDSG&@9"%KBI1IHIF2**%*4)QNVZW_;U[M$G8]KM5TW)9UH
MA/2&TW=2T,M-JCRW65K24'-1S*!2BC@V"!X>;TO#KVY+KM"UW")%MXBS;W:$
MN+D16EO7!I24EMI2DONI0QP*%.)<!1B'?+)M7=&YF18%[FW)#MT6()%DMK;[
MT9QR<B3+8"EI=C/ITHQ><5I+*$J3E*MXW"+MO<=VV[LA4!J[;LC,PF[<M^ZQ
MH,J"TTY)F,+(=;N#94XI"6F:*+[C2:*-OOXM4FS-W%*ELP94B!*<" HA*]:V
MRIL904!4%#RN'.AX?U=VJ;SYA;UTTRXE7$CD6GHZO@<']XX%P)6$%3I3G/DB
MJJ5/+@,7/P\M<&=:9FTTN/WW>SSSLP/QHL0R9#JK>$I0DN4JPE"TU%,RJ55B
MVNM;\#%JW&;2C:LYVU.:TAR[][2TF3'3)/=TH5#7G4%N=FBD!7DXDW:5OEY.
MWFHL!YBXL69;LAUV;.D6XM=V,I 2&WHRNT7.TD@@!79Q"M<R[P=OO;>7N5S=
MVYW5-A"V;3,:C-%*9<B*T.*P!G<;H#VC48LC-MW^RY,*]P2KYN%*(QM;EMLY
M01(C/NSFFR:+2**4E)*C5:0BJB]<]W1-RP9T?<?U61;8YE1+B+1;%/J?<EL2
M2E@H<<10)#B<R35030JMFYMP.-0KE=8U[4FZJNP;EB5!6$068EJX]X2XLA+B
MJ42"3F33%Q1MS<)CV5F]S;=>8J(*6TV<182IRE!V9-9;=8;;0H+<<<:RD$]H
M4)W!:V]Z)O%PMT")<[#:K3$8ES;G$E1%R]=#'?T#3:2FCBF%OY0<U"GB;"T_
MO2UW>]S9$-J^[8BNQS*AB6RT^E0#4EYPHRN92IQMHYO)2I)!Q<W(#KT4Q=ZS
MK"W(DNJ<;;A1V&G$*6 FI*2LE2@*D=&-WS)^Z;G<K?;]OBZ;7W)$MT<P)SHN
M+,-2X[K5R=0^U5S)7,""HU2"C*J_Q9.X!'A[:N]PMUVG)AJ6H,6VWN7!^0VT
M74YU9$90WF'$@E0''"8&WKFQ!AL;?V[<'-PS$+BG3EQ)$F7*7'=D!M*E)9XI
M4YE!\E83VL;E?LOB!%W;*LC7>8=ML+,6<\]%3&$AR2^&[A1MII56W%L=X2@B
MI-"*Q+K<]R?5JW-;?L]SEOLPW;BZ^]=9:HJ4I:+[0201F/:":#@*\#9H^X=P
M*=O%TO+\.W66-#U(TF-!N7<'W'):I#2F\ZD+*4I:6:4J4D\+AMVQW)FVQI4.
M3>H+2F'%MQXR+RY:PP3G)5E""L*Z?(I7CC:47;MR,E%XV^J7]8I<1Z&ZN0]?
MS;D.KBID.I):0H)H'"E0%?*Q'3:][N3K(]&EO.71%JTY"784]J \D17IC:2V
M"\',Y>!R G)F&7%YM5OOC,QN/NVU[;MNYM-80MJ<^\SWE+"'5)*#D"J%1-.2
MN.-D6BS[N[_:M[=Z$:^.6YQA;"H3KC+^:('7%+%6ZH(750(JE)[.+9*8WJN'
MMJ^1(SUIW%-M\:(DR),QZ"B*\W*N3(2M3C"BV&W'5+3R0#48@VEC>##>[;C[
M17%L9@NF/HVNXKM\A:INH*$EM2T)#1J!0Y32MZC6??$A<:U3+=:XTF3: RN3
M<+D^['0UIB<L-MH+=5.*76GQ*BAD6EGQ-MTJVPTMLS[]%3;G6HD]V68B(<K-
M=D-(6XH9FTI=4XH<-)*@1C;-K]IOSMU35;GCWF$XTIJ$IRRN/M(6R^F0%@!3
M:0 6P%5JJE*&V^'5JW*NXW]<[V;?G7H/=H\.0FFII*$AU;Z4@*-2ALFG!/'$
MQFS;W>BVWO<:VV:\7.WQ(3<NX26W5B+D<NN8*HV2 UJK*:JR"E#='4;Z"U[6
MM\.Z[T:3:W/T*+,MR[BDQBJ0GO2TI;*%).F*D'-3-EL,M'BE;H*MR17+I:K=
M+CQTSG+8WW@E],-JX.OERD=1* @H _S2H%.)=H>?<N6VW%J2V^_'T5NMJ^.M
MA"WLBCU!:J=>+=X>;<>G;NV7NZ21%LC4=TOVF0LYG)+6=*0& *EX5H/+'&H5
MN5;>?.FW/E.F7$KKD/DEIZ,L'[UU!^Z&&":U+:*UKU#K)/\ S_M]E)3GRKNK
MX<REP"@M\H]H(?:214?'0X*_%!HM/_ ['W3/_FDE_P L6_)T>9:K1=8UD;W0
MBYVW,V_):>M#L:2GS;B4%#Y"<A)2#VZ8M5\\.M_2_%*TWN?<)MX\0)S$F*]=
M;PY(7[1D&-*0VID*?"LK:4A"$T2CL@8L7AOXF>*MCM%_V)?FKEN?;%RLUSNJ
M2Q+M4N-I)5%B/-(D!J<EULE1*" 2GCCQ2N6R_$3:6_NXNV.RJ<VGMVX;?#-L
MMK$ENUN7,SVFC)FNMJ6''&TA "$@ 8O0 )/=5T "B>74@A7P8:^\3_ACQSL]
M[=N\F%_,#)AR]Y@/L9HK\!I+3#EN*HYTBD("JKS\?<X8\+;E;#<X0\(=JS]H
M;5M[;[?=UP+BPB.^N2"R5+=(1F"DJ2,Q)(.'MLVOQ:\5KALEVU3[.WL.;N1(
MM++%P2H+6RS%BQUMN-J45MJ2L45Q->.-PWS<FX=W>,%]W'8GMKR+UX@7;VO(
MCV22<TB!%*&HZ6VGE=I?9S$_&&-I;C1NG?&\V?#L/#PUVONF]FX6C;I>26BJ
MW1@RT4J2T=-)<4NB?NNUC=D+;<FX26=X[FN6Z[H;@ZVZI$VZ+#CZ&=-MK*T"
M.RDU(Z5''C5L^XOWM^U^.M_7N7=3W>61(AW$J;<;=MK@C^9TEM)6C.%T(XU'
M#%FW? WUOS8&^K;8X^W;IOK:-Y3;+G>($5(#*+FON[C3ZDE.;,&TJKTY0 -G
M^'-K;N]MLVS]VP]\)N#<P.W"Y7R(M3BI5QDR&W2\7UK)<H$]2<@ &+7_ ##)
M]I0]]VVVN6YR+&D(1;9>=E4<29,<M%2WT,JTTK"QV0D$'**7"@J>[.T%*U[!
MZ,CG_=/O'EC;H4G(H6R)F13+0Z*>%-&/3\TC[Q/(2W]Z7_<&\K,XS<V;3M6Z
M2F#"MOM=E4>4N,ZQ'9F*5I.*0V7Y#FF#YO*:$3OK'NO<V\+Q.]BM*W-=GX7?
MFXEAF)GPXC?=(<=D-ZX*W"6BXX5',LFE$W2U;DW#MF_-W^\;@CW^V/Q.\MKO
MR4(N$5*9,5]DL.AM%*MEQ!2%(<2H5PYX,H?N;FTUVU^UB4[*SW%+;ZUN:G>5
M).9Q*U5"E)-2.UFXUEL7C?6[EMWJU0;5N[N[]NCF])MCJGH;\S1MZ,CC2E$'
MN^DA:>RZA::C%LN;,JY&1:MWW;>L9*WFB@W&\H?;DH4 T"60)"LB0<PX54<,
MVZT;IW3M^,]:I5AW$($J(#>+5+FR)ZHDPO0W<H0Y+>2AR/HO!#BDZG*F\[9M
MF\7/:[>]I<65.=AHM\CNR8EOB6Q$>,S<(<MC25'AH2I+K:R:JXBHH-N661*F
M,.3)5PES9F@EQZ3,<+KR]**S'C,@J/!MAEMM/Q4#C_5W<$(U%>SUT1ES5XCH
M[O*_\I7_ ,OE![.\A(U%T!(X\3[^+/&^O%S#&WUH79&^]K_1E-(+:"V:U[*"
M4BO(<,+NLG=]P>N2Y$:6J<J2O4UX:5HC. UX*:2XH(IR"C3GB=#L^YWX2IJ&
M&DSD/+#[#3#[LG386%42E;KRU*%#4FO XB3+=NJ;#E0%250Y#<E04V9AS22"
M2?2GBNOE=. N-O.X1U"<[<P6Y!328^@H=? '#,M*B%=8YXND=&]KDVQ>G7'[
MLRB4I*9#CS>DZI8! )6CLJZQP.(5N?NBGH%M+IM\);A+3!>5G=TTDT3G4*FG
M,X5<HV[)S,]<Q=P7,3)4%JEN-EE;ZC7BM3:BDD\P:8N+CF^KFMV[H2W<WE2E
M%;Z$-Z24J4>- CL@ \!PQ:K;<]RRI\"QY?8\5]XK3&R )3IUXC*$@#CP QGD
MW^1(7WY5TS./%7Z:H *D\3Z0A(!5SX87/E;UN#\QR&[;G'U2#4Q'CF=8(Y9%
MD5(IQ/'%I<<WW=7'+$H+LRU3%DQE!HL9F^/ Z9*">E/ \,+NRMYW$W-:X[BY
M_>EZI5$"A')57_*"U!(Y $C%SC/;TGK8O1)NS6O02,R VK4I0FJ $GW.&.Y*
MOTA40,1XHC%Y631B++L=O+6F5I9*DCH.)-K=W?/>MTV:JXRH2Y"EH7+6Z'E/
MD$GMJ< 62.:N.%0F=^79F*J0J4IA$UQ(+RGDR%+X*K4NI#GWPKSPFZ2]Z7%^
MXH;2RB:J4O42VAX2$H20>"0Z X /C<>>)1AR(MV8DM*:$.XN22AK.^F0XIE4
M:1'<07'$@KHNBOC \,7"ZQKR;9(N-R1=WFH"N[M)F-+4XRZA"" DM%1R'F,6
M&\0[H'I.V7'7;(S(6I;4=3Y4IPH2E22FJE%7 CM<</W=C?MV;NLIAJ-)N"9:
MPZMICBT@FO (/%-.1XC#<MO=$UN4TA]MJ2B2M+B427C(?2% U <=45JZU&N'
MY%WW7-N#\KNYDO//DJ<,12EQRHBE2VI:BD\P2<+NZ=^W1%T<CIBN3TRE!U3*
M5EQ*%*'.BSF!/$'CA<7ZVSN[N29,U;7>54,B:E2)+O.N9Y*U!9^-4UQ:)MRW
M;.FS; 4FR3'9"B]%*"DI+3E<P(*10UZ,3+G'W]=(]PN(:3.F-2E(<=T 0T5%
M-.* H@$<>.'+C W?/ASWC'+TQJ4M+B^ZLJCL9C7M:;2BA(/))(Y8<C.[XN2X
M[KKCZVC)--1X*#BAU9PM5:<#4]>+9MO;,)=YO-W=2S!@L<2I1YE1Y)2D<5*/
M #B<%Q[1NN^+NVGZP[@">"1P(BQLW%+2#_>L]I70$[F"$:BS;G\J,N:IR'AE
M[O+K^97]Z>6(_1YM'#^X>XG_  ']OL@I1F";J^5JRURCV?+XU[N]3CP\MK[\
M^C7_ ,#:9OAI_,#=/#_=>S+1+VUO:!8_#.9XB10J8[&FH9FR(KK;<-UH)2K(
M36BJJZL6&X[D\4[7XSS[@J0^UXAV:V,VB%-84\L-);B,/R4)T@,A(<-2*\,'
MQAG_ ,R?BCX3V6Y;DC2/J9LV*Q=^\WJ3 <MP5;(8@2Y(?=9&98 6@(2X<@KF
M3OM5M\6/%CQ23&?MP==\4K$NRKA%:9%$V\+MEMU0Y2KM,^7*CR<W:W%+FO(C
MQ(T%UR2^[3(A"152E5(X >[@0T[CA&4RL,.,!SM)<#QC9".O524>_@RV]TV]
M<8(#A>#O9R%IEX&O5IR&U>\H8U5[G@);S*3G+HI5)D C^XQ'OP%=6&6CN6"'
M)"TH81J<5*4MAL >^J4T/?6GKQQW1 'FB_Z4>C#+D@J][2:6OW@<.1$;CA*D
MM.Z#C(<[0<#YC92.O524>_@RV]TV]<8(#A>#O9R%IEX&O5IR&U>\H8U5[G@)
M;S*3G+HI5)D C^XQ'OP%=6&6CN6"')"TH81J<5*4MAL >^J4T/?6GKQQW1 '
MFB_Z4>C#+D@J][2:6OW@<.1$;CA*DM.Z#C(<[0<#YC92.O524>_BXR6MTV]<
M?N3KA>U1E"#';>"B24"FG(;5Q4."AQ&-NJ=W/;TH1;HR"L.HRYD-/)4!D<>3
MP,1[DXH=A5%&E<,M'<L$.2%I0PC4XJ4I;#8 ]]4IH>^M/7CCNB /-%_TH]&&
M7)!5[VDTM?O X<B(W'"5):=T'&0YV@X'S&RD=>JDH]_!EM[IMZXP0'"\'>SD
M+3+P->K3D-J]Y0QJKW/ 2WF4G.712J3(!']QB/?@*ZL,M'<L$.2%I0PC4XJ4
MI;#8 ]]4IH>^M/7CCNB /-%_TH]&&7)!5[VDTM?O X<B(W'"5):=T'&0YV@X
M'S&RD=>JDH]_!EM[IMZXP0'"\'>SD+3+P->K3D-J]Y0QJKW/ 2WF4G.712J3
M(!']QB/?@*ZL,M'<L$.2%I0PC4XJ4I;#8 ]]4IH>^M/7CCNB /-%_P!*/1AE
MR05>]I-+7[P.'(B-QPE26G=!QD.=H.!\QLI'7JI*/?Q>4Q]QV^6P\RTI?;0I
M"FB8SZB0X]'206GVU<7!P4.?(E]S;^S@V5*!<,./2J3("OB=<1[\!75AEH[=
MV>')"TH81W./52E+8; '8Z52FA[ZT]>.-@V:/-%_YG']&&7)!5Y'+2:6OW@<
M.1$;;V>J2T[H.,B%'S!P/F-E(R<]5)1[^#+;L.S5Q@@.%X0X^7(6F7@:Y.6G
M(;5[RAC57M_9R6\RDYS#CTJDR 1Y'08CWX"NK#+1V[L\.2%I0PCN<>JE*6PV
M .QTJE-#WUIZ\<;!LT>:+_S./Z,,N2"KR.6DTM?O X<B(VWL]4EIW0<9$*/F
M#@?,;*1DYZJ2CW\&6W8=FKC! <+PAQ\N0M,O UR<M.0VKWE#&JO;^SDMYE)S
MF''I5)D CR.@Q'OP%=6&6CMW9X<D+2AA'<X]5*4MAL =CI5*:'OK3UXXV#9H
M\T7_ )G']&&7)!5Y'+2:6OW@<.1$;;V>J2T[H.,B%'S!P/F-E(R<]5)1[^#+
M;L.S5Q@@.%X0X^7(6F7@:Y.6G(;5[RAC57M_9R6\RDYS#CTJDR 1Y'08CWX"
MNK#+1V[L\.2%I0PCN<>JE*6PV .QTJE-#WUIZ\7DL6'9J9 M<F0RKN44T2(C
MT@+[>DF@;:4OBM(HDU4.>+?&7MS9ZYR&669#0A1:A[/W<IHG437624<%*%>D
M\\&6W8=FKC! <+PAQ\N0M,O UR<M.0VKWE#&JO;^SDMYE)SF''I5)D CR.@Q
M'OP%=6&6CMW9X<D+2AA'<X]5*4MAL =CI5*:'OK3UXXV#9H\T7_F<?T89<D%
M7D<M)I:_>!PY$1MO9ZI+3N@XR(4?,' ^8V4C)SU4E'OX,MNP[-7&" X7A#CY
M<A:9>!KDY:<AM7O*&-5>W]G);S*3G,./2J3(!'D=!B/?@*ZL,M';NSPY(6E#
M".YQZJ4I;#8 ['2J4T/?6GKQQL&S1YHO_,X_HPRY(*O(Y:32U^\#AR(C;>SU
M26G=!QD0H^8.!\QLI&3GJI*/?P9;=AV:N,$!PO"''RY"TR\#7)RTY#:O>4,:
MJ]O[.2WF4G.8<>E4F0"/(Z#$>_ 5U89:.W=GAR0M*&$=SCU4I2V&P!V.E4IH
M>^M/7A5RVZQMFQ7!456:;"899=[N6ER5=M"0<I;84L^XG#D1&XX2I+3N@XR'
M.T' ^8V4CKU4E'OXW,Y&W1;W&E6I]8>U$%&4QVG\QU'8Z::;[:NTX@44.T,1
MW7-SP$MY G.712J=<$<">1B/=/Q%=6&6CN6"')"TH81J<5*4MAL >^J4T/?6
MGKQQW1 'FB_Z4>C#+D@J][2:6OW@<.1$;CA*DM.Z#C(<[0<#YC92.O524>_@
MRV]TV]<8(#A>#O9R%IEX&O5IR&U>\H8U5[G@);S*3G+HI5)D C^XQ'OP%=6&
M6CN6"')"TH81J<5*4MAL >^J4T/?6GKQQW1 'FB_Z4>C#+D@J][2:6OW@<.1
M$;CA*DM.Z#C(<[0<#YC92.O524>_@RV]TV]<8(#A>#O9R%IEX&O5IR&U>\H8
MU5[G@);S*3G+HI5)D C^XQ'OP%=6&6CN6"')"TH81J<5*4MAL >^J4T/?6GK
MQQW1 'FB_P"E'HPRY(*O>TFEK]X'#D1&XX2I+3N@XR'.T' ^8V4CKU4E'OX,
MMO=-O7&" X7@[V<A:9>!KU:<AM7O*&-G21N2!HQ;I)6^X7$42E,*XM*/:=;(
MHN.X#E2X>R>R!5:66CN6"')"TH81J<5*4MAL >^J4T/?6GKQQW1 'FB_Z4>C
M#+D@J][2:6OW@<.1$;CA*DM.Z#C(<[0<#YC92.O524>_@RV]TV]<8(#A>#O9
MR%IEX&O5IR&U>\H8U5[G@);S*3G+HI5)D C^XQ'OP%=6&6CN6"')"TH81J<5
M*4MAL >^J4T/?6GKQQW1 'FB_P"E'HPRY(*O>TFEK]X'#D1&XX2I+3N@XR'.
MT' ^8V4CKU4E'OX,MO=-O7&" X7@[V<A:9>!KU:<AM7O*&-5>YX"6\RDYRZ*
M529 (_N,1[\!75AEH[E@AR0M*&$:G%2E+8; 'OJE-#WUIZ\-0+;?8DV8^E*V
M8[2ZJ4E:%.)('NH0H^\/ZV[-O[$_EM'C/M;<^Y+QNBW[KL6XK/8Y"'+W-=G/
ML7*/=%LJ6XTM_30MLK"FTBI2>R%1]\L6FW[JW%>KMN*\6*Q9C;;8NZRW)*8,
M92P"M+*5 *50!2\Q I3%BVIX,^&&[Y"=F7>#N.#XL[.W%M2,\W/;CRH[MN>M
M]]>!*-.15>=!2L$"A37&^?\ ^H-.\$2B_ ^JPW8]M)U6GE?[SW;ZJI2D"N3/
MK\?)R?'Q?$N)2I!B.!25A!213I#G9^'AALZ+=2E))RCW_P#'%-!NG*F0=0'5
MU 8IH-T^]'N^Y[IP#H-U'+LCW/<]P8] WRIY(Y4IU=1Q71;J34G*.=:]77QQ
M30;IRID'4!U=0&*:#=/O1[ON>Z< Z#=1R[(]SW/<&/0-\J>2.5*=74<5T6ZD
MU)RCG6O5U\<3TH82#W9T)R)-?(H*9 55X#D*]6+ 'F<SGLZ+JEY*]0JTA4KU
MDI<K4FN<!7$U%:X!T&ZCEV1[GN>X,>@;Y4\D<J4ZNHXKHMU)J3E'.M>KKXXI
MH-TY4R#J ZNH#%-!NGWH]WW/=. =!NHY=D>Y[GN#'H&^5/)'*E.KJ.*Z+=2:
MDY1SK7JZ^.*:#=.5,@Z@.KJ Q30;I]Z/=]SW3@'0;J.79'N>Y[@QZ!OE3R1R
MI3JZCBNBW4FI.4<ZUZNOCB]2&DK8[NTAQ;D9+VHE"'$%93W9"W?)3QRCESX8
M4@WR2<I(/_2Y!%037_+]TX!]N2JCE_TN3[G^G[@Q^NY7*GZKD\J4_)]1Q7VY
M*J34GV7)YUK^3Z^.*>VY5.5/9<CJ _)]0&*>W)5/_M<GW?\ 3]TX!]N2JCE_
MTN3[G^G[@Q^NY7*GZKD\J4_)]1Q7VY*J34GV7)YUK^3Z^.*>VY5.5/9<CJ _
M)]0&*>W)5/\ [7)]W_3]TX!]N2JCE_TN3[G^G[@Q^NY7*GZKD\J4_)]1Q7VY
M*J34GV7)YUK^3Z^.*>VY5.5/9<CJ _)]0&*>W)5/_M<GW?\ 3]TX!]N2JCE_
MTN3[G^G[@Q=(D6_2FY4J&^S&<%NE-Y5K;4A)SI;S)I7F.(Q!8?O\M<AB.TA]
MSV;*62M*1F.=3=5=KC4\3SQ3VW*IRI[+D=0'Y/J Q3VY*I_]KD^[_I^Z< ^W
M)51R_P"ER?<_T_<&/UW*Y4_5<GE2GY/J.*^W)52:D^RY/.M?R?7QQ3VW*IRI
M[+D=0'Y/J Q3VY*I_P#:Y/N_Z?NG /MR54<O^ER?<_T_<&/UW*Y4_5<GE2GY
M/J.*^W)52:D^RY/.M?R?7QQ3VW*IRI[+D=0'Y/J Q<(>S;JB;-MJ$NR(,B,N
M,\6E$C4;0ZE)6D$D$IY$\>> =!NHY=D>Y[GN#'H&^5/)'*E.KJ.*Z+=2:DY1
MSK7JZ^.-QB,TIM[V>^&E1TNZH.2@R=V0MVO 4R)*NH88!80?-IK5/'ETU%>D
M\\ Z#=1R[(]SW/<&/0-\J>2.5*=74<5T6ZDU)RCG6O5U\<4T&Z<J9!U =74!
MBF@W3[T>[[GNG .@W4<NR/<]SW!CT#?*GDCE2G5U'%=%NI-2<HYUKU=?'%-!
MNG*F0=0'5U 8IH-T^]'N^Y[IP#H-U'+LCW/<]P8] WRIY(Y4IU=1Q71;J34G
M*.=:]77QQ30;IRID'4!U=0&-G!MM26S<WA)2VEW(I/<91H[I(4C+F-?.D)S4
MH<^4$'0;J.79'N>Y[@QZ!OE3R1RI3JZCBNBW4FI.4<ZUZNOCBF@W3E3(.H#J
MZ@,4T&Z?>CW?<]TX!T&ZCEV1[GN>X,>@;Y4\D<J4ZNHXKHMU)J3E'.M>KKXX
MIH-TY4R#J ZNH#%-!NGWH]WW/=. =!NHY=D>Y[GN# 4AI"5#DH) /5_87]S<
M'C[=/Y;?&W<,)B?=;YMB7+9?D-O*26Y$F&N-+@.J=[JA"UEO5+:=/.E*C6Z6
M2)XO["_F5V#MU#+-X\3[#;Y>V;Y D/L.NM>T;6X%Q'1(<0IMH1BG(A!4X5*-
M,7LURTBKXDA/1UD$#X,-?>)_P_IVYX,^%_A/:O$6_7W:C^ZG)5UW'[!:98C2
M5QEM@F#+"CP!!J.?N5QX%;@\-O"-F_[J\:;S==OIVK>;ZBV,0)]G03)RSVHD
MM#[14A6182,PH:5-!O[Q!A^#-QD;[\+KS=[!OW8#5TBB+;9=FBN2Y$ERYN)0
M%1<J D*0RIPJ- T>>/!G?5GV$K</B#X\.VVW["\.F[@EAE=PN#!DJ3(N*V?-
MLL-H4I;FB3RHCCCQ1:N'@W/C>+?A%>V;'NSPWMMTBRHP7+:3)C3&KK(3$;,8
MQU:BU%O,D @(4: [*\4Y%A1ME[=L9U]RQMR3,1'+3[C!2'RTP5UTZUR#^FY:
ME,G=7L^;+2F0UKG!33WQ3&V>[A 8]E0]$-Z81DT49<NBE#=*<LB0GJ &'-OR
M]D7:%MWZX+V)'WL7X;D==Z#(=;;,5MXR4MN>2'"B@/E4!KB_,V_>MAG.[67I
M[G:CW**ZJW+*E(RS APE@YD*%'*<01T8N6Z8V^=OR-L69Y4>\;C:N<5<"(\@
MI2IM^2EPM-J25I!"E BHZ\62,G>EB5(W*EE>W(XN,4KN"9 <+*HB=2KP<#*\
MI17-E53R3B\WBS[WL%UM.W"M.X;I#N45^- +:2M8E.MN*0SE2*G.108V2N9O
M^Q+A>(<Y^W;3NK%PBNPY+T9*E.Y9"72W1*DY"0?+*4>40,2-P[KN$'84!J]S
M+$R[?;E;V6W9$60XPC(\B0MJKP;*TME0< X*2E0( O6Z-QVO;=G4XAI-VNDQ
MF'&*W?1IUGUH1570*\<6:P3=WV6'?MQ-I>V_9'[A&;ESFU5RKBL*<#CR3E-"
M@$<,.[7M^[K+.W,PTX^_MV//CNSD-,N%EQ:HR'"X$H<!0HE- K@>.+[=XV^M
MO2+3M=TL;FNC5SB+CVYU)H42W0Z4,J!X460<6F]/;ZV\U9[\,UCNR[G$3&FC
M50Q6,\7<COG'$([!/:4E/,C^C>'>@V6.X*SAT,E'E)I7O"'&^=.:?>XT.'\R
M0I.HO@14\SRZ<1&7FX$R\RG667-JP9 E7>.[)1J--OPVTE84H?%3F(/!5#BX
M0$[.O*I]I0'+M!%NDEZ*@I*PI]O3S-@I!-5 <..'+8QLR]OW)IIM]VW-VV4J
M0AIX$MN*:#96$K )22*'HQMZ7;[<]=I>Y'9[,*R0HSS\Q*[>X&W@II""H\37
M@#0#C3%ENWU0N;T3<$N3!M2683[CKDF(K*ZT6TMDA50J@YG*KY)Q<(K-BFPV
M;.W+5>;A(A2!'A.0XSLE3,E8;(:6H-%*4KH:D8EN63;UPO*(#>M<%P(;TD1V
MR"<[I:0H(31)XJH.!Q&N3FV[DW;9K"Y4.XJA/!AYAJA<>;=*,BD)J,R@:#I.
M)=Q.V;F+= 2VN?<#"?T&$O)"VE.NY,J M)!25$5!!&'&&]BW]Q]I@2G6$VJ6
M5H842 ZI(:J$$I("CPX'JQMN[4;D(W/WH08C2%%Y*HK_ '<I4*<2I7DA-?AQ
M>7KK:W]ORK(NW)>M=TBOQ9+@N;JF65I;<;"LH*:DD<1RKBZRD[>G3+;9'76;
MG>8L-]R$TIE00LJ?TPE(!(':IS%:5Q,D,V&7<8-MCL2;G<X420]&C-R&PZWK
MNZ02V<JOC4'42..+D+O9)FVU6^T2;TVB[0Y$4R6(RD)6& XVG,:N#CR]W%K8
MM>SKHZ+VT\]:);D&0B/)1'96^LLO%O*OL(-,I-30=.'FY-DF1G(Z$NR&W8SB
M%-H6YHI6L*2"D%PY 3P*NSSX8MTZ[6Y=G>N,>Y2TVRXQI$62ABV!@N+4AQJM
M' ^,AY&AJ1BW1F=GWEV3>&52;1'1;I*G);* "IV.D-U=0 02I (&-U[@#]JM
M"-G2F(=VM-VEH@SM9Y11E2P]10R$4.:G&H^*<;U[Q?=JOC8T*+.N08NK*U/H
MEURICIYJ6*<0>G*!Y0QZ,?!CT8^#'HQ\&/1CX,>C'P8]&/@QZ,?!CT8^#%AO
M&Q[BJP;UVJG-;YK7 NGB7$.)Y+2NI"DG@1PP\W)939MZV():W1MQ2NTA?(2&
M*\5LN'R3S2>RKCS_ *-U=[#9C>S)&N'@R6\N0US"0AQJGWZ2.L8CY:9=)%*4
MI3*.J@^#^WV'K!LN"\2.ZYPSFS^S9E<FHA2ZY:^C*54K4Y<P/_!^.EJVUMFU
M7.;X5[1MMUL29KCJW9]VN:)CC3+K+"5+3&2&$ J2,Q)4$@Y<>(>Q?&JP[*M&
M\=EHL\]F3L.;,F6U^#>42@REWO[+#[;[:X:RH%(!2I!'6;T02"(J^(*@>76D
M$_ ,-?>)_P /Z=NWK>VUTW7PKB^&MQL;U\3-2P_!OCTMQR,ZRRAU#Q6VA>=*
MBA2*\%=6/Y5]C^(%DD;6/@SN>]0-T[FVA>HMGE>Q6HQ9MMTA.V]UMQE;X"0I
M#8#@.8K S'&Z?";^7KPN>WM+WI&N5MNC4J^L0YBG[Q$=9D7B;.N2CWEW-E*T
MY@I710#'\N,T>%46S^)'\KVY8,B'L25N&WO)W-;&+:84AQB<QF8BN++QRH=/
M (-5<1C^8;Q>G^%$:Y^*7CI?8C\3PBA[@A-FVVV)#1:V=:[.CNJW0VDO+".!
MX &O 6;PP\4_#D;&E[$;$:U7--X@W1-V3)>?D.N);A*7W?2*DIHM1S5J.7]-
MP(K41G2*5!\@\LJD'X%#WQC;RUYLRK;%*LY455+*:U*W7E$_?.+/6I7/&]M\
MWV+'N&Z;INNYWW9\Q<R;*B0&YD=MAIWV>ZXB*W( 2M*EMMY\IIJ<3C=;.[[O
M8I?MC8$C9K$,3E/P%OO3XTHN,1&K1"1#B*0VXE,?SQ0"$YU@DXO6\MK1MO/L
M1[_M2_;?VE,==AQ):K';YMND-2ELQ7A'*4RD.,+2V[VFD I  IO>\7>/M[:D
MO>GAB-E,JL*5NFUS'YEUDR5L%;,<K;(FM**@4%Q:5$H1V3C<"4RH;.[U6FQ6
M2TW&;N$72*]!M,U,AQIEI6WHR+>Z$A1COEJ4II931)R<;!>I;]EO^X[5XFS=
MYOV^X75]P+M]RM:;>XVJXHMC>:0TNK@I%2ERGQ":BU;BL\#:V[+A!NN^-7;E
MYF2(T+N6[)S<MJ4AY$*2==I+(:<;+65:'%I#@IVO##=6UK7MZ\W+8+4^))V?
M<WW;;:W$7*(B.IZ,\U%FJ:7'+>5"2R06UK3F3SQ;W(-QV[9]JL7#:MQ%OM<E
M5MBL"QJCKDQW(*+6\Y*45-+$=TRVPA&1&E1)S65$:5;+*^C>F^;_ 'N\0<R9
M9B[JBW6,PMM0927'T=[8+@4H#S= M65.-M;8>M^U]HW[P\E;=<L,O;UP>2N\
M(L(>121+>MA[DE6KJ-(T)(;<S&JJU&P=UWR+$+VWE;PF7IJ;=E7V3[0W$JV!
MN1%DJMEN0D*1#<#B4M-Y<W#/F4?Z-VK1GS"WKIIE:5<2!P+;\97P.#^\=DN*
M:X+0Z5)52M"%5!^'#V]AM2ZM[BOC;[.Y].YH1'2F9$5&E.6X"/J-+659TZJE
MA/*A&+ W:;-<T6K;4NPNPA)N 5-?8LO?5E$EYME"5*<<F531(2@( "3BYP=S
M1;RM]+%MCL-V^=HRIG=KM-N149"V74)0V)"4%*P:^4D@\I,N5M]2!<Q?TW%<
M949UQL7N4B4#&3.C26:M%L).JVL+!/ 8$RX6VZ72X:U\:<N;SEN4M<2]H0E2
MU,+@JC]X:4VFATM)2<R2WQP[(N-KO5RND4WQ%KGF;%BI>:O<%$)7M!F+$:;<
M6R$)RZ00D@!)' 8O=KOUGF[BMUVRJ78DO1VH+CK;2T-.O%;"Y"%MJ75*F'4&
MG!68<,;:<?M<QR!";8B[IVNDV]FWS8J('LYY#*V82)25.,E5"\ZX$$\!P&+]
M9S#F6IZX2[BY;7H(MZT=TGMLLB)*5*AO/Y6FF0@%AQHD<^0QN?>5QVU*F2KW
M=8MR@.(>B.R8[49:E&$7)T24@-N I!6TA#@RC*H#&R+TW8]16SKS/NRHKKM4
MR!-GF8&P0BJ"@'*%<>-%>YB_1K):[LY"O4NTS$KNLQE^2VNVRE25I*V6&DJ#
MF:B>%1S-<+T[;+8B.N[M>=A"6=-:MSQ1&25)" DEBE22.WR&7%OM%RV]<HTJ
MQY%VEV).;3'?7W2+&<$YM3!4M)[KV2VI*@E66O"N)5BMNU)%OCR6+LTRA;D)
M#487-$=*6FFX<./F;8#% 72IQ0/:748VD\]MVYW2ZV!*HLV_2I49N6JWK@/0
MC#85'C-I*4ZN="GTN+&4)*B. @/0]J3Y%\M\&U6I$B9.;7$7$M%U;N3)6PF.
ME6JX&PA9SY0>TE(XC"(MHL5U3$;@;BBI5=;BB6]J[@=8>4K,AAM(;:4T:) [
M5:DUJ3'N$N/>XL!QIT7;;T3V*F$XM]AEAUM 5;"M;3B&J*UE+< RY%I*0<7:
MX6NT)LELFRW7H%F0XMY,9E:B4-!Q=5*R@TJ<>1CR<>3CR<>3CR<>3CR<>3AM
MJVORVYCSB6F&HBG ZMQ1RI2@-G,5$F@ PWXB>($J3,\0;I%4U%M[KZW$VR*\
M 5-N$J.=Y8 SUJ$^2GC51_HW*MO/G3;GRG3*PNN0^26GXRP?O74'[H88)K73
M3SKU#K)_Q/\ ;[*2G/E7=7PO*5@4]GRCV@A]H$5'QD."OQ0:+3_P=MW(-X[V
M\+MZ6R.8*-\>'U[=LER?@*5G5"DD(>9>:*P%C.T5)(["D@J"I5EV[+O%]N-W
ME&X;IWGN2>Y=+W>)JAE5)GS':%:J"@2A*4)'D(3QQ>@D$DQ5T "B>74@A7P8
M:^\3_A_9W  5)C.T%*U[!Z,CG_=/O'EC;H6G(H6R)F13+0Z*>%-&/3\TC[Q/
M(?VNXH;8[<R.EA)RE=-1Q":Y1'E$TK7T2O[O*"RCQ0RA:BHCV8.DU_+X^U(_
MLP>OQ]J1_9@]?C[4C^S!Z_'VI']F#U^/M2/[,'K\?:D?V8/7X^U(_LP>OQ]J
M1_9@]?C[4C^S!Z_'VI']F#U^/M2/[,'K\?:D?V8/7X^U(_LP>OQ]J1_9@]?C
M[4C^S!Z_'VI']F#U^+A.1XG:RX49Y]#)M:B%EM!4$G3<6OC2G923U GAB'*5
MXGZ:I+#;JFQ;#V2M(41VW4JX5Z4@]8&/M2/[,'K\?:D?V8/7X^U(_LP>OQ]J
M1_9@]?C[4C^S!Z_'VI']F#U^/M2/[,'K\?:D?V8/7X^U(_LP>OQ]J1_9@]?C
M[4C^S!Z_#N[KQ>#O*_L "Q.O1@PS!)!"W4MYUYG2#0*)[(Y<>/\ 4W,&T:BS
M;G\J,N:IR'AE$>77\RO[T\L1_P#PT?X#W$_X#^WV24HS)3=7RM66N4>SY?&O
M=WJ<>'EM??GT:_\ @+/FNEPM?L>YQ[F/9[^CW@Q\WZ/(X'.RO-VT=-!B.U]=
M-TK[O&O$;.JXDJ7[745%Q9R<5QJTCG_+'7A]GZZ;I;UXMGBZB+B0M'LA84'$
MG)P7)I20?\P=6&IWUKW$HMWF=>>ZJG$LJ,YG1,4HR\8[/E-(^*KC7'LWZ\[M
M(]@>P.^FYGO%.\=X[[GR?.OB:GR.%,;IF.;IW(4R9<6[KA(FO*:'<6 SW1+3
M"0YH/4S.MI-5*XUQ!9&]-U+$:#=8H6NXJ*EB[G,7%DHJ5QN4<_Y8Z\/L_73=
M+>O%L\741<2%H]D+"@XDY."Y-*2#_F#JPU.^M>XE%N\SKSW54XEE1G,Z)BE&
M7C'9\II'Q5<:X]F_7G=I'L#V!WTW,]XIWCO'?<^3YU\34^1PIAV?];-QI+MY
M@7GN@GD,I,%G1$5*,O".]Y3J/C*XUQ':^NFZ5]WC7B-G5<25+]KJ*BXLY.*X
MU:1S_ECKP^S]=-TMZ\6SQ=1%Q(6CV0L*#B3DX+DTI(/^8.K#4[ZU[B46[S.O
M/=53B65&<SHF*49>,=GRFD?%5QKCV;]>=VD>P/8'?3<SWBG>.\=]SY/G7Q-3
MY'"F'9_ULW&DNWF!>>Z">0RDP6=$14HR\([WE.H^,KC7$=KZZ;I7W>->(V=5
MQ)4OVNHJ+BSDXKC5I'/^6.O%X:.]-T-!^UVZ*74W+*I M *@XE2@D!<GE()(
MU!S*>>-K3T[MW Z&W5WD,)GI5'69\-+/=<K:GD&,U7.TA+B@E7$+5SQ[-^O.
M[2/8'L#OIN9[Q3O'>.^Y\GSKXFI\CA3#L_ZV;C27;S O/=!/(928+.B(J49>
M$=[RG4?&5QKB.U]=-TK[O&O$;.JXDJ7[745%Q9R<5QJTCG_+'7A]GZZ;I;UX
MMGBZB+B0M'LA84'$G)P7)I20?\P=6&IWUKW$HMWF=>>ZJG$LJ,YG1,4HR\8[
M/E-(^*KC7'LWZ\[M(]@>P.^FYGO%.\=X[[GR?.OB:GR.%,.S_K9N-)=O,"\]
MT$\AE)@LZ(BI1EX1WO*=1\97&N([7UTW2ON\:\1LZKB2I?M=147%G)Q7&K2.
M?\L=>'V?KINEO7BV>+J(N)"T>R%A0<2<G!<FE)!_S!U8:G?6O<2BW>9UY[JJ
M<2RHSF=$Q2C+QCL^4TCXJN-<>S?KSNTCV![ [Z;F>\4[QWCON?)\Z^)J?(X4
MP[/^MFXTEV\P+SW03R&4F"SHB*E&7A'>\IU'QE<:XCM?73=*^[QKQ&SJN)*E
M^UU%1<6<G%<:M(Y_RQUXOSCF]MQL-JA6.,X^Y<VT);3:)#:M7,\Y'0E<GE(4
M7!J#X"W-/C=53-YGW@Q%;@8+1,YDL&(I%?F[/E--_%5QKCV;_'V61[ ]@=].
MY6.\4[QWCON?_P!5\34^1PIAV?\ QOREV\P+SW0;@CAE)@LZ(BI17A'>\IU'
MQE<:XCM?QX?7W>->(V=6XV"I?M=147%FO%<:M(Y_RQUX?9_CP^WKQ;/%U$;C
M8"T>R%A0<2:\%R:4D'_,'5AJ=_&_,6[S.O/=5;@CEE1G,Z)BE%>,=GRFD?%5
MQKCV;_'V61[ ]@=].Y6.\4[QWCON?_U7Q-3Y'"F'9_\ &_*7;S O/=!N".&4
MF"SHB*E%>$=[RG4?&5QKB.U_'A]?=XUXC9U;C8*E^UU%1<6:\5QJTCG_ "QU
MX?9_CP^WKQ;/%U$;C8"T>R%A0<2:\%R:4D'_ #!U8:G?QOS%N\SKSW56X(Y9
M49S.B8I17C'9\II'Q5<:X]F_Q]ED>P/8'?3N5CO%.\=X[[G_ /5?$U/D<*8=
MG_QOREV\P+SW0;@CAE)@LZ(BI17A'>\IU'QE<:XCM?QX?7W>->(V=6XV"I?M
M=147%FO%<:M(Y_RQUX?9_CP^WKQ;/%U$;C8"T>R%A0<2:\%R:4D'_,'5AJ=_
M&_,6[S.O/=5;@CEE1G,Z)BE%>,=GRFD?%5QKCV;_ !]ED>P/8'?3N5CO%.\=
MX[[G_P#5?$U/D<*8W"^QXUJ<D39+5T9MZ+_&+6I$AJCIAH;4XV-!\]IULK2%
MJXYDXLD5WQUD!V%:KA"<U-Q1\Y5=4@J6NBUC/%/".<QTQPJKGA]G^/#[>O%L
M\741N-@+1[(6%!Q)KP7)I20?\P=6&IW\;\Q;O,Z\]U5N".65&<SHF*45XQV?
M*:1\57&N/9O\?99'L#V!WT[E8[Q3O'>.^Y__ %7Q-3Y'"F'9_P#&_*7;S O/
M=!N".&4F"SHB*E%>$=[RG4?&5QKB.U_'A]?=XUXC9U;C8*E^UU%1<6:\5QJT
MCG_+'7A]G^/#[>O%L\741N-@+1[(6%!Q)KP7)I20?\P=6&IW\;\Q;O,Z\]U5
MN".65&<SHF*45XQV?*:1\57&N/9O\?99'L#V!WT[E8[Q3O'>.^Y__5?$U/D<
M*8=G_P ;\I=O,"\]T&X(X928+.B(J45X1WO*=1\97&N([7\>'U]WC7B-G5N-
M@J7[745%Q9KQ7&K2.?\ +'7A]G^/#[>O%L\741N-@+1[(6%!Q)KP7)I20?\
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M*\M0Z5]K^N3SH*TQLSV5XM[1@;NWDF,S&\/Y%YB)O#-Q?(;, Q5K0ZIU+M4
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MQ[.8;@D+CBH+J49:E (()Y5Q>ER-LSHZ-M.):W"MR*XE,%:E!"4R"4T;)40
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M*<A-OMI)HI8*5A,FU2;)??$3<5PW5NNU6.VV&W0H:VV-O/C4:<5+N*&:-MK
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M6$+0A65'DC-C^8]R?NR5M]7B5>8#WAUMR7;KK(4B+:)+#A>D&+'>8CKF(8'
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M5)*AW2!V@%,$@_H_2&UCA^45TI1ERC?=P2K3*<XAV^N;2<1GXQJ5S+2NG*J
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MX4K-#V>RJEQDR9MP#%ON#MHN45VRW4/H?9:2\]GC*B:I:;:6E:W<FDE)!4L
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MK#)CQEZZF4@J=TLVFFBG,H(K"VK;7)-QN,EQ29$AJ+)$-E*8RY)_3%-".M8
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M>6RAY:6G65*2K3"P%<>"N'1_0Q<7H$=VX14*1%GK:0IYM*O*2APC,D'I /\
M40RRVEIIL!+;2 $I2!R  X ?T96T);22594@ 54:D\.LFO\ 5+F1.H4A)<H,
MQ2"2!7J%3_0014'@0<-1HC#<6,RG*S'90$(0.I*4@ #WOZA<RC.0$E=.-!Q
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G=!0* K6ZK1)>EN7:>[.><?*24EP)2&TY4I["$I 37C3I_P#T^__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
